讯飞医疗
Xunfei Healthcare

訊飛醫療科技股份有限公司
Xunfei Healthcare Technology Co., Ltd.

(A joint stock company incorporated in the People's Republic of China with limited liability)
（於中華人民共和國註冊成立的股份有限公司）

Stock Code 股份代號：2506

2026
INTERIM REPORT
中期報告

Contents
目錄

Definition
釋義

In this interim report, unless the context otherwise requires, the following terms have the meanings set forth below:

在本中期報告內，除文義另有所指外，下列詞語具有以下涵義：

"Anhui Yanzhi"	Anhui Yanzhi Technology Co., Ltd.* (安徽言知科技有限公司), a limited company established in the PRC on December 9, 2019	「安徽言知」	指	安徽言知科技有限公司，於2019年12月9日在中國成立的有限責任公司
"Audit Committee"	Audit Committee of the Board of Directors of the Company	「審計委員會」	指	本公司董事會審計委員會
"Board Committee(s)"	the board committees of our Company, namely the Audit Committee, the Remuneration Committee and the Nomination Committee and the Environmental, Social and Governance (ESG) Committee	「董事委員會」	指	本公司董事委員會，即審計委員會、薪酬委員會及提名委員會及環境、社會及治理(ESG)委員會
"Board of Directors" or "Board"	the board of Directors of the Company	「董事會」	指	本公司董事會
"China" or "PRC"	the People's Republic of China, for the purpose of this interim report and for geographical reference only, excluding the Hong Kong and Macau Special Administrative Region of China and the Taiwan Region	「中國」	指	中華人民共和國，就本中期報告而言及僅供地理參考，不包括香港、中國澳門特別行政區及台灣地區
"Companies Ordinance"	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time	「公司條例」	指	香港法例第622章公司條例，經不時修訂、補充或以其他方式修改
"Company", "our Company" or "Xunfei Healthcare"	Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司), a joint stock company established in the PRC on December 24, 2021, the H Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 2506)	「本公司」、「公司」或「訊飛醫療」	指	訊飛醫療科技股份有限公司，於2021年12月24日在中國成立的股份有限公司，其H股於聯交所主板上市（股份代號：2506）
"Controlling Shareholder"	has the meaning ascribed to it under the Listing Rules and, unless the context requires otherwise, refers to iFlytek	「控股股東」	指	具上市規則所賦予的涵義，除文義另有所指外，指科大訊飛

"Corporate Governance Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, as amended, supplemented or otherwise modified from time to time, and for the purpose of this report, it refers to the version of the Corporate Governance Code in effect as of the end of the Reporting Period	「企業管治守則」	指	上市規則附錄C1所載企業管治守則，經不時修訂、補充或以其他方式修改，就本報告而言，指截至報告期末生效版本的企業管治守則
"Director(s)"	the director(s) of the Company	「董事」	指	本公司董事
"Global Offering"	has the meaning ascribed to it in the Prospectus	「全球發售」	指	具招股章程所賦予的涵義
"Group", "our Group", "the Group", "we", "us", or "our"	the Company, subsidiaries and consolidated affiliated entities from time to time	「本集團」或「我們」	指	本公司、子公司及不時的合併聯屬實體
"H Share(s)"	overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, listed on the Stock Exchange and traded in Hong Kong dollars	「H股」	指	本公司普通股股本中每股面值人民幣1.00元的境外上市外資普通股，於聯交所上市並以港元買賣
"HK$" or "Hong Kong dollars"	Hong Kong dollars, the lawful currency of Hong Kong	「港元」	指	香港法定貨幣港元
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC	「香港」	指	中國香港特別行政區
"Hong Kong Stock Exchange" or "Stock Exchange"	The Stock Exchange of Hong Kong Limited	「香港聯交所」或「聯交所」	指	香港聯合交易所有限公司
"iFlytek"	iFlytek Co., Ltd. (科大訊飛股份有限公司), a company established in the PRC whose shares are listed on the Shenzhen Stock Exchange under the stock code of 002230, our Controlling Shareholder	「科大訊飛」	指	科大訊飛股份有限公司，一家在中國成立的公司，其股份於深圳證券交易所上市(股票代碼：002230)，為我們的控股股東

"iFlytek Information"	Anhui iFlytek Information Technology LLP (安徽科訊創業信息技術合夥企業(有限合夥)) (formerly known as "Anhui Kexun Venture Capital Fund Partnership (Limited Partnership) (安徽科訊創業投資基金合夥企業(有限合夥))"), a limited partnership established in the PRC on January 6, 2016, one of our Substantial Shareholders	「科訊創業」	指	安徽科訊創業信息技術合夥企業(有限合夥)(曾用名「安徽科訊創業投資基金合夥企業(有限合夥)」),於2016年1月6日在中國成立的有限合夥企業,為我們的主要股東之一
"Latest Practicable Date"	September 11, 2026, being the latest practicable date prior to the printing of this interim report for the purpose of ascertaining certain data contained in it	「最後實際可行日期」	指	2026年9月11日,即本中期報告付印前為確定其所載若干數據的最後實際可行日期
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time	「上市規則」	指	香港聯合交易所有限公司證券上市規則,經不時修訂、補充或以其他方式修改
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules, as amended, supplemented or otherwise modified from time to time	「標準守則」	指	上市規則附錄C3所載《上市發行人董事進行證券交易的標準守則》,經不時修訂、補充或以其他方式修改
"Nanjing Zhengchang"	Nanjing Zhengchang Technology Partnership (Limited Partnership)* (南京正昶科技合夥企業(有限合夥)), a limited partnership established in the PRC on December 9, 2022, one of our shareholding platforms	「南京正昶」	指	南京正昶科技合夥企業(有限合夥),於2022年12月9日在中國成立的有限合夥企業,為我們的持股平台之一
"Nanjing Zhenghui"	Nanjing Zhenghui Information Technology Partnership (Limited Partnership)* (南京正暉信息科技合夥企業(有限合夥)), a limited partnership established in the PRC on December 3, 2021, one of our shareholding platforms	「南京正暉」	指	南京正暉信息科技合夥企業(有限合夥),於2021年12月3日 在中國成立的有限合夥企業,為我們的持股平台之一
"Nanjing Zhengyang"	Nanjing Zhengyang Information Technology Partnership (Limited Partnership)* (南京正暘信息科技合夥企業(有限合夥)), a limited partnership established in the PRC on December 3, 2021, one of our shareholding platforms	「南京正暘」	指	南京正暘信息科技合夥企業(有限合夥),於2021年12月3日 在中國成立的有限合夥企業,為我們的持股平台之一

"Prospectus"	the prospectus of the Company dated December 18, 2024	「招股章程」	指	本公司日期為2024年12月18日的招股章程
"Reporting Period"	For the six months ended June 30, 2026	「報告期」	指	截至2026年6月30日止的六個月
"RMB"	Renminbi, the lawful currency of the PRC	「人民幣」	指	中國法定貨幣人民幣
"Securities and Futures Ordinance" or "SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time	「證券及期貨條例」	指	香港法例第571章《證券及期貨條例》，經不時修訂、補充或以其他方式修改
"Share(s)"	ordinary share(s) of RMB1.00 each in the share capital of the Company	「股份」	指	本公司股本中每股面值人民幣1.00元的普通股
"Shareholder(s)"	holder(s) of the Share(s)	「股東」	指	股份持有人
"subsidiary(ies)"	has the meaning ascribed to it in section 15 of the Companies Ordinance	「子公司」	指	具有公司條例第15條所賦予的涵義
"Substantial Shareholder(s)"	has the meaning ascribed to it under the Listing Rules	「主要股東」	指	具有上市規則所賦予的涵義
"treasury shares"	has the meaning ascribed to it under the Listing Rules	「庫存股份」	指	具有上市規則所賦予的涵義
"%"	percentage	「%」	指	百分比

Corporate Information
公司資料

NAME OF THE COMPANY

CHINESE NAME

訊飛醫療科技股份有限公司

ENGLISH NAME

Xunfei Healthcare Technology Co., Ltd.

DIRECTORS

EXECUTIVE DIRECTOR

Dr. Tao Xiaodong *(General Manager)*

NON-EXECUTIVE DIRECTORS

Dr. Liu Qingfeng *(Chairman)*
Mr. Zhao Zhiwei
Mr. Duan Dawei

INDEPENDENT NON-EXECUTIVE DIRECTORS

Prof. Wang Yang
Prof. Zhao Huifang
Mr. Tan Ching

AUDIT COMMITTEE

Prof. Zhao Huifang *(Chairwoman)*
Prof. Wang Yang
Mr. Duan Dawei

REMUNERATION COMMITTEE

Prof. Zhao Huifang *(Chairwoman)*
Mr. Zhao Zhiwei
Mr. Tan Ching

NOMINATION COMMITTEE

Dr. Liu Qingfeng *(Chairman)*
Prof. Zhao Huifang
Mr. Tan Ching

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) COMMITTEE

Dr. Liu Qingfeng *(Chairman)*
Dr. Tao Xiaodong
Prof. Wang Yang

公司名稱

中文名稱

訊飛醫療科技股份有限公司

英文名稱

Xunfei Healthcare Technology Co., Ltd.

董事

執行董事

陶曉東博士*（總經理）*

非執行董事

劉慶峰博士*（董事長）*
趙志偉先生
段大為先生

獨立非執行董事

汪揚教授
趙惠芳教授
談慶先生

審計委員會

趙惠芳教授*（主席）*
汪揚教授
段大為先生

薪酬委員會

趙惠芳教授*（主席）*
趙志偉先生
談慶先生

提名委員會

劉慶峰博士*（主席）*
趙惠芳教授
談慶先生

環境、社會及治理(ESG)委員會

劉慶峰博士*（主席）*
陶曉東博士
汪揚教授

JOINT COMPANY SECRETARIES

Dr. Liu Wei *(resigned on July 24, 2026)*
Ms. Yeung Siu Lam

聯席公司秘書

劉偉博士*（於2026年7月24日辭任）*
楊兆琳女士

AUTHORISED REPRESENTATIVES

Dr. Tao Xiaodong
Dr. Liu Wei *(resigned on July 24, 2026)*
Mr. Zhao Zhiwei *(appointed on August 18, 2026)*

授權代表

陶曉東博士
劉偉博士*（於2026年7月24日辭任）*
趙志偉先生*（於2026年8月18日獲委任）*

REGISTERED OFFICE AND HEAD OFFICE IN THE PRC

No. 666 Science and Innovation Road
Chengxiqiao Community Services Center, High-tech Zone
Hefei City, Anhui Province
PRC

註冊辦事處及中國總辦事處地點

中國
安徽省合肥市
高新區城西橋社區服務中心
科創路666號

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1922, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

香港主要營業地點

香港
銅鑼灣
希慎道33號
利園一期19樓1922室

H SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

H股證券登記處

卓佳證券登記有限公司
香港
夏愨道16號
遠東金融中心17樓

STOCK CODE

2506

股份代號

2506

COMPANY'S WEBSITE

https://www.iflyhealth.com/

公司網站

https://www.iflyhealth.com/

INDEPENDENT AUDITOR

Deloitte Touche Tohmatsu
Certified Public Accountants
Registered Public Interest Entity Auditors
35/F, One Pacific Place
88 Queensway
Hong Kong

獨立核數師

德勤•關黃陳方會計師行
註冊會計師
註冊公眾利益實體核數師
香港
金鐘道88號
太古廣場一期35樓

LEGAL ADVISORS TO OUR COMPANY

As to Hong Kong law:
Clifford Chance
27/F, Jardine House
One Connaught Place
Central
Hong Kong

As to PRC law:
CM Law Firm
Room 2805, Plaza 66 Tower 2
No. 1366 Nanjing West Road
Shanghai
PRC

PRINCIPAL BANKS

Huishang Bank Hefei High-Tech Zone Branch
No. 848 Changjiang West Road
Shushan District
Hefei, Anhui Province
PRC

China Merchants Bank Hefei Sanxiaokou Branch
CMB Building
No. 169 Funan Road
Luyang District
Hefei, Anhui Province
PRC

本公司法律顧問

有關香港法律：
高偉紳律師事務所
香港
中環
康樂廣場一號
怡和大廈27樓

有關中國法律：
上海澄明則正律師事務所
中國
上海市
南京西路1366號
恒隆廣場二期2805室

主要往來銀行

徽商銀行合肥高新區支行
中國
安徽省合肥市
蜀山區
長江西路848號

招商銀行合肥三孝口支行
中國
安徽省合肥市
廬陽區
阜南路169號
招銀大廈

In the first half of 2026, medical large models moved from a phase of technological exploration to a new stage of large-scale implementation, with vertical medical large models evolving towards multi-modal fusion and multi-AI agent collaboration. The continuous issuance of supportive national policies has accelerated the deep integration of artificial intelligence with public health, clinical diagnosis and treatment, and health management, providing a solid policy foundation and broad development space for the Company to deepen its presence in the smart healthcare market. Driven by technology innovation, policy support, and the demand for high-quality healthcare development, the Company's various businesses have encountered opportunities for accelerated development. Leveraging its leading medical large model technology and professional medical knowledge system, the Company continues to consolidate its core competitive advantages. With large model technology at its core, the Company has iteratively upgraded its three product systems–AI Medical Assistant, AI Health Partner, and AI Digital Base–and built a full-scenario AI empowerment matrix covering medical institutions, residents, and the government. The related products have achieved significant results in improving hospital operational efficiency, supporting residents' health management, and empowering industry supervision, laying a solid foundation for the Company's sustained high-quality development.

2026年上半年，醫療大模型由技術探索邁入規模化落地新階段，醫療垂直大模型向多模融合、多智能體協同方向演進。國家持續出台政策支持，人工智能與公共衛生、臨床診療、健康管理的深度融合進程不斷提速，為公司深耕智慧醫療市場提供了堅實政策保障與廣闊發展空間。在技術創新、政策利好與醫療高質量發展需求的共同驅動下，公司各項業務迎來加速發展機遇。公司依託領先的醫療大模型技術與專業醫學知識體系，持續夯實核心競爭優勢。以大模型技術為內核迭代升級AI診療助理、AI健康助手、AI數字基座三大產品體系，搭建起覆蓋醫療機構、居民、政府端的全場景AI賦能矩陣，相關產品在提升醫院運營效能、支撐居民健康管理、賦能行業監管等領域落地成效顯著，為企業持續高質量發展築牢根基。

I. CORE TECHNOLOGIES

Since the release of the industry's only medical large model trained on fully domestic computing power in 2023, the Company has continuously delved deeper into areas such as the construction of high-quality datasets, training of hospital-specific models, and R&D of medical professional AI agents, and has made continuous breakthroughs in key technical directions such as evidence-based inference and health interaction. In 2026, the Spark Medical Model V3.5 was officially released, with its core capabilities achieving a further leap and its technological level consistently remaining at the forefront of the industry.

一、核心技術

自2023年發佈業內唯一基於全國產算力訓練的醫療大模型以來，公司在高質量數據集構建、醫院專屬模型訓練、醫療專業智能體研發等方面不斷深耕，並在循證推理、健康交互等關鍵技術方向持續突破。2026年星火醫療大模型V3.5正式發佈，核心能力實現進一步躍升，技術水平持續保持業界領先。



Driven by continuous innovation and large-scale application, the Company's enduring world leadership stems from a double-helix evolutionary system built on a "technology foundation + closed-loop data ripple". On one hand, a fully domestic computing architecture, an authoritative medical knowledge base, and high-quality de-identified clinical data collectively form the Company's solid technology foundation. Leveraging this foundation, the Company has built systematic competitive barriers in underlying technological dimensions such as medical knowledge augmentation, deep reasoning architecture, and reinforcement learning from expert thinking chains. At the same time, it has established a knowledge reflection mechanism based on medical logic, a professionalism-oriented comment model, and a rationality-oriented process incentive model, comprehensively enhancing the medical large model's professionalism, operational safety, and clinical interpretability. On the other hand, with the large-scale deployment of products like the General Practice CDSS across the nation, over 1.7 million real-world diagnostic interactions per day are continuously accumulating high-value multi-modal model experience. In the vast majority of scenarios, the model's analytical results achieve a consistency rate of up to 95% with the diagnostic conclusions of practicing physicians, enabling the efficient accumulation and standardized retention of high-quality clinical diagnosis and treatment experience. In approximately 5.0% of complex cases, the system automatically triggers a review by a senior physician, precisely identifies key differences, and performs deep calibration using authoritative knowledge such as clinical guidelines and expert consensus. This creates a self-driven, dynamic learning loop that evolves from clinical practice to model improvement. With each cycle of feedback, the model continuously strengthens itself, building a hard-to-replicate evolutionary capability. This has laid a solid foundation for the iterative capability leaps of the Spark Medical Model across multiple generations.

在持續創新與規模化應用的共同驅動下，公司能夠長期保持世界領先地位，源於「技術底座+數據漣漪閉環」構建的雙螺旋式進化體系。一方面，全國產算力架構、權威醫學知識庫、高質量脱敏診療數據，共同構築起公司穩固的技術底座。依託該底座，企業在醫學知識增強、深度推理架構、專家思維鏈強化學習等底層技術維度構築了體系化競爭壁壘；同時搭建醫學邏輯知識反思機制、專業導向評語模型、合理性導向過程激勵模型，全方位提升醫療大模型的專業度、運行安全性以及臨床可解釋能力。另一方面，隨著智醫助理等產品在全國範圍內大規模落地，每天超過170萬次的真實診療交互持續沉澱高價值多模態模型經驗。在絕大多數場景中，模型研判結果與執業醫師診斷結論吻合度可達95%，能夠高效沉澱、標準化留存優質臨床診療經驗；在約5.0%的複雜案例中，系統會自動觸發上級醫生覆核，精準識別關鍵差異，並結合臨床指南、專家共識等權威知識進行深度校準。由此形成的從臨床實踐到模型進化的動態學習自驅閉環，使模型在每一次反饋中持續強化，構建出難以複製的演進能力，為星火醫療大模型多代迭代的能力躍遷奠定了堅實基礎。

(1) FULL-STACK UPGRADE OF SPARK MEDICAL MODEL X2: INDUSTRY-LEADING STRENGTH VALIDATED BY AUTHORITATIVE EVALUATIONS

In February 2026, the Spark Medical Model X2 completed its iterative upgrade. The model encompasses six core capabilities: massive medical knowledge Q&A, complex medical language comprehension, professional medical document generation, medical diagnosis and treatment plan recommendations, multi-round medical dialogues, and multi-modal medical interactions. Its overall performance improved from 91.2% to 91.6%, continuing to lead the industry. In terms of technical architecture, the Spark Medical Model X2 adopts a 293B MoE sparse architecture, combined with multiple engineering innovations such as weight quantization and low-precision KVCache, enabling efficient deployment on domestic platforms with a 50.0% improvement in inference performance compared to the previous generation.

The Spark Medical Model X2 has demonstrated excellent performance on key medical tasks: it achieved a rationality rate of 90.1% for intelligent analysis of resident health records, 89.2% for physical examination report interpretation, 92.7% for exercise and diet guidance recommendations, 92.4% for Top 5 auxiliary diagnosis and treatment plans, and an accuracy rate of 94.1% for intelligent medication review. Its comprehensive capabilities in core scenarios significantly surpass leading domestic and international large models. By virtue of its full-stack technical capabilities and mature implementation experience in medical scenarios, the Spark Medical Model was the first to pass the authoritative evaluation and verification by the Shanghai Medical Large Model Application Testing and Verification Center (上海市醫療大模型應用檢測驗證中心). It received all "A" ratings for tasks related to public health and well-being, such as resident health analysis, physical examination report interpretation, and exercise and diet recommendations, with its professional performance ranking at the forefront of the industry. This fully demonstrates the model's first-mover advantage, robust technical strength, and maturity in compliant implementation, building a solid foundation for its subsequent large-scale deployment and application in multiple scenarios.

（一） 星火醫療大模型X2全棧升級：權威評測驗證行業領先實力

2026年2月，星火醫療大模型X2完成迭代升級，模型涵蓋海量醫療知識問答、複雜醫療語言理解、專業醫療文書生成、醫療診療方案推薦、醫療多輪交互、醫療多模態交互六大核心能力，綜合效能由91.2%提升至91.6%，持續領跑行業。在技術架構上，星火醫療大模型X2採用293B MoE稀疏架構，結合權重量化、低精度KVCache等多種工程化創新，可在國產平台實現高效部署，推理性能較上一代版本提升50.0%。

星火醫療大模型X2在關鍵醫療任務方面表現優異：居民健康檔案智能分析合理率達90.1%，體檢報告解讀合理率達89.2%，運動飲食指導建議合理率達92.7%，輔助診療Top5方案合理率達92.4%，智能用藥審核準確率達94.1%，核心場景綜合能力顯著優於國內外主流大模型。憑藉在醫療場景下的全棧技術能力與成熟落地經驗，星火醫療大模型率先通過上海市醫療大模型應用檢測驗證中心權威評測驗證，其中，居民健康分析、體檢報告解讀、運動飲食建議等民生健康相關任務斬獲全A評級，專業性能位居行業前列。這充分彰顯了模型的先發優勢、硬核技術實力與合規落地成熟度，為後續多場景規模化落地應用築牢了堅實基礎。

(2) RELEASE OF UPGRADED SPARK MEDICAL MODEL V3.5: FIRST TO REACH PRACTICAL THRESHOLD FOR CORE INDUSTRY-DEMAND CAPABILITIES

In June 2026, the Company officially released the Spark Medical Model V3.5, trained on fully domestic computing power. The model comprehensively upgrades multi-modal capabilities in voice recognition, imaging-assisted diagnosis, and medical semantic understanding. It is the first to break through the practical implementation threshold in real-world medical scenarios for far-field multi-speaker voice recognition, automatic medical record generation, and automatic imaging report generation, with its imaging quality control capabilities surpassing the level of expert consultations.

Leveraging domestic computing platforms, the model has implemented efficient long-text training technology, increasing the throughput for long-context medical inference by 4.5 times. The average performance across its six core capabilities improved from 91.6% to 92.4%. It is highly adaptable to the needs of hospitals and regional healthcare for localized deployment and training based on local data. Meanwhile, through algorithmic iterations, high-quality medical data, and evidence-based reinforcement learning capabilities, the capabilities of AI agents for medical scenarios have been comprehensively enhanced, leading to a significant improvement in the practical capabilities of the entire medical product line.

（二） 星火醫療大模型V3.5升級發佈：行業剛需能力率先達到實用門檻

2026年6月，公司正式發佈基於全國產算力訓練的星火醫療大模型V3.5。模型全面升級語音識別、影像輔診、醫學語義理解多模態能力，率先突破真實醫療場景下遠場多人語音識別、病歷自動生成、影像報告自動生成的實用落地門檻，影像質控能力優於專家會診水平。

依託國產算力平台，模型實現高效長文本訓練技術落地，醫療長上下文推理吞吐量提升4.5倍，六大核心能力平均效果從91.6%提升至92.4%，高度適配醫院及區域醫療本地化部署與基於本地數據的訓練需求。同時，憑藉算法迭代、高質量醫療數據與循證強化學習能力，面向醫療場景的智能體能力全面提升，帶動全系醫療產品實用能力顯著提升。

In terms of performance on core medical tasks, the comprehensive performance of the Spark Medical Model V3.5 in key scenarios such as medical Q&A, document generation, auxiliary diagnosis, and multi-modal interaction significantly surpasses leading domestic and international large models, including GPT-5.5, DeepSeek-V4-Pro, and Qwen3.7-Max. According to the authoritative assessment in IDC's "China Medical Large Model Technology Assessment, 2026", the Spark Medical Model ranks first in the industry in terms of comprehensive strength. This assessment covered 15 core technical indicators. The model ranked first in the evaluation of 12 sub-capabilities, including auxiliary diagnosis, medical record generation, health consultation, post-discharge management and follow-up. It performed best in the dimensions of product implementation, operational safety, and large-scale application capability, fully verifying its leading technical strength and scenario adaptability. In addition, the model topped the list in the Shanghai Artificial Intelligence Laboratory's MedBench evaluation with a score of 98.9, ranking first in the industry across several core dimensions, including medical scenario perception and interaction, multi-AI agent collaboration in healthcare, and medical safety, ethics, and compliance.

在核心醫療任務表現上，星火醫療大模型V3.5在醫療問答、文書生成、輔助診斷、多模態交互等關鍵場景的綜合表現，顯著超越GPT-5.5、DeepSeek-V4-Pro、Qwen3.7-Max等海內外主流大模型。據IDC《中國醫療大模型技術評估，2026》權威測評，星火醫療大模型綜合實力位居行業第一。本次測評覆蓋15項核心技術指標，模型在輔助診斷、病歷生成、健康諮詢、診後管理及隨訪等12項細分能力測評中均斬獲榜首，在產品落地性、運行安全性、規模化應用能力維度表現最優，充分印證其領先的技術實力與場景適配能力。此外，模型在上海人工智能實驗室MedBench評測中以98.9分登頂榜單，在醫療場景感知與交互、醫療多智能體協作、醫療安全倫理與合規等多項核心維度位居行業首位。

During the Reporting Period, the upgrade of Spark Medical Model V3.5 achieved an innovative breakthrough in multi-modal technology, deeply integrating voice, imaging, and semantics supported by fully domestic computing power. It comprehensively enhanced the operational capabilities of AI agents in medical scenarios, achieved leapfrog breakthroughs from 0 to 1 in multiple capabilities within the two core tracks of clinical diagnosis and treatment for doctors and health management for residents, and was the first to meet the industry standard for large-scale practical implementation.

報告期內，星火醫療大模型V3.5的升級，實現了全國產算力支撐下語音、影像與語義深度融合的多模態技術創新突破，全面提升醫療場景智能體作業能力，在醫生臨床診療、居民健康管理兩大核心賽道實現多項能力從0到1的跨越式突破，率先達成行業規模化實用落地標準。

(3) CONTINUOUSLY PROMOTING THE STANDARDIZED DEVELOPMENT OF MEDICAL LARGE MODELS: CONTINUOUSLY DEEPENING STANDARDS DEVELOPMENT, SCIENTIFIC RESEARCH AND INNOVATION, AND ECOSYSTEM COLLABORATION

In terms of standards system development: The Company continued to play a leading role in the industry, further improving the standards system for medical large models. During the Reporting Period, two group standards, the "Specification for Construction of Healthcare Portrait System (《醫療健康畫像體系構建規範》)" (T/ISC 0112-2026) and the "Method for Evaluating the Capability and Effect of Large Models Based on Healthcare Portrait (《基於醫療健康畫像的大模型能力效果評估方法》)" (T/ISC 0110-2026), were officially released. These were led by Xunfei Healthcare, in collaboration with the China Academy of Information and Communications Technology (CAICT), relevant national and local health commissions, the People's Medical Publishing House, the Chinese Medical Association Publishing House, and over 30 top national medical institutions, including Peking Union Medical College Hospital and Beijing Anzhen Hospital. This initiative established the first standard framework covering the construction of healthcare portrait system and the capability evaluation of medical large models, forming a "system construction + capability evaluation" dual-engine standards system. It further improved the quality control, security governance of healthcare portraits, and the evaluation methods for medical large model capabilities, providing crucial standard support for the standardized development and large-scale application of medical artificial intelligence.

(三) 持續推進醫療大模型規範發展：標準建設、科研創新與生態協同持續深化

在標準體系建設方面：公司持續發揮行業引領作用，進一步完善醫療大模型標準體系。報告期內，由訊飛醫療牽頭，聯合中國信息通信研究院、國家及地方衛生健康委相關機構、人民衛生出版社、中華醫學會雜誌社以及北京協和醫院、北京安貞醫院等30餘家全國頂尖醫療機構，共同制定的《醫療健康畫像體系構建規範》(T/ISC 0112-2026)和《基於醫療健康畫像的大模型能力效果評估方法》(T/ISC 0110-2026)兩項團體標準正式發佈，首次搭建覆蓋醫療健康畫像體系構建與醫療大模型能力評估的標準框架，形成「體系構建+能力評估」雙輪驅動的標準體系，進一步完善了醫療健康畫像質量控制、安全治理及醫療大模型能力評價方法，為醫療人工智能規範化發展和規模化應用提供了重要標準支撐。

In terms of scientific research and innovation: The Company continued to strengthen its national-level scientific research capabilities and actively served the construction of the national public health system. The "Artificial Intelligence (AI)-Assisted Epidemiological Investigation System," jointly developed by the Public Health Emergency Center of the Chinese Center for Disease Control and Prevention (lead) and Xunfei Healthcare (core technical support), won the Gold Award at the 2nd "Chuang Qing Chun (創青春)" National Youth Innovation Competition for the Health Industry. An agreement of intent for the industrialization of the research results was signed concurrently, marking the official entry of this national-level scientific achievement into the nationwide large-scale promotion phase. The project originated from the "New Generation Artificial Intelligence" major project under the Sci-Tech Innovation 2030 Agenda. The Company was deeply involved in the core technology R&D, achieving significant breakthroughs in key technical areas for epidemiological investigation scenarios, such as specialized medical voice recognition, full-process intelligent human-computer interaction, and multi-modal intelligent data collection. This provided an innovative practice for empowering the construction of the public health emergency system with artificial intelligence and further enhanced the Company's technical influence and industrialization capabilities in major national scientific research projects.

在科研創新方面：公司持續強化國家級科研攻關能力，積極服務國家公共衛生體系建設。由中國疾病預防控制中心衛生應急中心牽頭、訊飛醫療作為核心技術支撐單位共同研發的「人工智能(AI)輔助流行病學調查系統」榮獲「創青春」第二屆全國衛生健康行業青年創新大賽金獎，並同步完成科研成果產業化轉化意向簽約，標誌著該國家級科研成果正式進入全國規模化推廣階段。該項目源自科技創新2030 —「新一代人工智能」重大項目，公司深度參與核心技術研發，圍繞流行病學調查場景，在專用醫療語音識別、全流程智能人機交互、多模態數據智能採集等關鍵技術方向取得重要突破，為人工智能賦能公共衛生應急體系建設提供了創新實踐，也進一步提升了公司在國家重大科研項目中的技術影響力和產業化能力。

In terms of business collaboration: The Company continued to deepen collaborative innovation with universities, research institutes, and leading medical institutions. It has established close cooperative relationships with several universities and Class A tertiary hospitals, including Zhejiang University, Qilu Hospital of Shandong University, Hainan General Hospital, and the First Affiliated Hospital of the University of Science and Technology of China. It released the "Hehe Huiyi (和合慧醫)" Knowledge Graph 2.0, the largest known Chinese clinical medical knowledge graph in the PRC, and simultaneously launched a new generation of primary care AI-assisted diagnosis and treatment systems, a whole-course disease management large model, and a series of clinical AI agents. This achieves deep integration of cutting-edge AI technology and authoritative medical knowledge in real-world diagnosis, treatment, and health management scenarios, continuously promoting the accessibility of quality medical resources, improving the quality and efficiency of clinical diagnosis and treatment, and advancing the large-scale implementation of medical artificial intelligence.

在業務協同方面：公司持續深化與高校、科研院所及頭部醫療機構的協同創新，先後與浙江大學、山東大學齊魯醫院、海南省人民醫院、中國科學技術大學附屬第一醫院等多家高校及三甲醫院建立緊密合作關係，發佈國內已知規模最大的中文臨床醫學知識圖譜 —「和合慧醫」知識圖譜2.0，並同步推出新一代基層AI輔助診療系統、全病程管理大模型及系列臨床智能體等，實現前沿AI技術與權威醫學知識在真實診療、健康管理場景中的深度融合，持續推動優質醫療資源下沉、臨床診療提質增效與醫療人工智能的規模化落地。

(4) ADVANCING CUTTING-EDGE TECHNOLOGY AND PRACTICAL APPLICATIONS: SOLIDIFYING CORE ADVANTAGES IN THE LARGE MODEL INDUSTRY DEPLOYMENT

(四) 堅守技術頂天、應用立地：築牢大模型行業落地核心優勢

Currently, the Company's medical LLMs continue to maintain the following advantages in terms of industry application:

當前，公司醫療大模型在行業落地方面持續保持以下優勢：

Multi-modal large model technology and systematic innovation capabilities: Achieved an innovative breakthrough in multi-modal technology with deep integration of voice, imaging, and semantics supported by fully domestic computing power, developed evidence-based reasoning technology for complex tasks featuring "evidence alignment — reflective verification — expert reinforcement", and comprehensively advanced the capabilities of the large model's clinical AI agents, becoming the first in the industry to cross the practical threshold for far-field multi-speaker voice recognition, automatic medical record generation, and automatic imaging report generation in real-world medical scenarios, thereby providing solid support for the high precision and multi-scenario adaptability of medical products.

多模態大模型技術及系統性創新能力：實現全國產算力支撐下語音、影像與語義深度融合的多模態技術創新突破，打造複雜任務「證據對齊 — 反思校驗 — 專家強化」循證推理技術，推動大模型臨床智能體能力全面進階，在業界率先跨越真實醫療場景下遠場多說話人語音識別與病歷自動生成、及影像報告自動生成的實用門檻，為醫療產品的高精準度與多場景適配築牢底層支撐。

Unique high-barrier data and knowledge accumulation in the industry: Achieved cross-modal alignment of data such as voice, images, and medical record text. The Spark Medical Model is continuously upgraded based on high-quality multi-modal medical datasets and an authoritative evidence-based medical knowledge base, learning clinical features from voice, imaging, and medical records in real clinical scenarios every day. Relying on the long-term accumulation of high-value medical resources, we have built a unique model iteration flywheel and autonomous evolution barrier in the industry.

行業獨有的高壁壘數據和知識沉澱：實現語音、影像、病歷文本等數據跨模態對齊，以高質量醫療多模態數據集和權威醫學循證知識庫為基礎持續升級星火醫療大模型，每天學習真實臨床場景中的語音、影像與病歷臨床特徵，依託高價值醫療資源的長期積累、構建起行業獨有的模型迭代飛輪和自主演進壁壘。

Systematic innovation capabilities combining general and specialized applications: Deeply integrated multi-modal capabilities of medical voice recognition, imaging-assisted diagnosis, and medical semantic understanding, being the first in the industry to break through the practical threshold for far-field multi-speaker voice recognition and automatic medical record generation in real-world medical scenarios. Building on imaging quality control that surpasses the level of expert consultations, the Spark Medical Model deeply integrates imaging recognition with diagnostic and treatment reasoning capabilities, enabling its imaging report generation capability to cross the practical threshold for the first time in the industry.

通專結合的系統性創新能力：深度融合醫療語音識別、影像輔診和醫學語義理解的多模態能力，在業界率先突破真實醫療場景下遠場多説話人語音識別與病歷自動生成的實用門檻；在影像質控超越專家會診水平的基礎上，星火醫療大模型將影像識別與診療推理能力深度結合，影像報告生成能力業界首次跨越實用門檻。

Fully localized and self-controllable hardware and software route: We possess a complete, integrated technical solution for efficient training and inference based on domestic computing platforms such as Huawei Ascend. We are the first to achieve efficient long-text training with DSA (Dynamic Sparse Attention) and MTP (Multi-Token Prediction) on domestic computing platforms, increasing inference throughput in long-context medical scenarios by 4.5 times. This provides strong underlying technical support for localized model deployment and efficient iteration in hospitals and regional healthcare.

軟硬件全國產化與自主可控路線：擁有完備的基於華為昇騰等國產化算力平台的高效訓練、推理的一體化技術方案，率先在國產算力平台上實現了DSA（動態稀疏注意力）與MTP（多Token預測）的長文本高效訓練，醫療長上下文場景推理吞吐量提升4.5倍，為醫院和區域醫療本地化模型部署及高效迭代提供了強大的底層技術支撐。

Unique system for large-scale deployment of core technologies in the industry: Leveraging the full-stack underlying capabilities of the Spark Medical Model, we have built a unique, end-to-end, replicable, and highly adaptable deployment and services system for medical AI. As one of the few companies capable of large-scale, nationwide commercialization of medical AI technologies in China, we have built a complete closed-loop system encompassing demand response, technology implementation and continuous iteration. We have successfully provided stable and standardized technical services to a massive user base, including graded hospitals, primary healthcare institutions, and regional imaging clouds, accumulating profound real-world clinical practice experience.

行業獨有的核心技術規模化落地體系：依託星火醫療大模型全棧底層能力，構建了行業獨有的全鏈路、可複製、高適配的醫療AI落地與服務保障體系，作為國內少數具備全國全域大規模醫療AI商業化落地能力的企業，擁有從需求響應、技術落地到持續迭代的完整閉環，已成功為等級醫院、基層醫療及區域影像雲等海量用戶提供穩定、標準化的技術服務，積累了深厚的真實臨床實踐經驗。

The enhancement of its core technology and product capabilities is attributable to the Company's unswerving investment in research and development (R&D). For the six months ended June 30, 2026, total R&D investment (including R&D expenses and development expenditures) was RMB194.8 million, an increase of 45.1% compared to the same period in 2025 (of which R&D investment in core technology amounted to RMB48.7 million, remaining largely unchanged from the prior period), accounting for 43.7% of the total revenue for the six months from January to June 2026.

核心技術及產品能力的提升得益於公司在研發領域堅定不移的投入。截至2026年6月30日止六個月，包括研發費用和開發支出在內的研發總投入為人民幣194.8百萬元，較2025年同期增加45.1%（其中核心技術研發投入為人民幣48.7百萬元，與上期基本持平），佔2026年1-6月總收入的43.7%。

II. BUSINESS REVIEW

In the first half of 2026, the Company actively pursued market expansion and continued to grow its customer base. As of June 30, 2026, the Company provided products and services to over 77,000 primary healthcare institutions, covering 828 districts and counties across 31 provinces, as well as more than 700 graded hospitals. The extensive market coverage underscores the technological leadership and market competitiveness of our AI-powered medical products. It also highlights the efficiency of our marketing system, laying a solid foundation for the next phase of rapid business development.

Leveraging its leading technological capabilities, extensive customer base, and brand recognition, the Company continues to improve its operational efficiency and seize new profit opportunities through synergistic commercialization strategies. For the six months ended June 30, 2026, the Company recorded revenue of RMB446.1 million, representing an increase of 49.4% as compared with the revenue of RMB298.6 million during the same period last year. For the six months ended June 30, 2026, the Company's gross profit was RMB236.1 million, reflecting an increase of 53.5% as compared with that of the same period last year. Our gross profit margin was 52.9%, maintaining at a reasonable high level with an increase of 1.4 percentage points from that of the same period last year, mainly due to the increase in the gross profit margin of the AI Digital Base business. As its product portfolio expands and matures, the Company anticipates rapid revenue growth alongside a relatively stable gross profit margin level.

二、業務回顧

2026年上半年，公司積極進行市場拓展，客戶基數持續增長。截至2026年6月30日，公司向超過7.7萬家基層醫療機構提供產品及服務，涵蓋31個省份828個區縣，以及700多家等級醫院。廣泛的市場覆蓋充分證明了公司AI醫療產品的技術領先性、市場競爭力以及公司營銷體系的效率，並為公司業務的下一步快速發展奠定了堅實的基礎。

依託領先的技術能力、廣泛的客戶群及品牌認可度，公司不斷提高運營效率，通過協同商業化戰略抓住新的盈利機遇。截至2026年6月30日止六個月，公司錄得收入人民幣446.1百萬元，較上年同期的收入人民幣298.6百萬元增加49.4%；截至2026年6月30日止六個月，公司的毛利為人民幣236.1百萬元，較上年同期的毛利增加53.5%；毛利率為52.9%，保持在合理的較高水平，較上年同期的毛利率增加1.4個百分點，主要因為AI數字基座業務毛利率提升。隨著公司產品的豐富及成熟，公司預期收入規模將快速增長，同時綜合毛利率水平相對穩定。

For the six months ended June 30, 2026, the Company's revenue was primarily derived from AI Medical Assistant and AI Health Partner businesses. The following table sets out a breakdown of its revenue by business segment for the periods indicated:

截至2026年6月30日止六個月，公司的收入主要來自於AI診療助理和AI健康助手業務，下表載列公司於所示期間按業務分部劃分的收入明細：

		Period ended June 30 Change 截至6月30日止期間變動							
		2026 2026年				2025 (As restated) 2025年（經重列）			
		Revenue 收入	**Percentage of total revenue 佔總收入**	**Gross profit 毛利**	**Gross profit margin 毛利率**	Revenue 收入	Percentage of total revenue 佔總收入	Gross profit 毛利	Gross profit margin 毛利率
		RMB in thousands 人民幣千元	**% %**	**RMB in thousands 人民幣千元**	**% %**	RMB in thousands 人民幣千元	% %	RMB in thousands 人民幣千元	% %
AI Medical Assistant	AI診療助理	**201,562**	**45.2%**	**112,981**	**56.1%**	136,674	45.8%	74,939	54.8%
AI Health Partner	AI健康助手	**182,387**	**40.9%**	**92,944**	**51.0%**	104,253	34.9%	64,003	61.4%
AI Digital Base	AI數字基座	**62,167**	**13.9%**	**30,186**	**48.6%**	57,625	19.3%	14,926	25.9%
Total	總計	**446,116**	**100.0%**	**236,111**	**52.9%**	298,552	100.0%	153,868	51.5%

To align with the Company's medium-and long-term strategic development, focus on improving the quality and efficiency of its core AI medical business, and further optimize resource allocation, the Company has integrated and upgraded its original four business lines into three major business segments: AI Medical Assistant, AI Health Partner, and AI Digital Base. Among them, "AI Medical Assistant" has taken over the business of the former primary solutions and hospital solutions; "AI Health Partner" corresponds to the former patient management services business; and "AI Digital Base" corresponds to the former regional solutions business.

為適配公司中長期戰略發展方向，聚焦AI醫療核心業務提質增效，進一步優化資源配置，公司將原有四大業務線整合升級為AI診療助理、AI健康助手、AI數字基座三大業務板塊。其中：「AI診療助理」承接原基層解決方案及原醫院解決方案業務；「AI健康助手」對應原患者管理服務業務；「AI數字基座」對應原區域解決方案業務。

Closely upholding its mission of becoming "an AI Medical Assistant for every doctor and an AI Health Partner for everyone", the Company, based on industry-leading artificial intelligence technology and in-depth industry insights, has created the AI Medical Assistant, AI Health Partner and AI Digital Base to empower medical institutions, patients and governments with AI, with its services mainly including:

1. AI Medical Assistant: Providing an intelligent support system for medical institutions to improve medical service quality, patient satisfaction, and management efficiency;

2. AI Health Partner: Providing patients with AI services throughout their entire life cycle, including the cloud medical imaging platform for auxiliary diagnosis, AI post-discharge patient management services, intelligent medical devices (intelligent hearing aids and AI blood pressure monitors), and the home health consultation and management APP (Xunfei Xiaoyi);

3. AI Digital Base: Providing AI Digital Base for the government to strengthen primary healthcare services, enhance disease prevention and control capabilities, and improve regional medical collaboration and health levels;

公司緊密圍繞成為「每個醫生的AI診療助理，每個人的AI健康助手」這一使命，基於業內領先的人工智能技術和深度的行業認知，打造了用AI賦能醫療機構、患者、政府的AI診療助理、AI健康助手及AI數字基座，其服務主要包括：

1. AI診療助理：為醫療機構提升醫療服務質量、患者滿意度、管理效率提供智能化支撐體系；

2. AI健康助手：為患者提供貫穿全生命週期的AI服務，包括影像雲與輔診平台、AI診後患者管理服務、以及智能醫療器械（智能助聽器、AI血壓計）及居家健康諮詢和管理APP（訊飛曉醫）；

3. AI數字基座：為政府強化基層醫療衛生服務、提升疾病防控能力、提升區域醫療協同和健康水平提供AI數字基座；



Driven by the dual engines of the "Digital China" strategy and the "Healthy China" initiative, China continually strengthened the deep integration and application of artificial intelligence in the healthcare sector. Since 2026, China has introduced a series of top-level designs and implementation policies to comprehensively strengthen the development of new healthcare infrastructure. By leveraging artificial intelligence and digital technologies, these initiatives aim to optimize medical resource allocation, facilitate the flow of quality resources to grassroots levels, and deepen public health reforms, providing all-around support for the high-quality development of public hospitals and the enhancement of primary healthcare capabilities.

In April 2026, the National Health Commission and the National Administration of Traditional Chinese Medicine launched a three-year action plan (2026–2028) to improve the quality of medical care in primary healthcare institutions. The plan aims to establish a basic medical quality management system for primary healthcare institutions nationwide by the end of 2028, incorporating village clinics and community health service stations into the system. The document also calls for strengthening the intelligent construction of county-level medical communities and primary healthcare institutions, and promoting the use of artificial intelligence to empower quality management in primary care.

在「數字中國」戰略和「健康中國」建設的雙重驅動下，國家持續加強人工智能在醫療健康領域的深度融合與應用。2026年以來，國家密集出台頂層設計與落地政策，全面加強新型醫療健康基礎設施建設，以人工智能與數字化技術優化醫療資源分配、促進優質資源下沉、深化公共衛生改革，全方位支撐公立醫院高質量發展與基層醫療服務能力提升。

2026年4月，國家衛生健康委、國家中醫藥局啟動基層醫療衛生機構醫療質量改善三年行動(2026–2028年)，提出到2028年底，全國基本建立基層醫療衛生機構醫療質量管理工作體系，村衛生室和社區衛生服務站納入醫療質量管理體系。文件同時要求加強智慧縣域醫共體、基層醫療衛生機構智慧化建設，推動人工智能賦能基層醫療質量管理。

In June 2026, the General Office of the National Health Commission issued the "Notice on Further Improving the Urban Community Health Service System and Enhancing Service Capabilities (《關於進一步健全城市社區衛生服務體系提升服務能力的通知》)," which identifies digitalization and intelligence as key measures to improve the quality and efficiency of primary care and promotes the digital and intelligent transformation of community health services. The document proposes supporting the large-scale application of medical artificial intelligence in community health institutions, promoting tools such as AI-assisted diagnosis, intelligent prescription audit, and voice-based electronic medical records to reduce the burden on primary healthcare workers and improve diagnostic and treatment efficiency; leveraging digitalization to improve basic public health and family doctor contract services, and achieving efficient health follow-ups and tiered health management for residents. It encourages the use of AI for full-process intelligent quality control of medical records, prescriptions, and doctor's orders to standardize primary medical documentation. The policy also requires integrating the information systems of communities and higher-level hospitals, unifying data standards, promoting the mutual interoperability and recognition of examination and test results, and building a collaborative digital network for hierarchical diagnosis and treatment.

2026年6月，國家衛健委辦公廳印發《關於進一步健全城市社區衛生服務體系提升服務能力的通知》，將數字化、智能化作為基層醫療提質增效關鍵舉措，推動社區衛生數智化轉型。文件提出，支持社區衛生機構規模化應用醫學人工智能，推廣AI輔助診斷、處方智能審核、語音電子病歷等工具，減輕基層醫護負擔、提升診療效率；依託數字化完善基本公衛與家庭醫生簽約服務，實現高效健康隨訪、居民分級健康管理。鼓勵利用AI對病歷、處方、醫囑實施全流程智能質控，規範基層醫療文書。政策同時要求打通社區與上級醫院信息系統，統一數據標準，推動檢查檢驗結果互通互認，搭建上下協同的分級診療數字化網絡。

In July 2026, the State Council issued the "Notice on the '15th Five-Year Plan' for National Health (《國民健康「十五五」規劃》)," advancing the digital and intelligent construction of national health by building a national platform for cross-provincial sharing of smart health examination and test results, enabling real-time access to medical images, mutual recognition of test results, and linkage of public health information. Strictly ensure information security and privacy protection. Promote real-time access for residents to their electronic health record homepage data. Advance the construction of intelligent application systems for compact county-level medical communities. Implement intelligent and embedded supervision based on electronic medical record information, and orderly promote the application of digital and intelligent technologies in scenarios such as auxiliary diagnosis and treatment, precision medicine, health management, medical insurance services, and elderly and disabled care.

2026年7月，國務院發佈《國民健康「十五五」規劃》的通知，推進全民健康數智化建設 — 建設國家智慧健康檢驗檢查結果跨省共享平台，實現醫學影像實時調閱、檢驗檢查結果共享互認、公共衛生信息對接聯動。嚴格信息安全和隱私保護。推動電子健康檔案首頁數據實現居民本人實時查詢。推進緊密型縣域醫共體智能應用體系建設。開展基於電子病歷信息的智能化和嵌入式監管，有序推動數智技術在輔助診療、精準醫療、健康管理、醫保服務、養老助殘等場景的應用。

Against the backdrop of national strategic guidance, continuous policy improvement, and the implementation of application scenarios, artificial intelligence is transforming from a technical tool into a core force for reshaping the healthcare service system. The Company's long-standing strategic direction is highly aligned with the medium- and long-term policies of the national healthcare system reform. Guided by national strategies such as the project to strengthen primary healthcare, the construction of compact county-level medical communities, the digital and intelligent transformation of healthcare, and the regulated development of AI-empowered healthcare, the Company will leverage its leading medical AI technology and full-scenario solutions to seize industry development opportunities and promote large-scale implementation with key base cities as fulcrums. Currently, AI Medical Assistant is in a window of opportunity for development, while the AI Health Partner has become a key theme in policy.

在國家戰略引領、政策持續完善、應用場景不斷落地的背景下，人工智能正由技術工具轉變為重塑醫療服務體系的核心力量。公司始終堅持的戰略方向和國家醫療體制改革的中長期政策高度契合，在醫療衛生強基工程、緊密型縣域醫共體建設、衛健數智化轉型、人工智能賦能醫療規範發展等國家戰略指引下，公司將依託領先的醫學AI技術與全場景解決方案，把握產業發展機遇，以根據地城市為支點推進規模化落地。當前AI診療助理迎來建設窗口期，AI健康助手成為政策主基調。

(1) AI MEDICAL ASSISTANT: CONTINUOUSLY EXPANDING ITS SCOPE BASED ON THE “GENERAL PRACTICE CDSS”

General Practice CDSS for Primary Care: The General Practice CDSS is a core artificial intelligence medical product designed for primary care scenarios. Powered by the continuously upgraded Spark Medical Model, the General Practice CDSS has achieved a comprehensive evolution of its core capabilities. It has newly expanded into innovative application scenarios driven by the large model, including medical record generation, diagnostic reasoning, interpretation of examination and test reports, medical knowledge Q&A, and AI-assisted traditional Chinese medicine diagnosis and treatment. It has also completed iterative upgrades of its two technical solutions for multi-source data auxiliary diagnosis and intelligent prescription audit. The product can empower primary healthcare services in an all-round way, effectively improving the diagnostic and treatment capabilities, service quality, and efficiency of primary care institutions, significantly reducing the risks of misdiagnosis, missed diagnosis, and medication errors, and strengthening the safety line of defense for primary medical care.

(一) AI診療助理：基於「智醫助理」不斷拓面

基層智醫助理：智醫助理是面向基層醫療場景打造的核心人工智能醫療產品。依託持續升級的星火醫療大模型，智醫助理實現了核心能力的全面進化，全新拓展大模型驅動的病歷生成、診斷推理、檢查檢驗報告解讀、醫學知識問答、中醫輔助診療等創新應用場景，並完成多源數據輔助診斷、智能處方審核兩大技術方案的迭代升級。產品可全方位賦能基層醫療服務，有效提升基層機構診療能力、服務質量與診療效率，顯著降低錯診、漏診及用藥失誤風險，築牢基層醫療診療安全防線。

From July 15 to 16, the Department of Primary Health of the National Health Commission held a promotion meeting on digital and intelligent empowerment of primary healthcare and the 2026 national primary healthcare policy training class in Hefei, Anhui. The meeting systematically deployed key tasks for the digitalization of primary healthcare nationwide and clarified the implementation path for the high-quality development of primary medical and health services. A number of benchmark achievements with significant demonstration value were showcased at the meeting, including the results of the regular implementation and application of the "General Practice CDSS" general practice auxiliary diagnosis system in benchmark regions across the country such as Anhui, Zhejiang, and Jiangxi; the Anhui provincial imaging cloud platform, the largest of its kind in the country, constructed and operated by Xunfei Healthcare; and the Anhui provincial consultation and referral service platform covering five levels: provincial, municipal, county, township, and village, intuitively demonstrating the mature and effective implementation of regional primary healthcare digitalization. After long-term practice and refinement in multiple regions and clinical scenarios, the Company's integrated primary digital and intelligent service system continues to release its empowering value. In areas such as improving the quality and efficiency of primary care, balancing regional medical resources, and upgrading family doctor contract services, it has formed a mature, replicable, quantifiable, and scalable operational service model.

7月15日至16日，國家衛生健康委基層衛生健康司於安徽合肥召開數智賦能基層衛生健康工作推進會暨2026年全國基層衛生健康政策培訓班，會議系統部署全國基層衛生健康數字化建設重點任務，明確了基層醫療衛生高質量發展的實施路徑。會議現場集中展示多項極具示範價值的標桿成果，包括「智醫助理」全科輔助診療系統在安徽、浙江、江西等全國標桿區域的常態化落地應用成果、訊飛醫療承建運營的全國規模最大的安徽省影像雲平台，以及覆蓋省、市、縣、鄉、村五級的安徽省會診轉診服務平台，直觀展現了區域基層衛生數字化建設的成熟落地成效。經過多區域、多臨床場景的長期實踐打磨，公司一體化基層數智服務體系持續釋放賦能價值，在基層診療提質增效、均衡區域醫療資源、升級家庭醫生簽約服務等領域，形成了可複製、可量化、可推廣的成熟運營服務模式。

During the Reporting Period, the Company continued to advance the construction of the Hefei pilot base project, positioning it as a key support platform for the engineering verification, scenario-based refinement, and large-scale delivery of medical artificial intelligence products. Focusing on scenarios such as primary care auxiliary diagnosis, multi-source data reasoning, prescription audit, interpretation of examination and test reports, medical knowledge Q&A, and AI-assisted traditional Chinese medicine diagnosis, the Company promoted the deep integration of large model capabilities with real-world primary care workflows. Through pilot verification, the Company has further strengthened its closed-loop capabilities, from algorithm capabilities, data adaptation, system integration, and deployment delivery to application feedback, providing support for the replication and promotion of the General Practice CDSS in multi-regional and multi-level primary healthcare institutions nationwide. The Company cooperated with the China Health Education Center (中國健康教育中心) to build an authoritative health knowledge platform that integrates health policies, technical guidelines, and health education materials, enhancing the professional health service capabilities of primary healthcare personnel while providing urban and rural residents with scientific, authoritative, personalized, convenient, and accessible health education and guidance services.

報告期內，公司持續推進合肥中試基地項目建設，將其作為醫療人工智能產品工程化驗證、場景化打磨和規模化交付的重要支撐平台，圍繞基層輔診、多源數據推理、處方審核、檢查檢驗報告解讀、醫學知識問答、中醫輔診等場景，推動大模型能力與基層真實診療流程深度融合。通過中試驗證，公司進一步強化了產品從算法能力、數據適配、系統集成、部署交付到應用反饋的閉環能力，為智醫助理在全國多區域、多層級基層醫療機構的複製推廣提供支撐。公司與中國健康教育中心合作，構建健康政策、技術指南、科普材料一體化的權威健康知識平台，提升基層醫療衛生人員的健康專業服務能力，同時為城鄉居民提供科學權威、個性化、便捷可及的健康科普與健康指導服務。

As of June 30, 2026, the General Practice CDSS has covered 31 provinces and cities and 828 districts and counties across China, serving over 77,000 primary healthcare institutions. To date, it has provided over 1.2 billion AI-assisted diagnostic suggestions and assisted in generating more than 490 million standardized electronic medical records. Meanwhile, the system has identified over 130 million inappropriate prescriptions and corrected more than 2.07 million clinically valuable diagnoses through alerts by the General Practice CDSS, demonstrating its powerful value in large-scale application.

截至2026年6月30日，智醫助理已覆蓋全國31個省市、828個區縣，服務超過7.7萬個基層醫療機構，累計提供AI輔診建議超12億次，輔助生成規範化電子病歷4.9億餘份。同時，系統累計識別不合理處方1.3億餘份，並經由智醫助理提醒而修正的有價值診斷207萬餘例，展現出強大的規模化落地應用價值。

In the future, the Company will continue to leverage the engineering verification capabilities of the Hefei pilot base project, combined with the R&D accumulation from the national key R&D program "Auxiliary Diagnosis Robot for Primary Healthcare Institutions" in areas such as primary care-specific large models, auxiliary diagnosis hardware and software systems, cloud-edge collaborative intelligent computing platforms, standard specifications, and application evaluation systems. This will continuously drive the evolution of the General Practice CDSS towards higher accuracy, stronger interpretability, better process integration, and broader scenario coverage, thereby helping to enhance primary healthcare services capabilities and the sinking of high-quality medical resources.

未來，公司將繼續依託合肥中試基地項目的工程化驗證能力，疊加國家重點研發計劃「基層醫療機構輔助診斷機器人」項目在基層醫療垂類大模型、輔助診斷軟硬件系統、雲邊協同智算平台、標準規範和應用評價體系方面的研發積累，持續推動智醫助理向更高準確率、更強可解釋性、更優流程嵌入、更廣場景覆蓋持續演進，助力基層醫療服務能力提升和優質醫療資源下沉。

Digital and Intelligent Family Doctor: Focusing on the two core scenarios of family doctor contract services and refined chronic disease management, it integrates multi-dimensional data sources such as public health, clinical diagnosis and treatment, and resident health records to build a dynamic resident health portrait and an intelligent chronic disease risk assessment system, continuously promoting the upgrade of primary healthcare services towards intelligence, efficiency, and precision. The product leverages large model capabilities to connect the service chain, building a closed loop of proactive resident health management and continuous services. It drives the transformation of the traditional family doctor contract model into a new model of proactive prediction, continuous service, and quantifiable assessment, creating a replicable and scalable primary digital and intelligent health service system.

數智家醫：聚焦家庭醫生簽約服務、慢病精細化管理兩大核心場景，整合公共衛生、臨床診療、居民健康檔案等多維度數據源，搭建動態居民健康畫像與慢病風險智能評估體系，持續推動基層醫療服務向智能化、高效化、精準化升級。產品依託大模型能力打通服務鏈路，構建居民主動健康管理與連續化服務閉環，推動傳統家庭醫生簽約模式向主動預判、持續服務、可量化考核的新型模式轉型，打造可複製、可規模化推廣的基層數智健康服務體系。

For residents, the product transforms professional clinical data into easy-to-understand health information, providing 7x24 personalized AI health consultation and continuous health intervention management services for the entire population. For high-risk health issues, the system can automatically connect with real family doctors, forming a closed-loop smart family doctor service model of "AI-first service + human-backed support." This achieves a closed-loop smart family doctor health service where residents' health problems can be asked at any time, are managed, and are followed up, effectively enhancing residents' sense of gain from contracted services.

面向居民，產品將專業臨床數據轉化為通俗易懂的健康信息，提供7×24小時個性化AI健康諮詢、持續化全人群健康干預管理服務。針對高風險健康問題，系統可自動對接真人家庭醫生，形成「AI前置服務+真人兜底承接」的閉環智慧家醫服務模式，實現居民健康問題隨時問、有人管、有承接的閉環式智慧家醫健康服務，切實提升居民對簽約服務的獲得感。

For family doctors, the product provides full-process intelligent empowerment tools. By automatically generating pre-consultation health summaries to improve reception efficiency, intelligently creating tiered to-do lists to prevent missed tasks, and managing key chronic disease populations in layers supplemented by batch intelligent follow-ups, it comprehensively reduces the administrative workload of family doctors and significantly enhances the overall efficiency of primary care services and public health management.

面向家庭醫生，產品提供全流程智能化賦能工具，通過自動生成診前健康摘要提升接診效率、智能生成分級待辦台賬避免工作漏辦、分層管控重點慢病人群並輔以批量智能隨訪，全方位減輕家醫事務性工作負擔，顯著提升基層診療服務與公共衛生管理的整體效能。

During the Reporting Period, the Digital and Intelligent Family Doctor accelerated its nationwide large-scale deployment and has now been implemented in over 120 key districts and counties in more than 10 provinces and cities, including Hainan Province, Longhua District and Bao'an District in Shenzhen, Tongzhou District in Beijing, Hefei City, and Jiuquan City. In addition, the Company undertook the development of the satisfaction survey system for residents contracted with family doctors for the Medical Administration Center of the National Health Commission (國家衛健委醫政醫管中心), helping to further strengthen the implementation of family doctor contracting services nationwide, promote the fulfillment of such contracts, and enhance the experience of contracted residents.

報告期內，數智家醫加速全國規模化部署，目前已在海南省、深圳龍華區、深圳寶安區、北京通州區、合肥市、酒泉市等10餘個省市的120餘個重點區縣完成落地。此外，公司還承接了國家衛健委醫政醫管中心家庭醫生簽約居民滿意度調查系統建設，助力全國進一步做實家庭醫生簽約服務，促進家庭醫生簽約履約，提高簽約居民感受度。

Hospital Medical Assistant: Targeting graded hospitals, the Company provides "three-in-one" integrated smart hospital solutions encompassing smart services, smart medical care, and smart management, with the aim of improving patient experience, enhancing the quality of medical services, and innovating big data applications. Currently, the solutions have been implemented in over 700 hospitals nationwide, including the First Affiliated Hospital of the University of Science and Technology of China, Peking Union Medical College Hospital, West China Hospital of Sichuan University, Qilu Hospital of Shandong University, Shandong Provincial Hospital, and the First Affiliated Hospital of Anhui Medical University, helping nearly 20 hospitals pass the Level 5 electronic medical record and Level 3 smart service evaluations.

醫院診療助理：公司面向等級醫院，以提升患者就醫體驗、醫療服務質量、創新大數據應用為目標，提供智慧服務、智慧醫療、智慧管理三位一體智慧醫院整體方案。目前方案已在中國科學技術大學附屬第一醫院、北京協和醫院、四川華西醫院、山東大學齊魯醫院、山東省立醫院、安徽醫科大學第一附屬醫院等全國700餘家等級醫院落地應用，助力近20家醫院通過電子病歷五級、智慧服務三級評測。

During the Reporting Period, the Sixth Affiliated Hospital of Sun Yat-sen University launched the "AI Medical Assistant" system. With the Spark Medical Model as its technical foundation, the system relies on the rich medical knowledge base and instruction orchestration embedded in the model to achieve real-time sharing and interaction of multi-modal diagnosis and treatment data, empowering clinical processes such as admission, ward rounds, surgery, and discharge. The product is now in regular use in 7 wards and 20 clinical teams, including colorectal surgery and medical oncology. As an essential application for the digital transformation of hospitals, AI Medical Assistant, with the core advantages mentioned above, has garnered high clinical recognition, strong scenario stickiness, and good replicability and scalability. Moving forward, the Company will continue to expand the specialty coverage and functional boundaries of its products, refine core capabilities, further broaden its commercialization space, and solidify its long-term growth momentum.

報告期內，中山大學附屬第六醫院上線「診療助理」系統。該系統以星火醫療大模型為技術底座，依託模型中內置的豐富醫學知識庫和指令編排，實現多模態診療數據的實時共享和交互，賦能入院、查房、手術、出院等診療環節。目前產品已在結直腸外科、腫瘤內科等7個病區、20個診療組常態化使用。作為醫院數字化轉型的剛需型應用，AI診療助理憑藉上述核心優勢，已具備高臨床認可度、強場景黏性與良好的複製推廣能力。未來，公司將持續拓展產品專科覆蓋與功能邊界，打磨核心能力，進一步拓寬商業化空間，夯實長期增長動能。

In addition, focusing on the core pain points and essential needs of empowering clinical research data and translating medical achievements in graded hospitals, the Company has deeply integrated the Spark Medical Model with core medical big data technologies to self-develop a hospital-wide AI research data platform. Using the collaboration project with Peking Union Medical College Hospital as a benchmark model, the Company has continuously expanded its partnership landscape, successively implementing projects in leading provincial and municipal hospitals such as the Affiliated Hospital of Hebei University in Hebei Province, Dongguan People's Hospital in Guangdong Province, and the First Affiliated Hospital of the University of Science and Technology of China. This has effectively broken down the barriers between clinical diagnosis and treatment and research applications, enabling the deep release of clinical data value and driving the continuous and large-scale growth of related businesses.

此外，公司聚焦等級醫院臨床科研數據賦能與醫學成果轉化的核心痛點與剛需，將星火醫療大模型與醫療大數據核心技術深度融合，自研打造全院級AI科研數據平台。公司以北京協和醫院合作項目為標桿樣板，持續拓展合作版圖，先後落地河北省河北大學附屬醫院、廣東省東莞市人民醫院、中國科學技術大學附屬第一醫院等省市級頭部醫院，有效打通臨床診療與科研應用壁壘，實現臨床數據價值深度釋放，推動相關業務持續規模化增長。

For the six months ended June 30, 2026, the Company recorded revenue of RMB201.6 million from AI Medical Assistant, representing an increase of 47.5% as compared to the same period in 2025, and accounting for 45.2% of its total revenue for the first half of 2026.

截至2026年6月30日止六個月，公司提供AI診療助理錄得收入人民幣201.6百萬元，較2025年同期增長47.5%，佔公司2026年上半年總收入的45.2%。

(2) AI HEALTH PARTNER: EXTENDING FROM IN-HOSPITAL MANAGEMENT TO HOME HEALTH

（二） AI健康助手：從院內管理延伸至家庭健康

In the C-end market, Xunfei Healthcare has developed the AI Health Partner for discharged patients and healthy individuals. Leveraging the cloud medical imaging platform for auxiliary diagnosis to provide digital imaging services and gradually build personal health records. Combined with the AI post-discharge management system and the Xunfei Xiaoyi C-end platform to undertake full-cycle health management services such as regular health consultations and rehabilitation follow-ups. Paired with self-developed intelligent medical devices, it implements an integrated hardware-software home health solution, extending medical services from in-hospital clinical diagnosis and treatment to the full spectrum of out-of-hospital home health management scenarios.

在C端市場，訊飛醫療面向出院患者和健康人群打造AI健康助手。依託影像雲與輔助診斷平台提供數字影像服務並逐步構建個人健康檔案；疊加AI診後管理系統、訊飛曉醫C端平台承接常態化健康諮詢、康復隨訪等全週期健康管理服務；同時搭配自研智能醫療器械，落地軟硬件一體化居家健康解決方案，實現醫療服務由院內臨床診療，向居家院外健康管理場景的全域延伸。

Cloud Medical Imaging Platform for Auxiliary Diagnosis: During the Reporting Period, the Company continued to promote the interoperability of medical imaging data, mutual recognition of examination results, and the implementation of AI in medical scenarios. It iterated and upgraded the construction and operation services of the Anhui provincial imaging cloud platform and replicated its mature platform architecture, operational experience, and ecosystem collaboration capabilities to other provinces. Currently, the Guangxi provincial cloud imaging project has been completed and implemented, and related projects in multiple other provinces are progressing in an orderly manner. This effectively accelerates the implementation of the "national network" for medical insurance cloud imaging.

影像雲與輔診平台：報告期內，公司持續推進醫療影像數據互通、檢查結果互認及AI醫療場景落地應用，迭代升級安徽省級影像雲平台的建設與運營服務，並將成熟的平台架構、運營經驗及生態協同能力對外省複製輸出。目前，廣西省級影像雲項目已建成落地，多個省份相關項目正有序推進，有效助力醫保影像云「全國一張網」建設提速落地。

In Anhui Province, the Company has built the PRC's largest regional platform for medical imaging data interoperability, sharing, and mutual recognition, and leverages the provincial imaging cloud platform to provide remote consultation and digital imaging services to all residents in the province. As of June 30, 2026, the Anhui provincial imaging cloud platform has connected over 1,980 medical institutions, covering nearly 100,000 physician workstations, has cumulatively aggregated over 160 million instances of imaging data, and provided over 12.7 million remote consultations and 90 million digital imaging services. The extensive institutional coverage, high-frequency clinical use, and continuous accumulation of imaging data collectively form the foundation for the platform to further expand value-added services such as intelligent quality control and imaging auxiliary diagnosis. The Company is currently actively exploring pan-imaging cloud services covering pathology, ECG, nuclear medicine, ultrasound, and endoscopy, as well as AI-SaaS service models, to further broaden its multi-layered and multi-scenario business models.

在安徽省內，公司已建成國內規模最大的區域醫學影像數據互聯互通與共享互認平台，並依託省級影像雲平台為全省居民提供遠程會診服務和數字影像服務。截至2026年6月30日，安徽省影像雲平台聯網醫療機構超過1,980家，覆蓋醫生工作站近10萬台，累計彙聚影像數據超過1.60億次，累計開展遠程會診服務超過1,270萬次、數字影像服務9,000萬次。廣泛的機構覆蓋、高頻的臨床使用和持續沉澱的影像數據，共同構成平台進一步拓展智能質控、影像輔助診斷等增值服務的基礎。公司目前正在積極探索覆蓋病理、心電、核醫學、超聲、內鏡等泛影像雲服務和AI-SaaS服務模式，進一步拓寬多層次、多場景的商業模式。

In February 2026, the Company won the bid for the Construction and Operation Project of the Imaging Cloud Platform of Guangxi Zhuang Autonomous Region, replicating and promoting the Anhui imaging cloud operation model nationwide. As of June 30, 2026, the platform had connected over 437 medical institutions, including over 370 Grade II and above hospitals, achieving 100% connectivity for all eligible Grade II and above hospitals. Currently, it covers over 70,000 physician workstations in Guangxi, with cumulative number of digital imaging services and data calls both exceeding 6.5 million. The project demonstrated outstanding delivery efficiency: the first hospital went live in 20 days, all tertiary hospitals were connected within 30 days, and full coverage of eligible secondary hospitals was completed in 90 days. It has become an industry benchmark case, recognized and featured in a special report by the National Healthcare Security Administration, and medical insurance departments from nine provinces (municipalities, autonomous regions) have visited for research and learning. Meanwhile, the Company is leveraging Guangxi's geographical advantages to establish an ASEAN imaging sharing center, promoting the cross-border extension of imaging data interoperability and AI-assisted diagnosis services.

2026年2月，公司中標廣西壯族自治區影像雲平台的建設和運營項目，將安徽影像雲的運營模式向全國複製推廣。截至2026年6月30日，平台聯網醫療機構超437家，二級及以上醫院超370家，符合條件的二級及以上醫院已實現100%接入；目前廣西覆蓋醫生工作站超7萬台，累計數字影像服務、數據調用量均超650萬次。該項目交付效率突出：20天首家醫院上線、30天實現全部三級醫院接入、90天完成達標二級醫院全覆蓋，成為行業標桿案例，獲國家醫保局認可並被專題報道，9個省（市、自治區）醫保部門前來調研學習。同時，公司依託廣西區位優勢佈局東盟影像共享中心，推動影像數據互通與AI輔診服務實現跨境延伸。

Leveraging the Xunfei Spark Medical Imaging Model, the Company continues to develop its intelligent imaging assistant, covering clinical processes such as intelligent quality control, intelligent image reading, and automatic report generation. Currently, the pilot application of AI report generation for certain modalities such as X-ray, CT, and MR has exceeded 900,000 cases, providing sufficient data support and scenario validation for the model's continuous iteration, optimization, and commercialization. Meanwhile, the Company has partnered with leading AI imaging vendors such as Shukun and InferVision to integrate their ecosystem partners' imaging auxiliary diagnosis services. It is exploring an annual service fee model based on disease types to continuously deepen the platform's value. As the number of connected institutions, accumulated imaging data, and clinical application scenarios continue to grow, the Company is gradually forming a business system with the platform as the entry point, data as the foundation, and AI as the incremental service. This lays the groundwork for participating in the construction of the national integrated medical insurance cloud imaging network and expanding sustainable operational space.

依託訊飛星火醫學影像大模型，公司持續打造智能影像助手，覆蓋智能質控、智能閱片、自動報告生成等診療環節。目前，X線、CT、MR等部分品類的AI報告生成功能試點應用量超90萬例，為模型持續迭代優化與商業化落地提供充足的數據支撐與場景驗證。同時，公司與數坤科技、推想醫療等頭部AI影像廠商達成合作，接入生態合作方的影像輔診服務，探索按病種年度服務費模式，持續深化平台價值。隨著聯網機構數量、影像數據沉澱及臨床應用場景持續增長，公司正逐步形成以平台為入口、以數據為基礎、以AI為增量服務的業務體系，為參與全國醫保影像雲一體化網絡建設、拓展可持續運營空間奠定基礎。

AI Post-discharge Patient Management: The Company has developed an AI-based post-discharge patient management platform. Through AI technology, it provides continuous, high-quality medical services to all hospital patients after discharge, addressing the gap in post-hospital care within the traditional healthcare system. Based on the Spark Medical Model, the platform analyzes all of a patient's clinical data during hospitalization. In accordance with relevant clinical guidelines and standards, and combined with the patient's personal health profile, it formulates and assists doctors in executing personalized rehabilitation management plans. Service scenarios cover the entire process, including health consultation, follow-up reminders, confirmation of follow-up data collection, medication guidance, rehabilitation education, and physician alerts for abnormal risk symptoms.

AI診後患者管理：公司打造了基於人工智能的AI診後患者管理平台，通過人工智能技術為全院患者提供離院後的延續性、高質量醫療服務，補齊了傳統醫療體系中院後醫療服務的缺失。平台基於星火醫療大模型對患者在院期間所有臨床數據進行分析，依據相關臨床指南和規範，結合患者個人健康畫像，制定並輔助醫生執行個性化康復管理方案，服務場景涵蓋健康諮詢、複診提醒、複診數據回收確認、用藥指導、康復宣教以及異常風險症狀醫生預警等全流程環節。

As the capabilities of the Spark Medical Model continue to iterate and upgrade, the platform can provide 7x24 interactive services with patients, supporting dialects from 14 provinces with a recognition accuracy of 92.3%. The platform adopts a tiered service model to precisely match patient needs: For patients with low-intervention needs, such as those with self-limiting diseases, the system automatically generates free rehabilitation management plans, providing basic services through regular AI phone follow-ups, follow-up reminders, and health education, and supports patients in initiating intelligent consultations at any time. For patients with key diseases that have a golden window for rehabilitation and complex recovery processes, the Company, in collaboration with hospitals, offers paid management services. It coordinates with the patient's attending physician, assigns health managers, and forms a patient management team to provide patients with richer, continuous medical services such as text/image consultations, video consultations, and regular health assessments. As of now, the paid services have covered 158 disease types, reaching approximately 53% of discharged patients from leading provincial hospitals.

隨著星火醫療大模型能力持續迭代升級，平台可實現與患者7×24小時全天候聯動服務，支持14省份方言，識別準確率達92.3%。平台採用分層服務模式精準匹配患者需求：針對自限性疾病等低干預需求患者，系統自動生成免費康復管理方案，通過常態化AI電話隨訪、複診提醒、健康宣教等方式提供基礎服務，支持患者隨時發起智能諮詢；針對存在康復黃金窗口期、康復流程複雜的重點病種患者，公司聯合醫院提供付費管理服務，協同患者的主管醫生，配備健康管理師，組建患者管理團隊，為患者提供圖文諮詢、視頻問診、定期健康評估等更豐富的連續性醫療服務。截至目前，付費服務已覆蓋158個病種，可觸達省級頭部醫院約53%的出院患者。

During the Reporting Period, the effectiveness of AI patient management and its outcomes continued to improve. The patient Net Promoter Score (NPS) increased from 50% last year to 56%, and the rehabilitation achievement rate for patients who purchased key disease-specific service packages remained above 96%. AI post-discharge patient management has established a tiered operational system ranging from free basic services to paid in-depth services, continuously driving growth in operating revenue and patient satisfaction. It provides a reusable and scalable practical paradigm for the refined development of smart hospitals and continuous, full-cycle patient health management.

報告期內，患者管理AI效果與管理成效持續優化，患者淨推薦值(NPS)由去年的50%升至56%，購買重點專病服務包患者的康復達標率保持在96%以上。AI診後患者管理已構建起從免費基礎服務到付費深度服務的分層運營體系，持續拉動運營收入增長和患者滿意度提升，為智慧醫院精細化建設、患者全週期連續性健康管理提供了可復用、可推廣的實踐範式。

Intelligent Medical Devices: The Company's smart hearing aids are equipped with its self-developed adaptive scene recognition system, which can perceive the user's environment in real time to precisely achieve core functions such as human voice enhancement and intelligent environmental noise reduction. Since the launch of its first in-ear hearing aid, the "Xiang Series (享系列)", in 2022, the Company has continuously iterated its acoustic technology and product forms to meet market demand, successively launching multi-category products such as the "Hongyu Series (鴻語系列)" (behind-the-ear), the "Xing Series" (behind-the-ear), and the "Yue Series" (behind-the-ear Pro), thereby enhancing its product matrix for all-scenario hearing health.

智能醫療器械：公司智能助聽器搭載公司自主研發的自適應場景識別系統，可實時感知用戶所處環境，精準實現人聲增強、環境智能降噪等核心功能。自2022年推出首款耳內式助聽器「享系列」以來，公司持續貼合市場需求迭代聲學技術與產品形態，陸續落地耳掛式「鴻語系列」、耳背式「星系列」、耳背式Pro「月系列」等多品類產品，完善全場景聽力健康產品矩陣。

In the first half of 2026, the Company completed a software iteration and upgrade for its core product "Xingyao (星耀)," and newly launched "Xingyao Pro (星耀Pro)," further optimizing the auditory experience and intelligent adaptation capabilities. As of June 30, 2026, the smart hearing aid business had established approximately 60 offline brand image stores and over 400 partner stores, creating an integrated online-to-offline marketing channel with continuously strengthening channel synergy.

2026年上半年，公司完成核心產品「星耀」的軟件迭代升級，全新推出「星耀Pro」，進一步優化聽覺體驗與智能適配能力。截至2026年6月30日，智能助聽器已佈局約60家線下品牌形象店，合作門店超400家，構建線上線下一體的營銷渠道，渠道協同效應持續增強。

In the home health field, the Company launched the iFLYTEK AI Cuff Blood Pressure Monitor X3/X5/X7 series products in April 2026. The products are equipped with the Spark Medical Model and innovatively integrate dual measurement algorithms of oscillometry and Korotkoff sound method, with a measurement error of only ±2mmHg, achieving in-hospital medical-grade accuracy. Leveraging the large model's capabilities, the equipment can generate personalized improvement plans based on personal health records, interpret blood pressure data in real time, and answer health questions, transforming into an exclusive virtual health manager that is "accurate, conversational, and analytical." This truly realizes a family health management model where "parents measure with ease, and children manage with convenience," marking the Company's gradual expansion from hearing health to the family health management field. The expansion of home-use intelligent medical devices not only provides users with reliable tools for continuous physiological indicator monitoring at home but also further enriches the data sources for personal health records, strengthening the data foundation for smart health services.

在家庭健康領域，公司於2026年4月推出科大訊飛AI臂筒血壓計X3/X5/X7系列產品。產品搭載星火醫療大模型，創新融合示波法與柯氏音法雙測量算法，測量誤差僅±2mmHg，精度達到院內醫用級標準。依託大模型能力，設備可基於個人健康檔案生成個性化改善方案，實時解讀血壓數據、解答健康疑問，化身「測得準、能對話、會分析」的專屬虛擬健康管家，真正實現「爸媽輕鬆測，子女方便管」的家庭健康管理模式，標誌著公司逐步從聽力健康延伸至家庭健康管理領域。家用智能醫療器械的拓展，不僅為用戶居家連續生理指標監測提供了可靠工具，也進一步豐富了個人健康檔案的數據來源，夯實了智慧健康服務的數據底座。

Xunfei Xiaoyi: During the Reporting Period, the Company continued to enhance its health consultation and management capabilities based on personal health records, providing users with more professional and authoritative health management services in the industry. While deepening its core product capabilities, Xunfei Xiaoyi continues to expand industrial ecosystem cooperation, deeply linking with primary healthcare institutions and hospitals at all levels to build a new paradigm of resident health management featuring "AI + family doctors + expert physicians". At the same time, it opens up and exports its medical large model technology capabilities to industry partners, creating an open, co-built, and shared medical and health ecosystem.

訊飛曉醫：報告期內，公司持續完善基於個人健康檔案的健康諮詢和健康管理能力，為用戶提供行業內更專業、嚴肅的健康管理服務。訊飛曉醫在深耕核心產品能力的基礎上，持續拓展產業生態合作，深度聯動基層醫療機構與各級等級醫院，構建「AI+家庭醫生+專家醫生」的居民健康管理新範式；同時面向行業夥伴開放輸出醫療大模型技術能力，打造共建共享的開放式醫療健康生態。

In February 2026, with the official release of the iFlytek Spark X2 Large Model, Xunfei Xiaoyi simultaneously completed the upgrade of the Spark Medical Model, achieving comprehensive improvements in health consultation capabilities such as multi-turn active inquiry, interpretation of examination and test reports, and interpretation of physical examination reports, thereby continuously consolidating its industry-leading advantage. As of June 30, 2026, the Xunfei Xiaoyi App had surpassed 35 million cumulative downloads and 200 million cumulative consultations. Through a comprehensive health profile and all-time health trajectory built with 170 types of tags, it now supports over 140 professional disease management pathways covering common chronic diseases in more than 20 departments, and has become a reliable digital tool for home-based rehabilitation and health management.

2026年2月，隨著科大訊飛星火X2大模型正式發佈，訊飛曉醫同步完成了星火醫療大模型的升級，在多輪主動問診、檢查檢驗單解讀、體檢報告解讀等健康諮詢能力全面實現提升，行業領先優勢持續鞏固。截至2026年6月30日，訊飛曉醫APP累計下載量突破3,500萬，累計諮詢量超2億次，通過170種標籤構建的全面健康畫像與全時段健康軌跡，已支撐140餘種專業疾病管理路徑，覆蓋20多個科室及常見慢性病，已成為居家康復與健康管理的可靠數字工具。

In March 2026, Xunfei Xiaoyi achieved a significant breakthrough in empowering regional family doctors. The Company, jointly with the Hainan Provincial Health Commission, launched "Ye Xiaoyi (椰曉醫)," deeply integrating AI family doctor capabilities into Hainan's primary healthcare service system to build a one-stop smart health service system for residents featuring "24-hour health consultation, risk warnings, and health service plans."

2026年3月，訊飛曉醫在賦能區域家庭醫生取得重要突破。公司與海南省衛健委共同發佈「椰曉醫」，將AI家庭醫生能力深度融入海南基層衛生服務體系，為居民構建起「24小時健康諮詢、風險預警、健康服務方案」的一站式智慧健康服務體系。

Meanwhile, Xunfei Xiaoyi continues to explore health management industry solutions for corporate clients such as pharmaceutical and insurance companies, continuously co-building new health management models with industry partners in areas like digital health management, chronic disease services, and employee health. In April 2026, Xunfei Healthcare signed a strategic cooperation agreement with CMRH Life. The two parties will fully leverage their core advantages in their respective fields, and through the comprehensive integration of technology, data, and ecosystems, jointly create a competitive "AI + Health + Insurance" innovative ecosystem. They will carry out comprehensive and systematic cooperation in areas such as corporate health management, refined services for specific diseases, and the intelligent upgrading of insurance services.

與此同時，訊飛曉醫持續探索面向藥企、保險等企業客戶的健康管理行業解決方案，在數字化健康管理、慢病服務、員工健康等領域持續與行業夥伴共建健康管理新模式。2026年4月，訊飛醫療與招商仁和人壽簽署戰略合作協議，雙方將充分發揮各自領域核心優勢，通過技術、數據、生態的全方位整合，共同打造具備行業競爭力的「AI+健康+保險」創新生態，圍繞企業健康管理、專病精細化服務、保險服務智能化升級等領域開展全方位、系統性合作。

For the six months ended June 30, 2026, the Company recorded revenue of RMB182.4 million from AI Health Partner, representing an increase of 74.9% as compared to the same period in 2025, and accounting for 40.9% of its total revenue for the first half of 2026.

截至2026年6月30日止六個月，公司提供AI健康助手錄得收入人民幣182.4百萬元，較2025年同期增長74.9%，佔公司2026年上半年總收入的40.9%。

(3) AI DIGITAL BASE: ACTIVELY IMPLEMENTING NATIONAL STRATEGIC DIRECTIVES

（三） AI數字基座：積極踐行國家戰略導向

Closely aligning with major national policy directives such as the "AI+" strategy and "Healthy China," the Company has built a diversified AI Digital Base system covering provincial, municipal, district, and county levels. These solutions are precisely tailored to meet the operational needs and development goals of clients at different tiers, driving the digital and intelligent transformation of the healthcare sector.

公司緊密圍繞國家「人工智能+」戰略、健康中國等重大政策導向，搭建覆蓋省市 — 區縣的多元化AI數字基座體系，精準匹配不同層級客戶的業務需求與發展目標，助力醫療健康領域數字化、智能化轉型。

For clients at the provincial, municipal, and county levels, the Company has developed three core digital bases that have achieved a market application landscape of broad coverage and deep implementation, as detailed below:

AI-Powered Urban Digital Base: The solution focuses on the reform and high-quality development of public hospitals. By deeply integrating medical big data with AI large models, it creates a "Resident Health Portrait" system that enables full-chain intelligent empowerment, from multi-source data integration, cleaning, and analysis to clinical decision support and health risk warning, providing precise data support for urban health management. Currently, the solution has been implemented in multiple cities, including Shanghai, Shenzhen, Hefei, Aksu, Jiuquan, and Yan'an. It builds a city-level collaborative platform for medical health data and intelligent services, fully unlocking the value of medical data to empower lifelong resident health management, while promoting the optimized allocation of medical resources and service coordination within regions. In May 2026, the Company took the lead in collaborating with entities such as Shanghai Municipality and the CAICT to formulate and release the PRC's first standard specification for large model-based resident health portraits. In the same month, at the Chinese side event of the 79th World Health Assembly, the "Jing'an AI-Driven Resident Health Portrait" was selected as a benchmark case for digital health in the PRC and included in the typical case library of "Empowering Primary Health Services with Digital Intelligence — China's Practice," demonstrating a significant industry-wide exemplary effect.

針對省、市、縣各級客戶，公司打造三大核心數字基座，已實現廣覆蓋、深落地的市場應用格局，具體如下：

AI城市數字基座：方案聚焦公立醫院改革與高質量發展，依託醫療大數據與AI大模型的深度融合，打造「居民健康畫像」系統，實現從多源數據整合、清洗、分析到臨床診療輔助決策、健康風險預警的全鏈條智能化賦能，為城市健康管理提供精準數據支撐。目前，該方案已在上海、深圳、合肥、阿克蘇、酒泉、延安等多個城市落地應用，構建城市級醫療健康數據協同與智能服務平台，充分釋放醫療數據價值，賦能居民全生命週期健康管理，推動區域內醫療資源優化配置與服務協同。2026年5月，公司牽頭聯合上海市、中國信通院等單位，牽頭制定並發佈國內首個大模型居民健康畫像標準規範。同月，在第79屆世界衛生大會中國邊會上，「靜安AI驅動居民健康畫像」作為中國數字健康標桿案例，入選「數智賦能基層醫療服務 — 中國實踐」典型案例庫，行業示範效應顯著。

AI Disease Control Digital Base: This solution has been implemented in four provinces: Shaanxi, Liaoning, Fujian, and Anhui. The contract value for the large model in both Shaanxi and Fujian provinces exceeded RMB10 million, leading the national market for large model digital bases in the public health sector. The solution leverages large model technology to enhance the capabilities of provincial disease control systems in surveillance and early warning, risk analysis, and emergency response. In the future, it is planned to be gradually extended to provincial disease control centers nationwide. In April 2026, the "Artificial Intelligence (AI)-Assisted Epidemiological Investigation System," jointly developed by the Company and the Chinese Center for Disease Control and Prevention, won the Gold Award at the 2nd "Chuang Qing Chun (創青春)" National Youth Innovation Competition for the Health Industry. Concurrently, an agreement of intent for the industrialization of this technological achievement was signed on-site. Through the "New Generation Artificial Intelligence" major project under the Sci-Tech Innovation 2030 initiative, the Company has achieved significant technological breakthroughs in key areas such as speech recognition for epidemiological investigation scenarios, full-process intelligent human-computer interaction, and multi-modal intelligent data collection, thereby establishing a comprehensive intelligent epidemiological investigation technology system. The signing of this industrialization agreement marks the official commencement of the nationwide, large-scale commercial promotion of this national-level research achievement.

AI疾控數字基座：該方案已在陝西、遼寧、福建、安徽四省落地應用，其中陝西和福建2省大模型合同額均超過千萬，領跑全國公共衛生領域大模型數字基座市場。方案依託大模型技術賦能省級疾控體系的監測預警、風險分析與應急處置能力提升，未來計劃逐步拓展至全國各省級疾控中心。2026年4月，公司與中國疾病預防控制中心聯合研發的「人工智能(AI)輔助流行病學調查系統」獲得「創青春」第二屆全國衛生健康行業青年創新大賽金獎，並在現場同步完成技術成果產業化轉化意向簽約。通過科技創新2030 —「新一代人工智能」重大項目，公司在流調場景專用語音識別、全流程智能人機交互、多模態數據智能採集等關鍵領域實現重要技術突破，構建起全流程智能流調技術體系。本次產業化簽約，標誌著該項國家級科研成果正式邁入全國規模化商業推廣階段。

AI Regional Collaborative Digital Base: Targeting the district and county levels, the Company is deeply involved in the planning, design, construction, and implementation of multiple projects focused on compact county-level medical communities, regional healthcare informatization, and primary healthcare capacity building (Strengthening Primary Healthcare Project). During the Reporting Period, the Company newly won bids for medical community and regional healthcare projects in areas such as Qingtongxia City and Weifang High-tech Zone, which are currently under steady construction. The Company will leverage its mature AI products and digital bases to help districts and counties integrate region-wide medical resources, optimize referral coordination mechanisms between different levels of care, and address the shortfalls in primary-level diagnostic and treatment capabilities, thereby continuously promoting the quality and efficiency of the county-level healthcare system and supporting its high-quality development.

For the six months ended June 30, 2026, the Company recorded revenue of RMB62.2 million from AI Digital Base, representing an increase of 7.9% as compared to the same period in 2025, and accounting for 13.9% of its total revenue for the first half of 2026.

AI區域協同數字基座：面向區縣級層面，公司深度參與多個緊密型縣域醫共體、區域醫療信息化及基層醫療服務能力提升（強基工程）項目的規劃設計與建設實施。報告期內新增中標青銅峽市、濰坊高新區等醫共體和區域醫療項目，目前正在穩步建設中。公司將依託成熟的AI產品與數字基座，助力區縣整合全域醫療資源、優化上下級轉診協同機制、補強基層診療能力短板，持續推動縣域醫療衛生體系提質增效、實現高質量發展。

截至2026年6月30日止六個月，公司提供AI數字基座錄得收入人民幣62.2百萬元，較2025年同期增長7.9%，佔公司2026上半年總收入的13.9%。

III. SOCIAL RESPONSIBILITY, STRATEGIC COOPERATION, AND INDUSTRY RECOGNITION

Xunfei Healthcare embraces the philosophy of "Tech for Warm, AI for Love." True to our founding mission of serving a Healthy China through artificial intelligence, we leverage core AI technologies to actively fulfill our corporate social responsibility across medical philanthropy, emergency assistance, and grassroots empowerment. By deeply integrating technological innovation with humanistic care, we contribute to national strategies and demonstrate, through concrete actions, the essence of tech for good — embodying the responsibility and commitment of a tech enterprise in the new era. Leveraging its clear development path and sustained technological barriers, the Company has received numerous authoritative industry awards, continuously consolidating its leading position. Its technological innovation and commercial value have been recognized by the capital market. The Company will, as always, remain true to its founding mission of safeguarding life and health with artificial intelligence, creating long-term value to reward its shareholders and society, and upholding the philosophy of "Tech for Warm, AI for Love."

三、社會責任、戰略合作與行業認可

訊飛醫療始終秉持「讓科技有溫度，讓AI暖人心」的理念，堅守「用人工智能服務健康中國」的初心，以核心AI技術為支撐，深度踐行企業社會責任，深耕醫療公益、應急幫扶、基層賦能等多個領域，將技術創新與人文關懷深度融合，既助力國家戰略落地，用實際行動詮釋科技向善的內涵，彰顯新時代科技企業的責任與擔當。憑藉清晰的發展路徑與持續的技術壁壘，公司榮獲多項行業權威獎項，龍頭地位持續鞏固，技術創新與商業價值獲得資本市場認可。公司將一如既往堅守人工智能守護生命健康的初心，以長期價值創造回饋股東與社會，讓科技有溫度，讓AI暖人心。

(1) SOCIAL PHILANTHROPY AND CORPORATE SOCIAL RESPONSIBILITY

1. Digital Healthy China Solution Presented at World Health Assembly, AI Resident Health Portrait Promoted Globally

In May 2026, during the 79th World Health Assembly, the PRC, along with nine other countries including Brazil and Ethiopia, hosted a side event themed "Shaping Future Health Systems for Equity and Access in Digital Era." Specially recommended by the National Health Commission, the AI-driven resident health portrait practice developed by Xunfei Healthcare was showcased as a benchmark case of primary digital health in the PRC, receiving widespread attention from international attendees. The project has covered over 1.49 million contracted residents in Shanghai and has been implemented in multiple other cities, including Shenzhen, Hefei, and Haikou. It has established a city-level health data collaboration platform, contributing a "China Solution" to global digital health governance.

(一) 社會公益與企業社會責任

1. 數字健康中國方案亮相世衛大會，AI居民健康畫像全球推介

2026年5月，第79屆世界衛生大會期間，中國聯合巴西、埃塞俄比亞等9國舉辦「數智時代構建更加公平可及的醫療衛生服務體系」主題邊會。經國家衛健委重點推介，由訊飛醫療承建的AI驅動居民健康畫像實踐作為中國基層數字健康標桿案例亮相，獲得國際與會嘉賓廣泛關注。該項目已在上海覆蓋超149萬簽約居民，並落地深圳、合肥、海口等多城，構建起城市級健康數據協同平台，為全球數字健康治理貢獻「中國方案」。

2. Proposals at the Two Sessions: "Using AI to Address Challenges in Chronic Disease Management and Rare Disease Prevention and Treatment"

During the National Two Sessions in March 2026, LIU Qingfeng, a deputy to the NPC, focusing on essential public needs for AI, proposed two key healthcare recommendations: using AI to help basic public health services address challenges in chronic disease management and health services, and establishing an access and regulatory system for AI applications in basic public health to include AI health services in the public health catalog; and advancing the "AI + Rare Diseases" special project and application pilots to comprehensively enhance prevention and treatment support, by establishing a national "AI + Rare Diseases" special project and conducting application pilots to promote "early screening, early detection, and early treatment" at the grassroots level. These recommendations, closely aligned with the "Healthy China" initiative under the "15th Five-Year Plan," reflect the Company's deep engagement in policy foresight and its concern for public welfare.

2. 兩會建言「以AI破解慢病管理與罕見病防治難題」

2026年3月全國兩會期間，全國人大代表劉慶峰圍繞AI民生剛需，提出兩項醫療重點建議：以AI助力基本公共衛生服務破解慢病管理與健康服務難題，建立基本公共衛生AI應用准入與監管體系，將AI健康服務納入公衛目錄；推進「AI+罕見病」專項與應用試點全面提升防治保障水平，設立「AI+罕見病」國家專項並開展應用試點，推動「早篩查、早發現、早診治」落地基層。建議緊扣「十五五」健康中國建設方向，體現了公司對政策前瞻與民生關切的深度參與。

3. Xunfei Smart Hearing Aid Enhances Rural Hearing Health for Two Consecutive Years

In January 2026, for the second consecutive year, the Xunfei Smart Hearing Aid was included in Liu Qiangdong's "New Year's Gifts for My Hometown (我給老家送年貨)" list. The initiative reached Guangming Village in Suqian, Jiangsu, providing free fitting services to over a thousand "left-behind" elderly residents. Featuring self-developed offline AI noise reduction technology, the product precisely addresses the pain points of rural hearing health. This represents the Company's ongoing practice of leveraging core technology to make inclusive healthcare more accessible to grassroots communities and serves as a warm testament to its "Tech for Good" philosophy.

3. 訊飛智能助聽器連續兩年點亮鄉村聽力健康

2026年1月，訊飛智能助聽器連續第二年入選劉強東「我給老家送年貨」清單，走進江蘇宿遷光明村，為千餘名留守老人提供免費驗配服務。產品搭載自研離線AI降噪技術，精準破解鄉村聽力健康痛點，是公司以硬核技術推動普惠醫療下沉的持續實踐，亦是「科技向善」理念的溫暖註腳。

(2) STRATEGIC COOPERATION AND BUSINESS PROGRESS

1. Breakthrough in Overseas Strategy: Partnering with Indonesia's Sinar Mas Group to Deepen Presence in the Southeast Asian AI Healthcare Market

Xunfei Healthcare entered into a strategic cooperation with PT DSST Mas Gemilang, a digital and intelligent infrastructure platform under Indonesia's Sinar Mas Group. The partnership innovatively adopts a "technology export + local ecosystem joint operation" model, where Xunfei Healthcare exports its full-stack AI medical technology and standardized solutions, while the Indonesian partner provides government and enterprise channels and localized operational support. The two parties will focus on core scenarios including AI systems for the full cycle of disease diagnosis and treatment, public health epidemic monitoring and early warning, and intelligent medical imaging. The cooperation will cover all levels of the Indonesian healthcare system. Xunfei Healthcare will use Indonesia as a strategic foothold to deepen its presence in the ASEAN market, continuously strengthening its strategic presence in the Southeast Asian digital and intelligent health industry.

（二）戰略合作與商業進展

1. 出海戰略破局：攜手印尼金光集團深耕東南亞AI醫療市場

訊飛醫療與印尼金光集團旗下數智基建平台PT DSST Mas Gemilang達成戰略合作，創新採用「技術輸出+本土生態聯營」模式，訊飛醫療輸出全棧AI醫療技術與標準化解決方案，印尼合作方提供政企渠道與本地化運營支撐。雙方聚焦疾病診療全週期AI系統、公共衛生疫情監測預警、智能醫學影像等核心場景，合作覆蓋印尼全層級醫療體系。訊飛醫療將以印尼為戰略支點深耕東盟市場，持續完善東南亞數智健康產業佈局。

2. Benchmark in Full-Course Disease Management: Deepening Strategic Cooperation with Qilu Hospital of Shandong University

Xunfei Healthcare signed a strategic cooperation agreement with Qilu Hospital of Shandong University to implement an intelligent follow-up platform centered on the jointly developed "Qilu·Spark Full-Course Disease Management Large Model." The two parties leverage the AI large model to integrate in-hospital and out-of-hospital data, building a continuous health management service that covers pre-hospital education, in-hospital coordination, and post-hospital monitoring and rehabilitation guidance. This forms a virtuous service loop of "discovery-feedback-improvement-enhancement," effectively improving the quality of medical services and the patient experience.

3. Establishing Presence in Hong Kong Science Park: Partnering with ALPHA CARE and CTI to Develop the Longevity and Health Industry

Xunfei Healthcare, in collaboration with ALPHA CARE and CTI, has officially established a tripartite deep strategic cooperation based in the Hong Kong Science Park. By integrating CTI's high-quality testing data, ALPHA CARE's professional health services, and Xunfei's AI clinical knowledge system, the partnership will build a full-chain, closed-loop "Data + Expert Knowledge + Intelligent Services" model. Using Hong Kong as an international pilot, it aims to create an innovative and globally replicable health management model.

2. 全病程管理標桿：與山東大學齊魯醫院戰略合作深化

訊飛醫療與山東大學齊魯醫院簽署戰略合作協議，以聯合研發的「齊魯·星火全病程管理大模型」為核心，落地智能隨訪平台。雙方以AI大模型打通院內外數據，構建覆蓋院前宣教、院中協同、院後監測及康復指導的連續性健康管理服務，形成「發現 — 反饋 — 改進 — 提升」的良性服務閉環，切實提升了醫療服務質量與患者就醫體驗。

3. 落戶香港科學園：攜手優家健康、華測檢測佈局長壽健康產業

訊飛醫療聯合優家健康、華測檢測，三方深度戰略合作正式落戶香港科學園。整合華測高質量檢測數據、優家專業健康服務與訊飛AI臨床知識體系，構建「數據+專家知識+智能服務」全鏈路閉環，以香港為國際化試點，打造可複製全球的健康管理創新模式。

(3) AWARDS, HONORS, AND INDUSTRY RECOGNITION

1. **Leading a National Key Sci-Tech Project to Build an AI Defense Line for Public Health**

   The national key sci-tech project led by Xunfei Healthcare, titled "AI Agent and Intelligent Warning Application System for Risk Assessment and Early Warning of New and Emerging Respiratory Infectious Diseases," was officially launched. Based on the Spark Medical Model, the project will build a full-chain AI warning system integrating risk assessment, intelligent analysis, automatic warning, and closed-loop response, thereby enhancing the nation's strategic biosecurity capabilities.

2. **Selected for the 2026 Future Healthcare Top 100, Highlighting Investment Value and Product Innovation**

   At the Vbdata.cn 2026 Future Healthcare & Pharma Top 100 Conference, Xunfei Healthcare was named one of the "Top 50 Most Investment-worthy Enterprises in the PRC's Healthcare Industry" for its GBC three-terminal, full-scenario closed-loop model; and the Xunfei Smart BTE Hearing Aid PRO was listed among the "Top 50 Most Innovative Products and Technologies in the PRC's Healthcare Industry" for its pioneering multimodal subtitled hearing assistance and deep-sea level noise reduction technology. These dual honors affirm the Company's leading position in the industry in terms of both capital market value and product technology.

（三）獎項榮譽與行業認可

1. **牽頭國家科技重大專項，構築公共衛生AI防線**

   訊飛醫療牽頭的《呼吸道新發突發傳染病風險評估及預警AI智能體和智慧化預警應用系統》國家科技重大專項正式啟動。項目以星火醫療大模型為底座，構建集風險評估、智能研判、自動預警、閉環處置於一體的全鏈條AI預警體系，助力國家生物安全戰略能力提升。

2. **入選2026未來醫療百強，彰顯投資價值與產品創新力**

   在動脈網2026未來醫療醫藥100強大會上，訊飛醫療憑藉GBC三端全場景閉環入選「中國醫療健康產業最具投資價值企業50強」；訊飛智能耳背式助聽器PRO憑藉首創多模態字幕助聽與深海級降噪技術，入選「中國醫療健康產業最具創新力產品技術50強」。雙重殊榮印證了公司在資本市場價值與產品技術維度的行業領軍地位。

3. Selected as One of Sichuan's First Batch of Typical Cases, Receiving Authoritative Endorsement for Grassroots Empowerment Achievements

The Health Commission of Sichuan Province announced the first batch of "AI + Healthcare" typical cases, which included multiple cases jointly submitted by Xunfei Healthcare with Xichong County, Yanyuan County, and Yibin City. The cases cover scenarios such as primary care and imaging quality control, demonstrating quantifiable and replicable results in enhancing primary diagnostic capabilities, optimizing public health service efficiency, and promoting regional medical resource collaboration. This fully validates the capability for large-scale implementation of AI in empowering primary healthcare and provides a regional model for the standardized and normalized promotion of "AI + Healthcare."

4. Xunfei Healthcare Wins Two HKMA Global Innovation Awards, Receiving International Authoritative Recognition for its AI Innovation in Healthcare

For its technological breakthroughs and large-scale implementation achievements in medical AI, Xunfei Healthcare won both the "Best in Healthcare Award" and the "Silver Award" at the "HKMA/HKT Global Innovation Award," co-organized by the Hong Kong Management Association (HKMA) and HKT, becoming a key award winner in the healthcare track of the competition. The "Best in Healthcare Award" is the highest honor in the healthcare category, while the "Silver Award" is a high-level comprehensive award. Winning both awards affirms the Company's professional depth in its vertical sector and the international competitiveness of its comprehensive innovation capabilities, accumulating authoritative brand endorsement for its global expansion.

3. 四川省首批典型案例入選，基層賦能成效獲權威背書

四川省衛健委公佈首批「人工智能+醫療衛生」典型案例，訊飛醫療聯合西充縣、鹽源縣、宜賓市申報的多個案例入選。案例覆蓋基層診療、影像質控等場景，在提升基層診療能力、優化公共衛生服務效率、推動區域醫療資源協同共享等方面形成可量化、可複製的實踐成效，充分驗證了AI賦能基層的規模化落地能力，為「人工智能+醫療健康」的規範化、標準化推廣提供了區域示範樣本。

4. 訊飛醫療榮獲HKMA環球創新獎雙料大獎，國際權威認證醫療AI創新實力

訊飛醫療憑藉在醫療人工智能領域的技術突破與規模化落地成效，摘得由香港管理專業協會(HKMA)與香港電訊(HKT)聯合主辦的「HKMA/HKT全球創新獎」的「最佳醫療獎」與「銀獎」兩項榮譽，成為本屆賽事醫療健康賽道的核心獲獎企業。「最佳醫療獎」為醫療健康領域專項最高榮譽，「銀獎」為綜合類高等級獎項，雙獎同獲印證了公司在垂直賽道的專業深度與綜合創新實力的國際競爭力，為國際化佈局積累了權威品牌背書。

5. Xunfei Xiaoyi Selected for MIIT's "Typical Cases of Digital Products and Services for the Elderly and Disabled"

The Ministry of Industry and Information Technology, together with five other departments including the Ministry of Civil Affairs, the Ministry of Transport, and the China Disabled Persons' Federation, announced the results of the "2025 Typical Cases of Digital Products and Services for the Elderly and Disabled" selection. Xunfei Xiaoyi stood out from hundreds of projects nationwide and was successfully selected as one of the 10 benchmark demonstrations in the innovative technology category, in recognition of its outstanding innovative practices in the age-friendly transformation of AI health services and accessible medical services. This selection signifies that the Company has received national-level authoritative recognition for fulfilling its "Tech for Good" mission and bridging the "digital divide."

5. 訊飛曉醫入選工信部「數字適老助殘產品和服務典型案例」

工信部聯合民政部、交通運輸部、中國殘聯等六部門公佈「2025年數字適老助殘產品和服務典型案例」評選結果，訊飛曉醫憑藉在AI健康服務適老化改造與無障礙醫療服務領域的突出創新實踐，從全國數百個項目中脱穎而出成功入選，成為10個創新技術類標桿示範之一。此次入選標誌著公司在履行科技向善使命、彌合「數字鴻溝」方面獲得國家級權威認可。

FINANCIAL REVIEW

REVENUE

The Company's total revenue increased by 49.4% from RMB298.6 million for the six months ended June 30, 2025 to RMB446.1 million for the six months ended June 30, 2026. Such increase was mainly attributable to the growth from AI Medical Assistant (47.5% year-on-year growth in revenue) and AI Health Partner (74.9% year-on-year growth in revenue).

COST OF SALES

The Company's cost of sales increased by 45.1% from RMB144.7 million for the six months ended June 30, 2025 to RMB210.0 million for the six months ended June 30, 2026, primarily due to the increase in costs as revenue grew.

財務回顧

收入

公司的總收入由截至2025年6月30日止六個月的人民幣298.6百萬元增加49.4%至截至2026年6月30日止六個月的人民幣446.1百萬元，該增加主要歸因於AI診療助理(收入同比增長47.5%)、AI健康助手(收入同比增長74.9%)帶來的增長。

銷售成本

公司的銷售成本由截至2025年6月30日止六個月的人民幣144.7百萬元增加45.1%至截至2026年6月30日止六個月的人民幣210.0百萬元，主要是伴隨著收入增長而帶來的成本增加。

GROSS PROFIT AND GROSS PROFIT MARGIN

The Company's gross profit increased by 53.5% from RMB153.9 million for the six months ended June 30, 2025 to RMB236.1 million for the six months ended June 30, 2026. The Company's gross profit margin was 51.5% and 52.9% for the six months ended June 30, 2025 and for the six months ended June 30, 2026, respectively, representing a small change.

毛利及毛利率

公司的毛利由截至2025年6月30日止六個月的人民幣153.9百萬元增加53.5%至截至2026年6月30日止六個月的人民幣236.1百萬元。公司的毛利率於截至2025年6月30日止六個月及截至2026年6月30日止六個月分別為51.5%及52.9%，毛利率波動較小。

IMPAIRMENT LOSSES UNDER EXPECTED CREDIT LOSS MODEL, NET OF REVERSAL

The Company's impairment losses under the expected credit loss model, net of reversal, increased by 329.9% from RMB3.2 million for the six months ended June 30, 2025 to RMB13.7 million for the six months ended June 30, 2026, primarily due to the increase in the balance of accounts receivable and the credit impairment loss rate during the period.

預期信貸虧損模型下的減值虧損(扣除撥回)

公司在預期信貸虧損模型下扣除撥回後的減值虧損由截至2025年6月30日止六個月的人民幣3.2百萬元增加329.9%至截至2026年6月30日止六個月的人民幣13.7百萬元，主要系本期應收賬款餘額增加及信用減值損失率增加所致。

OTHER GAINS AND LOSSES

The Company recorded other gains of RMB5.2 million for the six months ended June 30, 2025, compared to other gains of nil for the six months ended June 30, 2026, primarily due to a decrease in foreign currency exchange gains.

其他收益及虧損

公司於截至2025年6月30日止六個月錄得其他收益人民幣5.2百萬元，而於截至2026年6月30日止六個月錄得人民幣零百萬元，主要系匯兑收益減少所致。

SELLING EXPENSES

The Company's selling expenses increased by 0.1% from RMB102.1 million for the six months ended June 30, 2025 to RMB102.2 million for the six months ended June 30, 2026, remaining largely unchanged from the prior period.

銷售開支

公司的銷售開支由截至2025年6月30日止六個月的人民幣102.1百萬元增加0.1%至截至2026年6月30日止六個月的人民幣102.2百萬元，與上期基本持平。

ADMINISTRATIVE EXPENSES

The Company's administrative expenses decreased by 19.0% from RMB47.4 million for the six months ended June 30, 2025 to RMB38.4 million for the six months ended June 30, 2026, primarily due to a decrease in option costs and professional advisory fees.

行政開支

公司的行政開支由截至2025年6月30日止六個月的人民幣47.4百萬元減少19.0%至截至2026年6月30日止六個月的人民幣38.4百萬元，主要由於期權成本及中介諮詢費用減少所致。

RESEARCH AND DEVELOPMENT EXPENSES

The Company's research and development expenses increased by 32.2% from RMB114.5 million for the six months ended June 30, 2025 to RMB151.3 million for the six months ended June 30, 2026, primarily due to an increase in remuneration and intangible asset amortization.

研發開支

公司的研發開支由截至2025年6月30日止六個月的人民幣114.5百萬元增加32.2%至截至2026年6月30日止六個月的人民幣151.3百萬元，主要由於薪酬及無形資產攤銷增加所致。

FINANCE COSTS

The Company's finance costs decreased by 7.6% from RMB4.8 million for the six months ended June 30, 2025 to RMB4.5 million for the six months ended June 30, 2026, primarily due to a decrease in interest expense on borrowings.

財務成本

公司的財務成本由截至2025年6月30日止六個月的人民幣4.8百萬元減少7.6%至截至2026年6月30日止六個月的人民幣4.5百萬元，主要系借款利息支出減少所致。

INCOME TAX CREDIT

The Company's income tax credit amounted to RMB17.9 million and RMB19.5 million for the six months ended June 30, 2025 and for the six months ended June 30, 2026, respectively, primarily due to an increase in deferred income tax expense credit.

所得稅抵免

公司的所得稅抵免於截至2025年6月30日止六個月及截至2026年6月30日止六個月分別為人民幣17.9百萬元及人民幣19.5百萬元，主要系遞延所得稅費用抵免增加所致。

LOSS FOR THE PERIOD

Based on the foregoing, the Company's loss decreased by 41.5% from RMB82.3 million for the six months ended June 30, 2025 to RMB48.1 million for the six months ended June 30, 2026.

期內虧損

基於上文所述，公司的虧損由截至2025年6月30日止六個月的人民幣82.3百萬元減少41.5%至截至2026年6月30日止六個月的人民幣48.1百萬元。

NON-IFRS MEASURES

To supplement the Company's consolidated financial statements, which are presented in accordance with IFRS, the Company uses adjusted net loss for the period (non-IFRS measure) and adjusted net loss margin (non-IFRS measure) as additional financial measures, which are not required by, or presented in accordance with, IFRS. The Company believes that these non-IFRS measures help to compare operating results across periods and companies by eliminating the potential impacts of certain items. The Company believes that these non-IFRS measures, when presented in conjunction with the corresponding IFRS measures, provide useful information for potential investors and management by eliminating the potential impact of certain items, helping to compare the Company's operating performance across periods.

非國際財務報告準則計量

為補充公司根據國際財務報告準則呈列的綜合財務報表，公司使用經調整期內淨虧損(非國際財務報告準則計量)及經調整淨虧損率(非國際財務報告準則計量)作為額外財務計量，其不為國際財務報告準則所要求或根據國際財務報告準則呈列。公司認為該等非國際財務報告準則計量通過消除若干項目的潛在影響，幫助比較不同期間及公司的經營業績。公司認為，該等非國際財務報告準則計量與相應的國際財務報告準則計量一併呈列時，可通過消除若干項目的潛在影響，為潛在投資者及管理層提供有用資料，幫助比較公司各期間的經營業績。

The Company defines adjusted loss for the period (non-IFRS measure) as loss for the period adjusted by adding back equity-settled share-based payments. Equity-settled share-based payments are non-cash in nature and mainly refer to arrangements where the Company receives employee services as consideration for equity instruments. Equity-settled share-based payments are not expected to result in future cash payments. Listing expenses are expenses for professional fees, underwriting commissions and other expenses incurred in connection with the Global Offering. The use of non-IFRS measures as analytical tools has limitations, and they should not be considered in isolation or as a substitute for or superior to analysis of the Company's operating results or financial condition as reported under IFRS. In addition, the definition of non-IFRS measures may differ from similarly titled terms used by other companies.

公司將期內經調整虧損(非國際財務報告準則計量)界定為經加回以權益結算以股份為基礎的支付調整的期內虧損。以權益結算以股份為基礎的支付為非現金性質,主要指公司接受僱員服務作為權益工具代價的安排。以權益結算以股份為基礎的支付預計不會導致產生未來現金付款。上市開支為就全球發售產生的專業費用、包銷佣金及其他費用的開支。使用非國際財務報告準則計量作為分析工具存在局限性,不應將其視為獨立於或取代或優於公司根據國際財務報告準則所呈報的經營業績或財務狀況的分析。此外,非國際財務報告準則計量的定義可能與其他公司使用的類似術語有所不同。

The following table is a reconciliation of adjusted net loss for the period (non-IFRS measure) and adjusted net loss margin (non-IFRS measure) for the periods indicated:

下表為所示期間期內經調整淨虧損(非國際財務報告準則計量)與經調整淨虧損率(非國際財務報告準則計量)的對賬:

		Six months ended June 30, 截至6月30日止六個月	
		2026 2026年 RMB'000 人民幣千元	2025 2025年 RMB'000 人民幣千元
Loss and total comprehensive expense for the period	**期內虧損及全面開支總額**	**(48,100)**	(82,276)
Add: Equity-settled share-based payments	加:以權益結算以股份為基礎的支付	**5,157**	16,099
Adjusted net loss for the period (non-IFRS measure)	**期內經調整淨虧損(非國際財務報告準則計量)**	**(42,943)**	(66,177)
Adjusted net loss margin (non-IFRS measure) (%)	**經調整淨虧損率(非國際財務報告準則計量)(%)**	**(9.6)**	(22.2)

LIQUIDITY AND SOURCES OF FUNDS

For the six months ended June 30, 2026, the Company primarily met its cash requirements through bank borrowings and cash generated from operations. As at June 30, 2026 and December 31, 2025, the Company's cash and cash equivalents were RMB163.1 million and RMB123.6 million, respectively. Cash and cash equivalents of the Group are mainly held in RMB as at June 30, 2026.

The following table sets forth the Company's cash flows for the periods indicated:

流動資金及資金來源

於截至2026年6月30日止六個月，公司主要以銀行借款以及經營所得現金滿足現金需求。於2026年6月30日及2025年12月31日，公司的現金及現金等價物分別為人民幣163.1百萬元及人民幣123.6百萬元。於2026年6月30日，本集團的現金及現金等價物主要以人民幣持有。

下表載列公司於所示期間的現金流量：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB in millions** **人民幣百萬元**	2025 2025年 RMB in millions 人民幣百萬元
Net cash used in operating activities	經營活動所用現金淨額	**(181.6)**	(169.2)
Net cash from (used in) investing activities	投資活動所得(用)現金淨額	**203.7**	(24.2)
Net cash from financing activities	融資活動所得現金淨額	**17.3**	260.6
Net increase in cash and cash equivalents	**現金及現金等價物增加淨額**	**39.5**	67.2
Cash and cash equivalents at the beginning of the year	年初現金及現金等價物	**123.6**	676.8
Cash and cash equivalents at the end of the period, presented as bank balances and cash	**期末現金及現金等價物，以銀行結餘及現金列示**	**163.1**	743.9

Looking ahead, the Company believes that it will be able to meet its liquidity requirements by using cash generated from operating activities.

展望未來，公司認為能夠通過使用經營活動所得現金來滿足公司的流動性要求。

NET CASH USED IN OPERATING ACTIVITIES

For the six months ended June 30, 2026, the Company's net cash used in operating activities was RMB181.6 million, primarily due to loss before tax of RMB67.6 million, as adjusted by the non-cash and non-operating items, primarily comprising an increase in amounts due from an associate of RMB225.7 million, and such cash outflow was partially offset by (i) an increase in contract liabilities and amounts due to shareholders of RMB55.7 million; (ii) other intangible asset amortization of RMB29.2 million. For the six months ended June 30, 2025, the Company's net cash used in operating activities was RMB169.2 million, primarily due to loss before tax of RMB100.1 million, as adjusted by the non-cash and non-operating items, primarily comprising an increase in trade and other receivables of RMB62.7 million, and such cash outflow was partially offset by (i) equity-settled share-based payments of RMB16.1 million; (ii) other intangible asset amortization of RMB16.3 million.

經營活動所用現金淨額

於截至2026年6月30日止六個月，公司的經營活動所用現金淨額為人民幣181.6百萬元，主要是由於稅前虧損人民幣67.6百萬元，經非現金及非經營項目(主要包括應收聯營公司款項增加人民幣225.7百萬元)調整，且該等現金流出部分被(i)合同負債及應付股東款項增加人民幣55.7百萬元；(ii)其他無形資產攤銷人民幣29.2百萬元所抵銷。於截至2025年6月30日止六個月，公司的經營活動所用現金淨額為人民幣169.2百萬元，主要是由於稅前虧損人民幣100.1百萬元，經非現金及非經營項目(主要包括貿易及其他應收款項增加人民幣62.7百萬元)調整，且該等現金流出部分被(i)以權益結算以股份為基礎的支付人民幣16.1百萬元；(ii)其他無形資產攤銷人民幣16.3百萬元所抵銷。

NET CASH FROM/USED IN INVESTING ACTIVITIES

For the six months ended June 30, 2026, the Company's net cash from investing activities was RMB203.7 million, primarily due to the recovery of time deposits of RMB240.0 million, as partially offset by the expenditure for acquisition of equipment and intangible assets of RMB41.3 million. For the six months ended June 30, 2025, the Company's net cash used in investing activities was RMB24.2 million, primarily due to the expenditure for acquisition of equipment and intangible assets of RMB28.1 million.

投資活動所得╱所用現金淨額

於截至2026年6月30日止六個月，公司的投資活動所得現金淨額為人民幣203.7百萬元，主要是由於收回定期存款240.0百萬元，部分被購置設備及無形資產支出人民幣41.3百萬元所抵消。於截至2025年6月30日止六個月，公司的投資活動所用現金淨額為人民幣24.2百萬元，主要是由於購置設備及無形資產支出人民幣28.1百萬元。

NET CASH FROM FINANCING ACTIVITIES

For the six months ended June 30, 2026, the Company's net cash from financing activities was RMB17.3 million, primarily due to bank borrowings raised of RMB94.6 million, as partially offset by the repayment of bank borrowings of RMB73.3 million. For the six months ended June 30, 2025, the Company's net cash from financing activities was RMB260.6 million, primarily due to bank borrowings raised of RMB351.9 million, as partially offset by the repayment of bank borrowings of RMB83.2 million.

融資活動所得現金淨額

於截至2026年6月30日止六個月，公司的融資活動所得現金淨額為人民幣17.3百萬元，主要是由於所籌集銀行借款人民幣94.6百萬元，部分被償還銀行借款人民幣73.3百萬元所抵銷。於截至2025年6月30日止六個月，公司的融資活動所得現金淨額為人民幣260.6百萬元，主要是由於所籌集銀行借款人民幣351.9百萬元，部分被償還銀行借款人民幣83.2百萬元所抵銷。

INDEBTEDNESS

For the six months ended June 30, 2026, the Company had indebtedness in the form of bank borrowings and lease liabilities (both current and non-current). The Company did not have any outstanding mortgages, charges, debentures, other issued debt capital, bank overdrafts, borrowings, acceptance liabilities, or other similar indebtedness, any material guarantees, litigations, or claims that are pending or threatened against any member of our Group, or other material contingent liabilities.

債務

於截至2026年6月30日止六個月，公司有銀行借款及租賃負債等形式的債務(即期及非即期兩者)。公司並無任何未償還按揭、押記、債權證、其他已發行債務資本、銀行透支、借款、承兑負債或其他類似債務、本集團任何成員公司未決或面臨威脅的任何重大擔保、訴訟或申索或其他重大或有負債。

BANK BORROWINGS

As at June 30, 2026 and December 31, 2025, the Company's bank borrowings were RMB298.1 million and RMB276.8 million, respectively, which mainly refer to unsecured bank borrowings for working capital replenishment, all of which are repayable within three years. The Company's bank borrowings are all denominated in RMB. For the six months ended June 30, 2026, the interest rates of the Company's fixed-rate bank borrowings ranged from 2.11% to 2.40% per annum. As of August 18, 2026, the Company's unutilized committed banking facilities amounted to approximately RMB1,056.7 million.

銀行借款

於2026年6月30日 及2025年12月31日， 公司的銀行借款分別為人民幣298.1百萬元及人民幣276.8百萬元，指主要用於補充營運資金的無抵押銀行借款，均須於三年內償還。公司的銀行借款均以人民幣計值。於截至2026年6月30日止六個月，公司固定利率銀行借款的利率介乎每年2.11%至2.40%。截至2026年8月18日，公司的未動用已承諾銀行融資約為人民幣1,056.7百萬元。

GEARING RATIO

As of June 30, 2026, the Company's gearing ratio based on total liabilities/total assets was 62.2%. As of December 31, 2025, the Company's gearing ratio was 59.0%.

資本負債比率

截至2026年6月30日，以總負債／總資產計算，公司資產負債率為62.2%，截至2025年12月31日，公司資產負債率為59.0%。

CONTINGENT LIABILITIES

As of June 30, 2026, the Company did not have any material contingent liabilities (as at December 31, 2025: nil).

或有負債

截至2026年6月30日，公司並無任何重大或有負債(截至2025年12月31日：無)。

CAPITAL EXPENDITURES

For the six months ended June 30, 2026, the Company's capital expenditures were RMB41.3 million, primarily due to purchases of fixed assets and intangible assets. The Company primarily funds its capital expenditure needs with borrowings and cash generated from sales.

資本開支

於截至2026年6月30日止六個月，公司的資本開支為人民幣41.3百萬元，主要由於購置固定資產及無形資產所致。公司主要以借款及銷售所得現金撥付資本開支需求。

PLEDGE OF ASSETS

As of June 30, 2026, the Company did not have any material pledge of assets (as at December 31, 2025: nil).

資產抵押

截至2026年6月30日，公司並無任何重大資產抵押(截至2025年12月31日：無)。

MATERIAL INVESTMENTS HELD

As of June 30, 2026, (i) the Group held a direct investment in Anhui Heshu Zhiyi Technology Co., Ltd.* (安徽省合數智醫科技有限公司) ("**Heshu Zhiyi**") at a cost of approximately RMB186.7 million, representing a 49% equity interest; (ii) for the 6 months ended June 30, 2026, the Group recognised its share of relevant losses attributable to Heshu Zhiyi of approximately RMB5.5 million; (iii) for the 6 months ended June 30, 2026, the Group recognised unrealised gains on transactions with Heshu Zhiyi of RMB56.2 million; (iv) no dividend/profit distribution was received during the 6 months ended June 30, 2026. The book value of the investment in Heshu Zhiyi was RMB122.1 million, representing approximately 5.1% of the Group's total assets as at June 30, 2026. Heshu Zhiyi is a technology company focused on the construction and operation of pilot bases for medical artificial intelligence applications. Considering its core business and development prospects, the Group expects to receive financial returns from its investment in Heshu Zhiyi.

所持重大投資

截至2026年6月30日，本集團(i)直接持有安徽省合數智醫科技有限公司(「**合數智醫**」)投資的成本約為人民幣186.7百萬元，持有其49%的股權；(ii)截至2026年6月30日止6個月，本集團確認應佔合數智醫的相關損失約為人民幣5.5百萬元；(iii)截至2026年6月30日止6個月，本集團確認對合數智醫的交易中未實現收益為人民幣56.2百萬元；(iv)於截至2026年6月30日止6個月期間並無收取股息╱溢利分配。於合數智醫投資的賬面值為人民幣122.1百萬元，佔本集團於2026年6月30日的資產總額比率約為5.1%。合數智醫是一家專注於醫療人工智能應用中試基地建設與運營的科技企業。考慮到其核心業務及發展前景，本集團預期將從對合數智醫的投資中獲得財務回報。

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

As of June 30, 2026, the Company did not have other plans for material investments and capital assets (as at December 31, 2025: nil).

重大投資及資本資產的未來計劃

截至2026年6月30日，公司並無重大投資及資本資產的其他計劃(截至2025年12月31日：無)。

* *For identification purposes only*

MATERIAL ACQUISITIONS AND/OR DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

Reference is made to the announcement of the Company dated June 18, 2026 in relation to the deemed disposal of the subsidiary (the "**Announcement**"). Unless otherwise defined, terms used in this report shall have the same meanings as those defined in the Announcement.

On June 18, 2026 (after trading hours), the Existing Shareholders (including the Company) and Sanya Gaozhuo Jiayin entered into the Investment Agreement, pursuant to which, the parties agreed that Sanya Gaozhuo Jiayin shall pay RMB1,527,500 to Beijing Huiji to subscribe for the new registered capital of RMB1,294,500 of Beijing Huiji, and the balance (i.e., RMB233,000) will be credited to the capital reserve of Beijing Huiji. Upon completion of the capital contribution, the registered capital of Beijing Huiji will increase from RMB20,280,000 to RMB21,574,500, and the Company's equity interest in Beijing Huiji will decrease from 52.13% to 49.00%. Notwithstanding the foregoing, as the Company will maintain effective control over Beijing Huiji, its financial results will continue to be consolidated into the Company's consolidated financial statements.

Upon completion of the Investment Agreement, the Company's equity interest in Beijing Huiji will decrease from 52.13% to 49.00%. Therefore, the Investment Agreement constitutes a deemed disposal of the Company under Rule 14.29 of the Listing Rules.

For details, please refer to the Announcement.

Save as disclosed above, for the six months ended June 30, 2026, the Company did not have any material acquisitions and/or disposals of subsidiaries and affiliated companies.

FOREIGN EXCHANGE RISK

The functional currency of the Company's entities is RMB. During the Reporting Period, the Company primarily operated its business in the PRC. The Company does not currently have a foreign exchange hedging policy. However, the Company's management monitors foreign exchange risks and will consider hedging significant foreign exchange risks when necessary.

子公司及聯屬公司的重大收購及╱或出售

茲提述本公司日期為2026年6月18日之公告，內容有關視作出售附屬公司(「**該公告**」)。除非另有指明，本報告所用詞彙與該公告所界定者具有相同涵義。

於2026年6月18日(交易時段後)，現有股東(包括本公司)及三亞高卓佳音訂立投資協議，據此，訂約方同意三亞高卓佳音向北京惠及繳付人民幣152.75萬元認購北京惠及新增的人民幣129.45萬元註冊資本，餘額(即人民幣23.3萬元)將計入北京惠及的資本公積。出資完成後，北京惠及的註冊資本將從人民幣2,028萬元增加至人民幣2,157.45萬元，本公司於北京惠及之權益將由52.13%減少至49.00%，儘管如此，由於本公司將維持對北京惠及之實際控制權，其財務業績將繼續綜合計入本公司的綜合財務報表。

投資協議完成後，本公司於北京惠及持有的權益將由52.13%減少至49.00%。因此，根據上市規則第14.29條，投資協議構成本公司的視作出售。

有關詳情，請參閱該公告。

除上文所披露者外，於截至2026年6月30日止六個月，公司並無子公司及聯屬公司的重大收購及╱或出售。

外匯風險

公司的實體之功能貨幣為人民幣，於報告期內，公司主要在中國經營業務。公司目前並無外匯對沖政策，然而，公司的管理層監控外匯風險，並將於有需要時考慮對沖重大外匯風險。

FUTURE OUTLOOK

Adhering to a long-term philosophy and insisting on independent innovation in core source technologies, the Company, through long-term technological development and industry expertise, has grown into a leading enterprise in the PRC's AI healthcare sector, with an extensive business footprint and a market share that is consistently among the top in the industry. The Company has always been guided by its mission to be "an AI Medical Assistant for every doctor and an AI Health Partner for everyone," continuously deepening its focus on the intelligent healthcare sector, concentrating on core product value, and steadily expanding its industry-leading advantages.

Looking ahead, the Company will remain steadfast in its healthcare mission and vision, further clarify its business objectives, and focus on its core activities. In terms of AI Medical Assistant, the Company will leverage the advantages of its Hefei base, using the General Practice CDSS to penetrate the primary care market and establish nationwide control over the primary care sector. In terms of the AI Health Partner, the Company will continue to deepen its patient operation business system, focusing on refined operations to create a stable and profitable growth model, while continuously expanding its coverage of top-tier hospitals; and further explore multi-level, multi-scenario business models, from digital imaging services to pan-imaging cloud and AI-SaaS imaging. The Company will also leverage the organic combination of the real economy and financial capital to steadily expand its market coverage, explore new opportunities in AI healthcare, and advance steadily in the wave of digital health. By delivering health care through technology and fulfilling its social responsibilities with commitment, the Company will continue to create value for its shareholders.

未來展望

公司秉持長期主義理念，堅持源頭核心技術自主創新，憑藉長期技術攻堅與產業沉澱，已成長為中國AI醫療領域的領軍企業，業務版圖覆蓋廣泛，市場佔有率穩居行業前列。公司始終以「每個醫生的AI診療助理、每個人的AI健康助手」為使命，持續深耕智能醫療賽道，聚焦核心產品價值，穩步擴大行業領先優勢。

面向未來，堅定醫療使命、願景不動搖，進一步明確業務目標，聚焦核心業務。在AI診療助理方面，公司將立足合肥基地優勢，以智醫助理切入基層業務，建立全國基層控盤能力。在AI健康助手方面，將持續深耕患者運營業務體系，聚焦精細運營打造穩定盈利增長格局，不斷擴大頭部醫院覆蓋；從數字影像服務、到泛影像雲，再到AI-SaaS影像，進一步探索多層次、多場景的商業模式。公司還將依託實體經濟與金融資本的有機結合，穩步擴大市場覆蓋，探索AI醫療新機遇，在數字健康浪潮中穩健前行，以科技傳遞健康關懷、以擔當踐行社會責任，持續為股東創造價值。

EMPLOYEES, TRAINING, AND REMUNERATION POLICIES

As of June 30, 2026, our Group had 1,045 full-time employees (December 31, 2025: 1,045), most of whom are based in Hefei City, Anhui Province, China.

The remuneration package of employees generally includes basic salary and performance-based bonus. In general, the Group determines the remuneration package based on the qualifications, position and performance of its employees.

員工、培訓及薪酬政策

截至2026年6月30日，本集團擁有1,045名全職員工（2025年12月31日：1,045人），其中大部分員工位於中國安徽省合肥市。

僱員的薪酬待遇一般包括基本工資和績效獎金。一般而言，本集團根據僱員的資歷、職位及表現釐定薪酬待遇。

The Company provides employees with an insurance package consisting of pension insurance, maternity insurance, unemployment insurance, work-related injury insurance, medical insurance and housing funds, as required by Chinese laws and regulations. The Company offers a flexible work system to accommodate employees' flexible work needs and strictly enforce work hours and vacation policies to enhance work efficiency and employee satisfaction. The Company's dismissal procedures are structured to ensure fairness and legality. They include clear guidelines on performance management, regular feedback sessions, and a structured grievance redressal mechanism that employees can use to contest decisions or seek clarification. In addition, the Company maintains a zero-tolerance policy towards discrimination and harassment in the workplace. This policy is supported by mandatory training sessions on diversity and inclusion for all employees, regular reviews of workplace practices, and a confidential reporting system for any incidents of discrimination or harassment. The Company also regularly organizes health and safety training programs to improve employees' first aid knowledge and skills.

公司根據中國法律法規的規定為員工提供保險，包括養老保險、生育保險、失業保險、工傷保險、醫療保險及住房公積金。公司提供彈性工作制，以適應員工的彈性工作需求，並嚴格執行工作時間及假期政策，以提高工作效率及員工滿意度。公司的解僱程序旨在確保公平合法，其中包括明確的績效管理指引、定期反饋會議以及員工可用於質疑決定或尋求澄清的結構化申訴機制。此外，對工作場所中發生的歧視和騷擾行為實行零容忍政策。為支持該政策，所有僱員均須參加有關多元化及包容性的強制性培訓課程、定期檢討工作場所慣例，以及就任何歧視或騷擾事件設立保密報告制度。公司亦定期組織健康及安全培訓計劃，以提高僱員的急救知識及技能。

For the six months ended June 30, 2026, our total employee compensation and benefits expenses were RMB194.5 million.

截至2026年6月30日止六個月，員工薪酬福利開支總額為人民幣194.5百萬元。

The Group has adopted a share ownership plan to attract and retain the talents and to provide incentives to employees of our Group and talents who have made contribution to the development of our Group, for long-term development of our Company. Details of the share ownership plan are set out in the Prospectus.

本集團已採納一項持股計劃，以吸引及挽留人才，並向本集團員工以及對本集團的發展作出貢獻的人才提供激勵，以促進本公司的長期發展。持股計劃詳情載於招股章程。

The remuneration of the Directors and senior management is recommended by the Remuneration Committee and approved by the Board. The corporate goals and objectives set by the Board, the remuneration paid by comparable companies, the time and responsibilities committed by the Directors, and the employment conditions of other positions within the Group are taken into consideration in determining the remuneration of the Directors and senior management.

董事及高級管理層的薪酬由薪酬委員會提出建議及由董事會批准。在釐定董事及高級管理人員的薪酬時，會考慮董事會所訂企業方針及目標，同類公司支付的薪酬、董事付出的時間及職責以及本集團內其他職位的僱傭條件等。

SUBSEQUENT EVENTS

期後事項

There were no other material events subsequent to the Reporting Period and up to the Latest Practicable Date that would likely have a significant impact on the Group.

於報告期後及截至最後實際可行日期，並無其他可能對本集團造成影響的重大事件。

DIVIDENDS

The Board has resolved not to declare an interim dividend for the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2026, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including the sale of treasury shares). The Company did not hold any treasury shares as of June 30, 2026.

USE OF PROCEEDS FROM THE LISTING

The Company was listed on the Main Board of the Stock Exchange on December 30, 2024 (the "**Listing**"), issuing 7,035,550 new shares at an offer price of HK$82.80 per share, with net proceeds from the Listing of approximately HK$507.1 million after deducting underwriting commissions, fees and other expenses related to the Global Offering. The proceeds from the Listing will be utilized in accordance with the plans disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus, namely:

股息

董事會決議不宣派截至2026年6月30日止六個月之中期股息(截至2025年6月30日止六個月：無)。

購買、出售或贖回本公司的上市證券

截至2026年6月30日止六個月，本公司或其任何子公司概無購買、出售或贖回本公司任何上市證券(包括出售庫存股份)。於2026年6月30日，本公司並未持有任何庫存股份。

上市所得款項用途

本公司於2024年12月30日在聯交所主板上市(「**上市**」)，以每股82.80港元的發售價發行7,035,550股新股，扣除與全球發售有關的包銷佣金、費用及其他開支後，上市所得款項淨額約為507.1百萬港元。上市所得款項將按招股章程中「未來計劃及所得款項用途」一節所披露的計劃動用，即：

Item 項目	Percentage 百分比 % %	Proceeds to be used for related purpose and unutilized as at the beginning of the Reporting Period 用於相關用途且於報告期初尚未動用款項 (HK$ in millions) (百萬港元)	Utilized proceeds during the Reporting Period 於報告期內已動用款項 (HK$ in millions) (百萬港元)	Unutilized proceeds as of the end of the Reporting Period 於報告期末尚未動用款項 (HK$ in millions) (百萬港元)	Expected timetable for the fully utilizing of unutilized proceeds 悉數動用尚未動用款項的預期時間表
Investing in research and development to continuously reinforce our core competence 投資研發，以不斷加強我們的核心能力	32.3	83.2	56.6	26.6	By the end of December 2026 2026年12月底之前使用完畢
Further enriching our products and services through upgrading existing products and developing new products 通過升級現有產品及開發新產品進一步豐富我們的產品及服務	26.6	68.3	52.3	16.0	By the end of December 2026 2026年12月底之前使用完畢
Reinforcing our commercialization capabilities and expand our service network 加強商業化能力並擴展我們的服務網絡	24.7	74.9	40.1	34.8	By the end of December 2026 2026年12月底之前使用完畢
Acquiring companies that may generate synergy with our existing capacities, such as medical device manufactures 收購可能與我們現有產能產生協同效應的公司，例如醫療器械製造商	6.4	32.3	–	32.3	By the end of December 2026 2026年12月底之前使用完畢
Working capital and other general corporate purposes 營運資金及其他一般企業用途	10.0	1.6	–	1.6	By the end of December 2026 2026年12月底之前使用完畢
Total **總計**	**100**	**260.3**	**149.0**	**111.3**	

Note: The expected timetable for the fully utilizing of unutilized proceeds was based on the estimate of the Group, which is subject to the current and future development of the market conditions.

註： 悉數動用尚未動用款項的預期時間表乃基於本集團的預測作出，具體將取決於現時及未來市況的發展情況。

The Company has placed the net proceeds that have not yet been utilized in short-term interest-bearing accounts with licensed commercial banks and/or other authorized financial institutions. The Company will comply with PRC laws regarding foreign exchange registration and remittance of proceeds.

本公司已將尚未動用的所得款項淨額存放於持牌商業銀行及／或其他授權金融機構的短期計息賬戶。本公司將遵守有關外匯登記及所得款項匯款的中國法律。

SHARE OWNERSHIP PLAN

持股計劃

Our Group established a Share Ownership Plan (the "**Plan**") on September 1, 2021 to attract and retain the talents and to provide incentives to employees of our Group and talents who have made contribution to the development of our Group, for long-term development of our Company. The Plan became effective on September 15, 2021, and three employee shareholding platforms were established, namely Nanjing Zhengyang, Nanjing Zhenghui, and Nanjing Zhengchang. As the Plan will not involve the grant of new Shares or awards by our Company after the Listing, the terms of the Plan are not subject to the provisions of Chapter 17 of the Listing Rules.

本集團於2021年9月1日制定一項持股計劃（「**該計劃**」），以吸引及挽留人才，並向本集團員工以及對本集團的發展作出貢獻的人才提供激勵，以促進本公司的長期發展。該計劃自2021年9月15日起生效，並設立有三個員工持股平台，即南京正暘、南京正暉及南京正昶。由於該計劃不會涉及本公司於上市後授出新股份或獎勵，故該計劃的條款不受上市規則第17章的條文規限。

As of the Latest Practicable Date, awards corresponding to a total of 19,473,294 Shares (approximately 16.11% of the total number of Shares issued by our Company) under the Plan have been granted to eligible participants. No further Shares will be granted under the Plan after the Listing. Please refer to the Prospectus for further details regarding the Plan.

截至最後實際可行日期，該計劃項下的合共19,473,294股股份（約佔本公司已發行股份總數的16.11%）所對應的獎勵已授予合資格參與者。於上市後將不會根據該計劃進一步授出股份。有關該計劃的進一步詳情，請參閱招股章程。

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS AND CHIEF EXECUTIVE IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF OUR COMPANY AND ITS ASSOCIATED CORPORATIONS

董事及最高行政人員於本公司及其相聯法團之股份、相關股份及債券證之權益及淡倉

As at June 30, 2026, the interests and short positions of the following Directors and chief executive in the Shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as notified to the Company and the Hong Kong Stock Exchange under Divisions 7 and 8 of Part XV of the SFO or as recorded in the register required to be kept by the Company under Section 352 of the SFO or as otherwise notified to the Company and the Hong Kong Stock Exchange pursuant to the requirements in the Model Code, were as follows:

於2026年6月30日，下列董事及最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）的股份、相關股份及債券證中擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及香港聯交所，或根據證券及期貨條例第352條規定須予本公司備存之登記冊所記錄，或根據標準守則須知會本公司及香港聯交所的權益及淡倉如下：

(I) INTERESTS IN OUR COMPANY

(I) 於本公司的權益

					As at June 30, 2026 截至2026年6月30日	
Name 姓名	Position in the Company 於本公司的職位	Capacity/Nature of interest 身份／權益性質	Class of Shares held 所持股份類別	Number of Shares held[1] 所持股份數目[1]	Approximate percentage of shareholding in the relevant class of Shares[2] 於相關類別股份中的持股概約百分比[2]	Approximate percentage (in aggregate) of shareholding in the total issued share capital of our Company[2] 於本公司已發行股本總額中的持股概約百分比(總計)[2]
Dr. Liu Qingfeng 劉慶峰博士	Non-executive Director and Chairman 非執行董事及董事長	Interest held by controlled corporation[3] 受控法團所持權益[3]	Unlisted Shares 非上市股份	676,829	1.55%	1.12%
			H Shares H股	676,830	0.88%	

Notes:

1. All interests shown are long positions.

2. As at June 30, 2026, the number of unlisted Shares of the Company was 43,581,121 shares, the number of H Shares was 77,297,112 shares, and the total number of issued Shares was 120,878,233 shares.

3. Anhui Yanzhi holds 1.12% equity interest in the Company and is owned as to 69.5248% by Dr. Liu Qingfeng. Therefore, Dr. Liu Qingfeng is deemed to have an interest in the Shares held by Anhui Yanzhi.

附註：

1. 所示全部權益均為好倉。

2. 於2026年6月30日，本公司非上市股份數目為43,581,121股，H股股份數目為77,297,112股，已發行股份總數為120,878,233股。

3. 安徽言知持有本公司1.12%的股權，並由劉慶峰博士持有69.5248%。因此，劉慶峰博士被視為於安徽言知持有的股份中擁有權益。

(II) INTERESTS IN ASSOCIATED CORPORATIONS OF OUR COMPANY

(II) 於本公司相聯法團的權益

Name 姓名	Position in the Company 於本公司的職位	Name of associated corporation 相聯法團名稱	Nature of interest 權益性質	As at June 30, 2026 截至2026年6月30日 Number of Shares held in associated corporation[1] 所持相聯法團股份數目[1]	Approximate percentage of shareholding interest in the total share capital of the associated corporation 於相聯法團股本總額中的持股權益概約百分比
Dr. Liu Qingfeng 劉慶峰博士	Non-executive Director and Chairman 非執行董事及董事長	iFlytek 科大訊飛	Beneficial owner[2] 實益擁有人[2]	128,297,167	5.34%
			Interest held by controlled corporation[2] 受控法團所持權益[2]	57,291,611	2.39%
			Interest held through voting rights proxy arrangement[2] 通過表決權委託安排持有的權益[2]	84,431,161	3.51%
Mr. Duan Dawei 段大為先生	Non-executive Director 非執行董事	iFlytek 科大訊飛	Beneficial owner 實益擁有人	555,000	0.02%

Notes:

1. All interests shown are long positions.

附註：

1. 所示全部權益均為好倉。

2. As at June 30, 2026, Dr. Liu Qingfeng had interests in approximately 11.24% equity interests in iFlytek, among which, (i) Dr. Liu Qingfeng directly held approximately 5.34% equity interests in iFlytek; (ii) Anhui Yanzhi, which was held as to 69.5248% by Dr. Liu Qingfeng, held 2.39% equity interests in iFlytek; and (iii) certain individuals have respectively entrusted, among others, their voting power at general meetings of iFlytek, representing approximately 3.51% of the equity interests in iFlytek, to Dr. Liu Qingfeng.

2. 於2026年6月30日，劉慶峰博士於科大訊飛約11.24%的股權中擁有權益，其中，(i)劉慶峰博士直接持有科大訊飛約5.34%的股權；(ii)安徽言知(由劉慶峰博士持有69.5248%)持有科大訊飛2.39%的股權；及(iii)若干人士各自已委託(其中包括)其於科大訊飛股東會上的投票權予劉慶峰博士，佔科大訊飛約3.51%的股權。

Save as disclosed above, as at June 30, 2026, none of the Directors and the chief executive of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as notified to the Company and the Hong Kong Stock Exchange under Divisions 7 and 8 of Part XV of the SFO or as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and the Hong Kong Stock Exchange pursuant to the requirements of the Model Code.

除以上披露外，於2026年6月30日，概無本公司董事及最高行政人員於本公司或其任何相聯法團(定義見證券及期貨條例第XV部)的股份、相關股份及債券證中擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及香港聯交所，或本公司根據證券及期貨條例第352條規定須予備存之登記冊所記錄，或根據標準守則須知會本公司及香港聯交所的權益及淡倉。

During the Reporting Period, our Company did not grant any rights to subscribe for shares or debentures of our Company or any associated corporation to any of the Directors and chief executive (including their spouses or children under the age of 18) of the Company.

於報告期內，本公司並無授權本公司董事及最高行政人員(包括配偶或十八歲以下子女)認購任何本公司或任何相關法團股份或債權證的權利。

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN THE SHARES AND UNDERLYING SHARES

主要股東於股份及相關股份中的權益及淡倉

As at June 30, 2026, so far as is known to the Directors, the following persons (who are not Directors or chief executive of our Company) had interests or short positions in the Shares and underlying Shares of our Company as notified to our Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the Securities and Futures Ordinance, or which were recorded in the register required to be kept by our Company under Section 336 of the Securities and Futures Ordinance:

於2026年6月30日，就董事所知，下列人士(並非董事或本公司最高行政人員)於本公司股份及相關股份中擁有根據證券及期貨條例第XV部第2及第3分部的規定須知會本公司及香港聯交所，或本公司根據證券及期貨條例第336條規定須予備存之登記冊所記錄的權益或淡倉：

Name of Shareholder 股東名稱	Nature of interest 權益性質	Class of Shares 股份類別	Number of Shares held[1] 所持股份數目[1]	Approximate percentage of shareholding in the relevant class of Shares[2] 於相關類別股份中的持股概約百分比[2]	Approximate percentage (in aggregate) of the total registered capital of our Company[2] 佔本公司註冊股本總額的概約百分比(總計)[2]
iFlytek 科大訊飛	Beneficial owner 實益擁有人	Unlisted Shares 非上市股份	29,869,072	68.54%	50.93%
		H Shares H股	31,699,333	41.01%	
Hefei Zhengsheng Information Technology Partnership (Limited Partnership) ("**Hefei Zhengsheng**")[3] 合肥正昇信息科技合夥企業(有限合夥)(「**合肥正昇**」)[3]	Beneficial owner 實益擁有人	Unlisted Shares 非上市股份	9,736,647	22.34%	15.70%
		H Shares H股	9,239,247	11.95%	
Mr. Lu Xiaoliang[3] 鹿曉亮先生[3]	Interest in controlled corporation 於受控法團的權益	Unlisted Shares 非上市股份	9,736,647	22.34%	15.70%
		H Shares H股	9,239,247	11.95%	
Nanjing Zhengyang[3] 南京正暘[3]	Interest in controlled corporation 於受控法團的權益	Unlisted Shares 非上市股份	9,736,647	22.34%	15.70%
		H Shares H股	9,239,247	11.95%	
iFlytek Information[4] 科訊創業[4]	Beneficial owner 實益擁有人	H Shares H股	17,448,567	22.57%	14.43%

Name of Shareholder 股東名稱	Nature of interest 權益性質	Class of Shares 股份類別	Number of Shares held[1] 所持股份數目[1]	Approximate percentage of shareholding in the relevant class of Shares[2] 於相關類別股份中的持股概約百分比[2]	Approximate percentage (in aggregate) of the total registered capital of our Company[2] 佔本公司註冊股本總額的概約百分比(總計)[2]
Mr. Xu Jingming[456] 徐景明先生[456]	Interest in controlled corporation 於受控法團的權益	Unlisted Shares 非上市股份	626,524	1.44%	15.47%
		H Shares H股	18,075,092	23.38%	
Hefei Kexun Ruijin Investment Management Partnership (Limited Partnership) ("**Kexun Ruijin**")[4] 合肥科訊睿進投資管理合夥企業(有限合夥)(「**科訊睿進**」)[4]	Interest in controlled corporation 於受控法團的權益	H Shares H股	17,448,567	22.57%	14.43%
Anhui Development Investment Co., Ltd. ("**Anhui Investment**")[4] 安徽省開發投資有限公司(「**安徽投資**」)[4]	Interest in controlled corporation 於受控法團的權益	H Shares H股	17,448,567	22.57%	14.43%
iFlytek Haihe (Tianjin) AI Venture Capital Fund Partnership (Limited Partnership) ("**iFlytek Haihe**")[5] 訊飛海河(天津)人工智能創業投資基金合夥企業(有限合夥)(「**訊飛海河**」)[5]	Beneficial owner 實益擁有人	Unlisted Shares 非上市股份	476,524	1.09%	0.79%
		H Shares H股	476,525	0.62%	

Name of Shareholder 股東名稱	Nature of interest 權益性質	Class of Shares 股份類別	Number of Shares held[1] 所持股份數目[1]	Approximate percentage of shareholding in the relevant class of Shares[2] 於相關類別股份中的持股概約百分比[2]	Approximate percentage (in aggregate) of the total registered capital of our Company[2] 佔本公司註冊股本總額的概約百分比(總計)[2]
Hefei Kexun Lianshan Innovation Industry Investment Fund Partnership (Limited Partnership) (“**Kexun Lianshan**”)[6] 合肥科訊連山創新產業投資基金合夥企業(有限合夥)(「**科訊連山**」)[6]	Beneficial owner 實益擁有人	Unlisted Shares 非上市股份	150,000	0.34%	0.25%
		H Shares H股	150,000	0.19%	
Mr. Hu Guoping 胡國平先生	Beneficial owner 實益擁有人	H Shares H股	4,479,871	5.80%	3.71%
Shenzhen Tianzheng Investment Co., Ltd. (“**Tianzheng Investment**”)[7] 深圳市天正投資有限公司(「**天正投資**」)[7]	Beneficial owner 實益擁有人	H Shares H股	3,900,000	5.05%	3.23%
China Merchants Industry Development (Shenzhen) Limited (“**CMID**”)[7] 招商局實業發展(深圳)有限公司(「**招商局實業**」)[7]	Interest in controlled corporation 於受控法團的權益	H Shares H股	3,900,000	5.05%	3.23%
China Merchants China Direct Investments Limited (“**CMCDI**”)[7] 招商局中國基金有限公司(「**CMCDI**」)[7]	Interest in controlled corporation 於受控法團的權益	H Shares H股	4,238,150	5.48%	3.51%

Notes:

1. All interests shown are long positions.

2. As at June 30, 2026, the number of unlisted Shares of the Company was 43,581,121 shares, the number of H Shares was 77,297,112 shares, and the total number of issued Shares was 120,878,233 shares.

3. The general partner of Hefei Zhengsheng is Mr. Lu Xiaoliang. Nanjing Zhengyang holds 53.42% of the partnership interest in Hefei Zhengsheng. Therefore, Mr. Lu Xiaoliang and Nanjing Zhengyang are deemed to have interests in the Shares held by Hefei Zhengsheng.

4. The general partner of iFlytek Information is Kexun Ruijin, which has appointed Mr. Xu Jingming as its representative and is ultimately controlled by him. Anhui Investment holds approximately 49.83% of the partnership interest in iFlytek Information. Therefore, Mr. Xu Jingming, Kexun Ruijin and Anhui Investment are deemed to have interests in the Shares held by iFlytek Information.

5. The general partner of iFlytek Haihe is Tianjin Kexun Haihe Technology Partnership (Limited Partnership) ("**Tianjin Kexun**"), and the general partner of Tianjin Kexun is Hefei Kexun Venture Capital Management Partnership (Limited Partnership) ("**Hefei Kexun**"), which is ultimately controlled by Mr. Xu Jingming. Therefore, Mr. Xu Jingming is deemed to have an interest in the Shares held by iFlytek Haihe.

6. The general partner of Kexun Lianshan is Hefei Kexun, which is ultimately controlled by Mr. Xu Jingming. Therefore, Mr. Xu Jingming is deemed to have an interest in the Shares held by Kexun Lianshan.

7. Tianzheng Investment is wholly owned by CMID, which is wholly owned by CMCDI. Therefore, CMID and CMCDI are deemed to have interests in the Shares held by Tianzheng Investment.

Save as disclosed above, as at June 30, 2026, the Directors are not aware of any other persons (who are not Directors or chief executive of our Company) who had interests or short positions in the Shares and underlying Shares of our Company as notified to our Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the Securities and Futures Ordinance, or which were recorded in the register required to be kept by our Company under Section 336 of the Securities and Futures Ordinance.

附註：

1. 所示全部權益均為好倉。

2. 於2026年6月30日，本公司非上市股份數目為43,581,121股，H股股份數目為77,297,112股，已發行股份總數為120,878,233股。

3. 合肥正昇的普通合夥人為鹿曉亮先生。南京正暘持有合肥正昇53.42%的合夥權益。因此，鹿曉亮先生及南京正暘均被視為於合肥正昇持有的股份中擁有權益。

4. 科訊創業的普通合夥人為科訊睿進，而科訊睿進已委任徐景明先生作為其代表並受其最終控制。安徽投資持有科訊創業約49.83%的合夥權益。因此，徐景明先生、科訊睿進及安徽投資均被視為於科訊創業持有的股份中擁有權益。

5. 訊飛海河的普通合夥人為天津科訊海河科技合夥企業(有限合夥)(「**天津科訊**」)，而天津科訊的普通合夥人為合肥科訊創業投資管理合夥企業(有限合夥)(「**合肥科訊**」)，合肥科訊由徐景明先生最終控制。因此，徐景明先生被視為於訊飛海河持有的股份中擁有權益。

6. 科訊連山的普通合夥人為合肥科訊，合肥科訊由徐景明先生最終控制。因此，徐景明先生被視為於科訊連山持有的股份中擁有權益。

7. 天正投資由招商局實業全資擁有，而招商局實業則由CMCDI全資擁有。因此，招商局實業及CMCDI均被視為於天正投資持有的股份中擁有權益。

除以上披露外，於2026年6月30日，董事概不知悉有任何其他人士(並非董事或本公司最高行政人員)於本公司股份及相關股份中擁有根據證券及期貨條例第XV部第2及第3分部的規定須知會本公司及香港聯交所，或本公司根據證券及期貨條例第336條規定須予備存之登記冊所記錄的權益或淡倉。

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Our Company is committed to maintaining high standards of corporate governance to protect Shareholders' interests, enhance corporate value, and ensure accountability. The Company has adopted the Corporate Governance Code as its own code of corporate governance. To the best of the Directors' knowledge, our Company has complied with the applicable code provisions set out in Part 2 of the Corporate Governance Code during the six months ended June 30, 2026.

The Board will continue to review and monitor the Company's corporate governance practices to ensure compliance with the Corporate Governance Code and maintain high standards of corporate governance.

遵守企業管治守則

本公司致力於維持高水平的企業管治，以保障股東利益、提升企業價值及確保問責性。本公司已採納企業管治守則，作為其本身的企業管治守則。據董事所知，本公司於截至2026年6月30日止六個月已遵守企業管治守則第二部分載列的適用守則條文。

董事會將繼續檢討及監察本公司的企業管治常規，確保本公司遵守企業管治守則及維持高標準的企業管治常規。

COMPLIANCE WITH THE MODEL CODE

Our Company has adopted the Model Code as its code of conduct for securities transactions by Directors. Each of the Directors has confirmed, after making specific inquiries of all Directors, that they have complied with the Model Code during the six months ended June 30, 2026.

遵守標準守則

本公司已採納標準守則作為董事進行證券交易之守則。在向所有董事作出特定查詢後，各董事均確認彼等於截至2026年6月30日止六個月已遵守標準守則。

AUDIT COMMITTEE

The Company has established the Audit Committee in accordance with Rule 3.21 of the Listing Rules and the Corporate Governance Code. The Audit Committee comprises one non-executive Director (namely, Mr. Duan Dawei) and two independent non-executive Directors (namely, Prof. Wang Yang and Prof. Zhao Huifang). Prof. Zhao Huifang is the chairwoman of the Audit Committee.

Deloitte Touche Tohmatsu served as the independent auditor of our Company during the six months ended June 30, 2026. Deloitte Touche Tohmatsu and the Audit Committee have reviewed the Company's interim results and interim report for the six months ended June 30, 2026, and the financial statements contained in this interim report.

審計委員會

本公司已根據上市規則第3.21條及企業管治守則成立審計委員會。審計委員會由一名非執行董事(即段大為先生)及兩名獨立非執行董事(即汪揚教授及趙惠芳教授)組成。趙惠芳教授為審計委員會主席。

於截至2026年6月30日止六個月期間內，本公司獨立核數師由德勤•關黃陳方會計師行擔任。德勤•關黃陳方會計師行與審計委員會已審閱本公司截至2026年6月30日止六個月的中期業績及中期報告，及本中期報告所載財務報表。

CHANGES IN INFORMATION OF DIRECTORS AND CHIEF EXECUTIVE

Since the publication of the Company's 2025 annual report, the information of Directors and chief executive required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules is as follows:

Mr. Zhao Zhiwei has resigned as the executive director of Xi'an Xunfei Super Brain Information Technology Co., Ltd. (西安訊飛超腦信息科技有限公司), a subsidiary of iFlytek, in June 2026, Mr. Zhao was appointed as a director of Beijing Huiji Zhiyi Technology Co., Ltd. (北京惠及智醫科技有限公司) in January 2026. Mr. Zhao was also appointed as the legal representative, general manager and director of Anhui Yaofang Intelligent Technology Co., Ltd. (安徽爻方智能科技有限公司) in July 2026.

Save as disclosed above, no other information is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

SUBSEQUENT EVENTS

Save as disclosed in this interim report, there were no material events that have occurred in our Group from June 30, 2026 up to the Latest Practicable Date.

XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.
Dr. Tao Xiaodong
Executive Director

August 18, 2026

董事及最高行政人員的資料變動

自刊發本公司2025年年度報告以來，根據上市規則第13.51B(1)條須予披露的董事及最高行政人員資料如下：

趙志偉先生於2026年6月辭任科大訊飛子公司西安訊飛超腦信息科技有限公司執行董事。趙先生於2026年1月獲委任為北京惠及智醫科技有限公司董事。趙先生亦於2026年7月獲委任為安徽爻方智能科技有限公司法定代表人、經理及董事。

除上文所披露者外，並無其他資料須根據上市規則第13.51B(1)條作出披露。

期後事項

除本中期報告披露事項外，自2026年6月30日起直至最後實際可行日期，本集團並無發生任何重大事項。

訊飛醫療科技股份有限公司
執行董事
陶曉東博士

2026年8月18日

Report on Review of Condensed Consolidated Financial Statements
簡明綜合財務報表審閱報告

TO THE SHAREHOLDERS OF
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.
(訊飛醫療科技股份有限公司)
(incorporated in the People's Republic of China with limited liability)

致
訊飛醫療科技股份有限公司
股東
(於中華人民共和國註冊成立的有限公司)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of Xunfei Healthcare Technology Co., Ltd. ("**訊飛醫療科技股份有限公司**") (the "**Company**") and its subsidiaries (collectively referred to as the "**Group**") set out on pages 74 to 110, which comprise the condensed consolidated statement of financial position as at June 30, 2026, the condensed consolidated statement of profit or loss and other comprehensive income, the condensed consolidated statement of changes in equity and the condensed consolidated statement of cash flows for the six-months then ended, and notes to the condensed consolidated financial statements. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting" ("**IAS 34**") as issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

緒言

我們已審閱第74至110頁所載訊飛醫療科技股份有限公司(「**貴公司**」)及其子公司(統稱「**貴集團**」)的簡明綜合財務報表，簡明綜合財務報表包括於2026年6月30日的簡明綜合財務狀況表、截至該日止六個月期間的簡明綜合損益及其他全面收益表、簡明綜合權益變動表及簡明綜合現金流量表，以及簡明綜合財務報表附註。香港聯合交易所有限公司證券上市規則規定須編製中期財務資料報告，而該報告須符合其相關條文及由國際會計準則理事會頒佈的國際會計準則第34號「中期財務報告」(「**國際會計準則第34號**」)。 貴公司董事負責根據國際會計準則第34號編製及呈報此等簡明綜合財務報表。我們的責任為根據我們的審閱對此等簡明綜合財務報表作出結論，並根據我們協定的委聘條款，僅向 閣下(作為整體)報告我們的結論，除此之外，我們的報告不可用作其他用途。我們不就本報告的內容向任何其他人士承擔任何責任或接受任何義務。

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" ("**HKSRE 2410**") as issued by the Hong Kong Institute of Certified Public Accountants. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

審閱範圍

我們已根據香港會計師公會頒佈的香港審閱工作準則第2410號「實體的獨立核數師審閱中期財務資料」(「**香港審閱工作準則第2410號**」)進行審閱。審閱此等簡明綜合財務報表包括向主要負責財務及會計事項的人士作出查詢,以及應用分析及其他審閱程序。審閱範圍遠遜於根據香港審計準則進行的審核,因此,無法令我們保證我們會注意到在審核中可能會發現的所有重大事項。因此,我們不會發表審核意見。

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

結論

根據我們的審閱,我們並無發現任何事項,令我們相信簡明綜合財務報表在各重大方面未有根據國際會計準則第34號編製。

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
August 18, 2026

德勤•關黃陳方會計師行
執業會計師
香港
2026年8月18日

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
簡明綜合損益及其他全面收益表

For the six months ended June 30, 2026 截至2026年6月30日止六個月

		NOTES 附註	Six months ended June 30, 截至6月30日止六個月 2026 2026年 RMB'000 人民幣千元 (unaudited) (未經審核)	2025 2025年 RMB'000 人民幣千元 (unaudited) (未經審核)
Revenue	收益	4	**446,116**	298,552
Cost of sales	銷售成本		**(210,005)**	(144,684)
Gross profit	毛利		**236,111**	153,868
Other income	其他收入	5	**11,904**	12,797
Impairment losses (including reversals of impairment losses) on financial assets	金融資產減值虧損（包括減值虧損撥回）	8	**(13,681)**	(3,182)
Other gains and losses	其他收益及虧損	6	**(36)**	5,166
Selling expenses	銷售開支		**(102,183)**	(102,060)
Administrative expenses	行政開支		**(38,414)**	(47,399)
Research and development expenses	研發開支		**(151,326)**	(114,505)
Share of results of an associate	應佔一間聯營公司業績		**(5,545)**	—
Finance costs	財務成本	7	**(4,454)**	(4,819)
Loss before tax	税前虧損	10	**(67,624)**	(100,134)
Income tax credit	所得税抵免	9	**19,524**	17,858
Loss and total comprehensive expense for the period	**期內虧損及全面開支總額**		**(48,100)**	(82,276)
(Loss) profit and total comprehensive (expense) income attributable to:	以下應佔（虧損）利潤及全面（開支）收益總額：			
— Owners of the Company	— 本公司擁有人		**(59,303)**	(74,086)
— Non-controlling interests	— 非控股權益		**11,203**	(8,190)
			(48,100)	(82,276)
Loss per share	每股虧損			
— Basic (RMB yuan)	— 基本（人民幣元）	12	**(0.49)**	(0.61)

Condensed Consolidated Statement of Financial Position
簡明綜合財務狀況表

As at June 30, 2026 於2026年6月30日

		NOTES 附註	June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Non-current assets	**非流動資產**			
Equipment	設備	13	**113,408**	20,149
Right-of-use assets	使用權資產		**3,745**	5,264
Goodwill	商譽		**23,777**	23,777
Other intangible assets	其他無形資產	13	**193,669**	179,483
Interests in an associate	於一間聯營公司的權益		**122,079**	162,082
Equity instruments at fair value through other comprehensive income ("**FVTOCI**")	按公允價值計入其他全面收益(「**按公允價值計入其他全面收益**」)的權益工具		**2,731**	2,731
Deferred tax assets	遞延税項資產		**186,504**	168,043
Long-term trade receivables	長期貿易應收款項	14	**40,984**	42,118
Deposit for acquisition of equipment	購置設備按金		**—**	26,466
			686,897	630,113
Current assets	**流動資產**			
Inventories	存貨		**144,445**	131,436
Bills, trade and other receivables	票據、貿易及其他應收款項	15	**1,039,501**	1,082,012
Contract assets	合同資產	16	**35,999**	35,919
Amount due from the ultimate holding company	應收最終控股公司款項	17	**4,017**	3,204
Amounts due from fellow subsidiaries	應收同系子公司款項	17	**103,005**	53,424
Amount due from an associate	應收一間聯營公司款項	17	**235,052**	9,332
Pledged/restricted bank deposits	質押/受限制銀行存款		**1,943**	2,143
Time deposits	定期存款		**—**	241,176
Cash and cash equivalents	現金及現金等價物		**163,132**	123,636
			1,727,094	1,682,282
Current liabilities	**流動負債**			
Bill, trade and other payables	票據、貿易及其他應付款項	18	**728,492**	683,823
Bank borrowings	銀行借款	19	**250,600**	140,600
Amount due to the ultimate holding company	應付最終控股公司款項	20	**162,031**	127,998
Amounts due to related companies	應付關聯公司款項	20	**111,710**	108,794
Lease liabilities	租賃負債		**3,397**	4,072
Provision	撥備		**91,650**	86,364
Contract liabilities	合同負債		**48,734**	27,112
Deferred income	遞延收入		**193**	8,836
Tax liabilities	税項負債		**1,721**	1,789
			1,398,528	1,189,388

Condensed Consolidated Statement of Financial Position
簡明綜合財務狀況表

As at June 30, 2026 於2026年6月30日

		NOTES 附註	June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Net current assets	**淨流動資產**		**328,566**	492,894
Total assets less current liabilities	**總資產減流動負債**		**1,015,463**	1,123,007
Non-current liabilities	**非流動負債**			
Lease liabilities	租賃負債		**1,749**	2,166
Deferred income	遞延收入		**31,638**	24,901
Bank borrowings	銀行借款	19	**47,500**	136,150
Long term payables	長期應付款項	18	**11,797**	—
Deferred tax liabilities	遞延税項負債		**10,862**	11,930
			103,546	175,147
Net assets	**淨資產**		**911,917**	947,860
Capital and reserves	**股本及儲備**			
Share capital	股本	21	**120,879**	120,879
Reserves	儲備		**735,815**	775,697
Equity attributable to owners of the Company	本公司擁有人應佔權益		**856,694**	896,576
Non-controlling interests	非控股權益		**55,223**	51,284
Total equity	**總權益**		**911,917**	947,860

		Attributable to owners of the Company 本公司擁有人應佔							
		Share capital 股本 RMB'000 人民幣千元	Share premium 股份溢價 RMB'000 人民幣千元	Capital reserve 資本公積 RMB'000 人民幣千元 (Note) (附註)	Share-based payments reserve 以股份為基礎的支付儲備 RMB'000 人民幣千元	Accumulated losses 累計虧損 RMB'000 人民幣千元	Subtotal 小計 RMB'000 人民幣千元	Non-controlling interests 非控股權益 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
As at January 1, 2025 (audited)	於2025年1月1日(經審核)	120,879	1,061,292	7,598	271,575	(521,445)	939,899	46,943	986,842
Loss and total comprehensive expense for the period	期內虧損及全面開支總額	–	–	–	–	(74,086)	(74,086)	(8,190)	(82,276)
Equity-settled share-based payments (Note 22)	以權益結算以股份為基礎的支付(附註22)	–	–	51	15,803	–	15,854	245	16,099
As at June 30, 2025 (unaudited)	於2025年6月30日(未經審核)	120,879	1,061,292	7,649	287,378	(595,531)	881,667	38,998	920,665
As at January 1, 2026 (audited)	於2026年1月1日(經審核)	**120,879**	**1,061,292**	**2,696**	**297,942**	**(586,233)**	**896,576**	**51,284**	**947,860**
(Loss) profit and total comprehensive (expense) income for the period	期內(虧損)利潤及全面(開支)收益總額	**–**	**–**	**–**	**–**	**(59,303)**	**(59,303)**	**11,203**	**(48,100)**
Partial disposal of a subsidiary (Note 25)	部分出售一家子公司(附註25)	**–**	**–**	**12,564**	**–**	**–**	**12,564**	**(7,091)**	**5,473**
Capital contribution to a subsidiary by non-controlling interests (Note 25)	非控股權益向一家子公司注資(附註25)	**–**	**–**	**1,709**	**–**	**–**	**1,709**	**(182)**	**1,527**
Equity-settled share-based payments (Note 22)	以權益結算以股份為基礎的支付(附註22)	**–**	**–**	**136**	**5,012**	**–**	**5,148**	**9**	**5,157**
As at June 30, 2026 (unaudited)	於2026年6月30日(未經審核)	**120,879**	**1,061,292**	**17,105**	**302,954**	**(645,536)**	**856,694**	**55,223**	**911,917**

Note: The capital reserve represented the recognition of equity-settled share-based payments issued by iFLYTEK Co., Ltd. (科大訊飛股份有限公司) ("**iFLYTEK**"), the ultimate holding company of the Company, to certain employees of the Group.

附註： 資本公積指確認由本公司的最終控股公司科大訊飛股份有限公司(「**科大訊飛**」)向本集團若干僱員發出的以權益結算以股份為基礎的支付。

Condensed Consolidated Statement of Cash Flows
簡明綜合現金流量表

For the six months ended June 30, 2026 截至2026年6月30日止六個月

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
NET CASH USED IN OPERATING ACTIVITIES	**經營活動所用現金淨額**	**(181,567)**	(169,222)
INVESTING ACTIVITIES	**投資活動**		
Interest received	已收利息	**462**	4,126
Proceeds from disposal of equipment	出售設備所得款項	**17**	—
Proceeds from partially disposal of a subsidiary	部分出售一家子公司的所得款項	**2,738**	—
Purchase of equipment	購買設備	**(857)**	(8,404)
Payment of additions of other intangible assets	添置其他無形資產的支付	**(40,428)**	(19,680)
Placement of pledged/restricted bank deposits	存入質押／受限制銀行存款	**(1,875)**	(410)
Withdrawal of pledged/restricted bank deposits	提取質押／受限制銀行存款	**2,075**	200
Withdrawal in time deposit	提取定期存款	**241,600**	—
NET CASH FROM (USED IN) INVESTING ACTIVITIES	投資活動所得(所用)現金淨額	**203,732**	(24,168)
FINANCING ACTIVITIES	**融資活動**		
Interest paid	已付利息	**(4,375)**	(4,819)
Repayment of lease liabilities	償還租賃負債	**(1,171)**	(2,008)
Bank borrowings raised	所籌集銀行借款	**94,600**	351,900
Repayment of bank borrowings	償還銀行借款	**(73,250)**	(83,200)
Capital contribution to a subsidiary by non-controlling interests	非控股權益向一家子公司注資	**1,527**	—
Issue costs paid	已付發行成本	**—**	(1,297)
NET CASH FROM FINANCING ACTIVITIES	融資活動所得現金淨額	**17,331**	260,576
NET INCREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物增加淨額	**39,496**	67,186
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	期初現金及現金等價物	**123,636**	676,754
Effect of foreign exchange rate changes	外匯匯率變動的影響	**—**	(55)
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	期末現金及現金等價物	**163,132**	743,885

1. GENERAL INFORMATION

Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司) (the "**Company**"), formerly known as Anhui Xunfei Medical Co., Ltd. (安徽訊飛醫療股份有限公司), Anhui iFLYTEK Medical Information Technology Company Limited (安徽科大訊飛醫療信息技術有限公司) and Anhui Puji Information Technology Company Limited (安徽普濟信息科技有限公司), was established as a company with limited liability in Hefei City, Anhui Province, the PRC, on May 13, 2016, under the Company Law of the PRC. The immediate holding company and the ultimate holding company of the Company is iFLYTEK. The address of the registered office and the principal place of business of the Company is 4 to 5/F (North Area), No.1 Building, iFLYTEK AI Research and Development Production Base (Phase I), No. 666 Science and Innovation Road, Chengxiqiao Community Services Center, High-tech Zone, Hefei City, Anhui Province, PRC.

On December 24, 2021, the Company was converted into a joint stock company with limited liability. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 30, 2024 (the "**Listing**").

The Group are principally engaged in the provision of comprehensive healthcare AI solutions in the PRC.

The condensed consolidated financial statements are presented in Renminbi ("**RMB**"), which is also the functional currency of the Company and its subsidiaries.

1. 一般資料

訊飛醫療科技股份有限公司(「**本公司**」)的前身為安徽訊飛醫療股份有限公司、安徽科大訊飛醫療信息技術有限公司及安徽普濟信息科技有限公司，於2016年5月13日根據《中華人民共和國公司法》在中國安徽省合肥市成立為有限公司。本公司的直接控股公司及最終控股公司均為科大訊飛。本公司的註冊辦事處及主要營業地點的地址為中國安徽省合肥市高新區城西橋小區服務中心科創路666號科大訊飛人工智能研發生產基地(一期)1號樓4層至5層(北區)。

於2021年12月24日，本公司轉制為股份有限公司。本公司股份於2024年12月30日在香港聯合交易所有限公司主板上市(「**上市**」)。

本集團的主要業務為在中國提供全面醫療人工智能解決方案。

簡明綜合財務報表以本公司及其子公司功能貨幣人民幣(「**人民幣**」)呈列。

2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standards 34 ("**IAS 34**") as issued by the International Accounting Standards Board ("**IASB**") as well as with the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

2. 編製基準

簡明綜合財務報表乃根據國際會計準則理事會(「**國際會計準則理事會**」)頒佈的國際會計準則第34號(「**國際會計準則第34號**」)以及香港聯合交易所有限公司證券上市規則的適用披露規定而編製。

於批准簡明綜合財務報表時，本公司董事合理預期，本集團擁有充足資源於可見未來繼續經營。因此，彼等編製簡明綜合財務報表時繼續採納持續經營會計基準。

3. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for equity instruments at FVTOCI, which is measured at fair values.

Other than additional in accounting policies resulting from application of amendments to IFRS Accounting Standards, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended June 30, 2026 are the same as those presented in the Group's annual consolidated financial statements for the year ended December 31, 2025.

APPLICATION OF AMENDMENTS TO IFRS ACCOUNTING STANDARDS

In the current interim period, the Group has applied the following amendments to IFRS Accounting Standards as issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2026 for the preparation of the Group's condensed consolidated financial statements:

3. 會計政策

簡明綜合財務報表乃按歷史成本基準編製，惟按公允價值計入其他全面收益之權益工具乃按公允價值計量除外。

除因應用國際財務報告準則會計準則的修訂本而新增的會計政策外，截至2026年6月30日止六個月的簡明綜合財務報表所採用的會計政策及計算方法，與本集團截至2025年12月31日止年度的年度綜合財務報表所呈列者相同。

應用國際財務報告準則會計準則的修訂本

於本中期期間，本集團已就編製本集團簡明綜合財務報表首次應用下列由國際會計準則理事會頒佈的國際財務報告準則會計準則的修訂本，該等修訂本於本集團自2026年1月1日開始的年度期間強制生效：

Amendments to IFRS 9 and IFRS 7 國際財務報告準則第9號及國際財務報告準則第7號的修訂本	Amendments to the Classification and Measurement of Financial Instruments 金融工具分類及計量修訂
Amendments to IFRS 9 and IFRS 7 國際財務報告準則第9號及國際財務報告準則第7號的修訂本	Contracts Referencing Nature-dependent Electricity 涉及依賴自然能源生產電力的合約
Amendments to IFRS Accounting Standards 國際財務報告準則會計準則的修訂本	Annual Improvements to IFRS Accounting Standards — Volume 11 國際財務報告準則會計準則的年度改進 — 第11冊

The application of the amendments to IFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

於本中期期間應用國際財務報告準則會計準則的修訂本對本集團於本期間及過往期間的財務狀況及表現及／或此等簡明綜合財務報表所載的披露並無重大影響。

4. REVENUE AND SEGMENT INFORMATION 4. 收益及分部信息

(I) DISAGGREGATION OF REVENUE FROM CONTRACTS WITH CUSTOMERS (I) 客戶合同收益分拆

		Six months ended June 30, 截至6月30日止六個月	
		2026 2026年 RMB'000 人民幣千元 (unaudited) （未經審核）	2025 2025年 RMB'000 人民幣千元 (unaudited) （未經審核）
Types of goods or services	**貨品或服務類型**		
Project implementation services	項目實施服務	**393,257**	238,425
Operation services	營運服務	**26,070**	23,580
AI healthcare products	人工智能醫療產品	**26,789**	36,547
		446,116	298,552
By business lines	**按業務線劃分**		
AI Medical Assistant	AI診療助理	**201,562**	136,674
AI Health Partner	AI健康助手	**182,387**	104,253
AI Digital Base	AI數字基座	**62,167**	57,625
		446,116	298,552
Timing of revenue recognition	**收益確認時間**		
A point in time	某一時間點	**420,046**	274,972
Overtime	某段時間	**26,070**	23,580
		446,116	298,552

To align with the Company's medium-and long-term strategic development, focus on improving the quality and efficiency of its core AI medical business, and further optimize resource allocation, the Company has integrated and upgraded its original four business lines into three major business segments: AI Medical Assistant, AI Health Partner, and AI Digital Base. Among them, "AI Medical Assistant" has taken over the business of the former primary healthcare services and hospital solutions; "AI Health Partner" corresponds to the former patient services; and "AI Digital Base" corresponds to the former regional healthcare solutions.

為適配公司中長期戰略發展方向，聚焦AI醫療核心業務提質增效，進一步優化資源配置，公司將原有四大業務線整合升級為AI診療助理、AI健康助手、AI數字基座三大業務板塊。其中：「AI診療助理」承接原基層醫療服務及原醫院解決方案業務；「AI健康助手」對應原患者服務；「AI數字基座」對應原區域管理平台解決方案。

4. REVENUE AND SEGMENT INFORMATION *(Continued)*

(II) SEGMENT INFORMATION

Information is reported to the executive director of the Company, being the chief operating decision maker ("**CODM**"), for the purposes of resource allocation and performance assessment. The accounting policies are the same as the Group's accounting policies described in Note 3. No other analysis of the Group's results nor assets and liabilities is regularly provided to the CODM for review and the CODM reviews the overall results and financial position of the Group as a whole. Accordingly, the CODM has identified one operating segment and only entity-wide disclosures, major customers and geographical information are presented in accordance with IFRS 8 *Operating Segments*.

Geographical information

The Group primarily operates in the PRC. The Group's non-current assets are all located in the PRC.

Information about major customers

Revenue from customers of the corresponding periods contributing over 10% of the total revenue of the Group are as follows:

4. 收益及分部信息*(續)*

(II) 分部信息

有關信息乃報告予本公司的執行董事，即主要營運決策者(「**主要營運決策者**」)，以進行資源分配及績效評估。會計政策與附註3所述的本集團會計政策相同。本集團的其他業績、資產及負債的分析並無定期提供給主要營運決策者進行審閱，而主要營運決策者乃審閱本集團整體的總體業績及財務狀況。因此，主要營運決策者識別出一項經營分部，並且僅根據國際財務報告準則第8號*營運分部*呈列實體層面的披露、主要客戶及地理信息。

地區資料

本集團主要在中國經營業務。本集團所有非流動資產均位於中國。

有關主要客戶的資料

來自相應期間對本集團總收益貢獻超過10%的客戶的收益如下：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **(未經審核)**	2025 2025年 RMB'000 人民幣千元 (unaudited) (未經審核)
Customer A	客戶A	**163,022**	—
Customer B	客戶B	**57,806**	39,028

5. OTHER INCOME

5. 其他收入

		Six months ended June 30, 截至6月30日止六個月	
		2026 2026年 RMB'000 人民幣千元 (unaudited) (未經審核)	2025 2025年 RMB'000 人民幣千元 (unaudited) (未經審核)
Government grants (Note i)	政府補助(附註i)	**8,783**	5,020
Value-added tax refund (Note ii)	增值稅退稅(附註ii)	**219**	1,424
Interest income from bank deposits	銀行存款的利息收入	**886**	4,126
Imputed interest income for long-term trade receivables (Note iii)	長期貿易應收款項的估算利息收入(附註iii)	**1,644**	1,620
Others	其他	**372**	607
		11,904	12,797

Notes:

i. The amount represents various subsidies received from the PRC local government authorities as incentives mainly for the Group's research and development activities. Unconditional government grants are recognized in profit or loss when received while conditional government grants are initially recognized as deferred income and recognized in profit or loss when the Group fulfilled the conditions.

ii. In accordance with the Notice of Ministry of Finance and State Administration of Taxation on Value-added Tax Policies for Software Products which was promulgated by the Ministry of Finance and the State Administration of Taxation on October 13, 2011 and came into effect on January 1, 2011, enterprises engaged in the sales of self-developed software in the PRC are entitled to the value-added tax refund to the portion of value-added tax actually paid which exceeds 3% of the related sale amounts.

iii. The imputed interest rates applied to long-term trade receivables ranged from 3.50% to 4.75% (six months ended June 30, 2025: 3.50% to 4.75%) per annum as at June 30, 2026.

附註：

i. 該金額指來自中國地方政府部門主要作為鼓勵本集團研發活動的各項補貼。無條件政府補助於收到時於損益內確認，而有條件政府補助初步確認為遞延收入並於本集團達成條件時於損益確認。

ii. 根據財政部、國家稅務總局於2011年10月13日發佈並自2011年1月1日起生效的《財政部、國家稅務總局關於軟件產品增值稅政策的通知》，對在中國境內銷售自主開發軟件的企業增值稅實際稅負超過相關銷售額3%的部分可予退還。

iii. 截至2026年6月30日，長期貿易應收款項的估算年利率介乎3.50%至4.75%(截至2025年6月30日止六個月：3.50%至4.75%)。

6. OTHER GAINS AND LOSSES　6. 其他收益及虧損

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **(未經審核)**	2025 2025年 RMB'000 人民幣千元 (unaudited) (未經審核)
Net losses on disposal of equipment	出售設備虧損淨額	**(16)**	(17)
Net foreign exchange (losses) gains	匯兑(虧損)收益淨額	**(20)**	5,486
Donations	捐款	**–**	(300)
Others	其他	**–**	(3)
		(36)	5,166

7. FINANCE COSTS　7. 財務成本

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **(未經審核)**	2025 2025年 RMB'000 人民幣千元 (unaudited) (未經審核)
Interest expense on bank borrowings	銀行借款利息開支	**4,375**	4,682
Interest expense on lease liabilities	租賃負債利息開支	**79**	137
		4,454	4,819

8. IMPAIRMENT LOSSES UNDER EXPECTED CREDIT LOSS MODEL, NET OF REVERSAL

8. 預期信貸虧損模型下的減值虧損（扣除撥回）

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **（未經審核）**	2025 2025年 RMB'000 人民幣千元 (unaudited) （未經審核）
Impairment losses recognized, net of reversed on:	已確認的減值虧損，扣除以下撥回：		
— trade receivables and long-term trade receivables	— 貿易應收款項及長期貿易應收款項	**12,571**	2,482
— amount due from the ultimate holding company	— 應收最終控股公司款項	**13**	2
— amounts due from fellow subsidiaries	— 應收同系子公司款項	**416**	406
— contract assets	— 合同資產	**681**	292
		13,681	3,182

9. INCOME TAX CREDIT

9. 所得稅抵免

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **（未經審核）**	2025 2025年 RMB'000 人民幣千元 (unaudited) （未經審核）
Current tax	即期稅項	**—**	—
Deferred tax	遞延稅項	**(19,524)**	(17,858)
		(19,524)	(17,858)

10. LOSS BEFORE TAX

10. 稅前虧損

Loss for the year has been arrived at after charging:

年內虧損已扣除：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **（未經審核）**	2025 2025年 RMB'000 人民幣千元 (unaudited) （未經審核）
Directors' remuneration	董事酬金	**2,440**	6,643
Other staff:	其他員工：		
Salaries, discretionary bonus and other benefits	薪金、酌情花紅及其他福利	**173,023**	137,987
Retirement benefit scheme contributions	退休福利計劃供款	**14,572**	11,416
Equity-settled share-based payments	以權益結算以股份為基礎的支付	**4,420**	11,529
Total staff costs	總員工成本	**194,455**	167,575
Less: Capitalised in development costs	減：開發成本資本化	**(13,976)**	(8,557)
		180,479	159,018
Depreciation of equipment	設備折舊	**9,081**	3,024
Depreciation of right-of-use assets	使用權資產折舊	**1,519**	1,519
Amortization of other intangible assets	其他無形資產攤銷	**26,602**	16,344
Total depreciation and amortization	總折舊及攤銷	**37,202**	20,887

11. DIVIDENDS

No dividend was paid, declared or proposed during the six months ended June 30, 2026 (six months ended June 30, 2025: nil). The directors of the Company have determined that no dividend will be paid in respect of the interim period (six months ended June 30, 2025: nil).

11. 股息

於截至2026年6月30日止六個月內並無派付、宣派或建議派付股息（截至2025年6月30日止六個月：無）。本公司董事已釐定不會就中期期間派付任何股息（截至2025年6月30日止六個月：無）。

12. LOSS PER SHARE

12. 每股虧損

The calculation of the basic loss per share attributable to owners of the Company is based on the following data:

本公司擁有人應佔每股基本虧損乃基於下列數據計算得出：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **'000** **千** **(unaudited)** **（未經審核）**	2025 2025年 '000 千 (unaudited) （未經審核）
Loss for the purposes of calculating basic loss per share attributable to owners of the Company (RMB)	就計算本公司擁有人應佔每股基本虧損而言的虧損（人民幣）	**(59,303)**	(74,086)
Weighted average number of ordinary shares for the purpose of basic loss per share calculation	就計算每股基本虧損而言的普通股加權平均數	**120,879**	120,879

The potential ordinary shares arising from restricted shares scheme were not included in the calculation of diluted losses per share for both periods, as their inclusion would be anti-dilutive.

因受限制股份計劃而產生的潛在普通股具反攤薄影響，故並無計入兩個期間的每股攤薄虧損計算內。

13. EQUIPMENT AND OTHER INTANGIBLE ASSETS

13. 設備及其他無形資產

During the current interim period, the Group incurred expenditures on electronic equipment and office furniture amounting to RMB100,721,000 (six months ended 30 June 2025: RMB8,404,000).

於本中期期間，本集團產生電子設備和辦公傢具開支人民幣100,721,000元（截至2025年6月30日止六個月：人民幣8,404,000元）。

During the current interim period, the Group incurred additional expenditures on other intangible assets amounting to RMB43,428,000 (six months ended 30 June 2025: RMB19,680,000), consisting of intellectual properties and development costs.

於本中期期間，本集團產生其他無形資產額外開支人民幣43,428,000元（截至2025年6月30日止六個月：人民幣19,680,000元），包括知識產權及開發成本。

14. LONG-TERM TRADE RECEIVABLES

14. 長期貿易應收款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Long-term trade receivables (Note)	長期貿易應收款項(附註)	**218,723**	226,615
Less: due within one year	減:一年內到期	**(171,885)**	(179,327)
		46,838	47,288
Less: allowance for credit losses	減:信貸虧損撥備	**(5,854)**	(5,170)
		40,984	42,118

Note: According to the payment terms in the sales contracts with certain customers, certain part of the sales consideration will be collected after one year.

附註: 根據銷售合約的付款條款,就若干客戶而言,銷售代價的若干部分將於一年後收回。

The following is an aged analysis of long-term trade receivables net of allowance for credit losses presented based on invoice dates:

以下為按發票日期呈列經扣除信貸虧損撥備的長期貿易應收款項的賬齡分析:

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
181–365 days	181至365日	**—**	7,544
1–2 years	1至2年	**27,697**	20,710
2–3 years	2至3年	**13,287**	13,864
		40,984	42,118

15. BILLS, TRADE AND OTHER RECEIVABLES 15. 票據、貿易及其他應收款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Trade receivables	貿易應收款項	**1,018,076**	1,072,402
Bills receivables	應收票據	**4,268**	—
Less: allowance for credit losses	減：信貸虧損撥備	**(68,436)**	(56,549)
		953,908	1,015,853
Other receivables	其他應收款項	**17,308**	15,502
Advance to suppliers	向供應商墊款	**50,744**	38,752
Tax recoverable	可收回稅項	**215**	88
Other tax recoverable	其他可收回稅項	**17,326**	11,817
		1,039,501	1,082,012

The following is an aged analysis of trade receivables net of allowance for credit losses presented based on invoice dates:

以下為按發票日期呈列經扣除信貸虧損撥備的貿易應收款項的賬齡分析：

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
0–90 days	0至90日	**128,017**	307,486
91–180 days	91至180日	**72,674**	63,538
181–365 days	181至365日	**263,160**	147,219
1–2 years	1至2年	**219,056**	221,093
2–3 years	2至3年	**88,561**	98,278
Over 3 years	3年以上	**178,172**	178,239
		949,640	1,015,853

16. CONTRACT ASSETS

16. 合同資產

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
AI Medical Assistant	AI診療助理	**16,043**	17,224
AI Health Partner	AI健康助手	**7,838**	7,466
AI Digital Base	AI數字基座	**13,539**	11,968
		37,420	36,658
Less: allowance for credit losses	減：信貸虧損撥備	**(1,421)**	(739)
		35,999	35,919

17. AMOUNT(S) DUE FROM THE ULTIMATE HOLDING COMPANY/FELLOW SUBSIDIARIES

17. 應收最終控股公司╱同系子公司款項

AMOUNT DUE FROM THE ULTIMATE HOLDING COMPANY

應收最終控股公司款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
iFLYTEK	科大訊飛		
Trade related	貿易相關	**4,268**	3,442
Less: allowance for credit losses	減：信貸虧損撥備	**(251)**	(238)
		4,017	3,204

The balances of trade nature are unsecured and non-interest bearing.

貿易性質結餘為無抵押及不計息。

17. AMOUNT(S) DUE FROM THE ULTIMATE HOLDING COMPANY/FELLOW SUBSIDIARIES *(Continued)*

17. 應收最終控股公司／同系子公司款項*（續）*

AMOUNT DUE FROM THE ULTIMATE HOLDING COMPANY *(Continued)*

應收最終控股公司款項*（續）*

The following is an aged analysis of the Group's trade related balances net of allowance for credit losses presented based on invoice dates:

以下為本集團按發票日期列示的貿易相關結餘（扣除信貸虧損撥備）的賬齡分析：

		June 30, 2026 2026年 6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年 12月31日 RMB'000 人民幣千元 (audited) （經審核）
0–90 days	0至90日	**823**	672
181–365 days	181至365日	**670**	1,311
1–2 years	1至2年	**1,307**	—
2–3 years	2至3年	**1,217**	1,221
		4,017	3,204

17. AMOUNT(S) DUE FROM THE ULTIMATE HOLDING COMPANY/FELLOW SUBSIDIARIES *(Continued)*

17. 應收最終控股公司／同系子公司款項*（續）*

AMOUNTS DUE FROM FELLOW SUBSIDIARIES

應收同系子公司款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) （經審核）
Trade related	*貿易相關*		
iFLYTEK Zhiyuan Technology Co., Ltd. (訊飛智元信息科技有限公司)	訊飛智元信息科技有限公司	**57,617**	28,985
Guangxi Kexun Zhongmeng Artificial Intelligence Technology Co., Ltd. (廣西科訊中盟人工智能科技有限公司)	廣西科訊中盟人工智能科技有限公司	**29,243**	—
Anhui iFLYTEK New Retail Co., Ltd. (安徽訊飛新零售有限公司)	安徽訊飛新零售有限公司	**6,701**	7,898
Shandong Zixun Information Technology Co., Ltd. (山東淄訊信息科技有限公司)	山東淄訊信息科技有限公司	**4,708**	4,708
Zhejiang Xunzhi Future Technology Co., Ltd. (浙江訊智未來科技有限公司)	浙江訊智未來科技有限公司	**3,828**	2,358
Gongqingcheng Qingxun Artificial Intelligence Technology Co., Ltd (共青城青訊人工智能科技有限公司)	共青城青訊人工智能科技有限公司	**1,585**	1,585
Others	其他	**2,165**	10,317
		105,847	55,851
Less: allowance for credit losses	減：信貸虧損撥備	**(2,842)**	(2,427)
		103,005	53,424

The balances of trade nature are unsecured and non-interest bearing.

貿易性質結餘為無抵押及不計息。

17. AMOUNT(S) DUE FROM THE ULTIMATE HOLDING COMPANY/FELLOW SUBSIDIARIES *(Continued)*

17. 應收最終控股公司╱同系子公司款項*(續)*

AMOUNTS DUE FROM FELLOW SUBSIDIARIES *(Continued)*

應收同系子公司款項*(續)*

The following is an aged analysis of the Group's trade related balances net of allowance for credit losses presented based on invoice dates:

以下為本集團按發票日期列示的貿易相關結餘(扣除信貸虧損撥備)的賬齡分析：

		June 30, 2026 **2026年6月30日** **RMB'000** **人民幣千元** **(unaudited)** **(未經審核)**	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
0–90 days	0至90日	**48,797**	30,979
91–180 days	91至180日	**13,369**	226
181–365 days	181至365日	**22,743**	7,973
1–2 years	1至2年	**7,267**	3,246
2–3 years	2至3年	**7,094**	10,980
Over 3 years	3年以上	**3,735**	20
		103,005	53,424

17. AMOUNT(S) DUE FROM THE ULTIMATE HOLDING COMPANY/FELLOW SUBSIDIARIES *(Continued)*

17. 應收最終控股公司╱同系子公司款項*(續)*

AMOUNT DUE FROM AN ASSOCIATE

應收一間聯營公司款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Anhui Heshuzhi Medical Technology Co., Ltd. (安徽省合數智醫科技有限公司)	安徽省合數智醫科技有限公司		
Trade related	貿易相關	**235,052**	9,332

The balances of trade nature are unsecured and non-interest bearing.

貿易性質結餘為無抵押及不計息。

The following is an aged analysis of the Group's trade related balances net of allowance for credit losses presented based on invoice dates:

以下為本集團按發票日期列示的貿易相關結餘(扣除信貸虧損撥備)的賬齡分析：

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
0–90 days	0至90日	**225,720**	9,332
181–365 days	181至365日	**9,332**	—
		235,052	9,332

18. BILLS, TRADE AND OTHER PAYABLES 18. 票據、貿易及其他應付款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Trade payables	貿易應付款項	**460,728**	481,084
Bills payables (Note)	應付票據(附註)	**197,363**	78,335
Total trade and bills payables	貿易應付款項及應付票據總額	**658,091**	559,419
Payroll payables	應付薪資	**41,654**	62,426
Value-added tax and other tax payables	增值税及其他應付税項	**36,107**	50,526
Others	其他	**4,437**	11,452
		740,289	683,823
Less: Amounts due for settlement after one year shown under long-term payables	減：長期應付款項項下所示一年後到期結算的款項	**(11,797)**	—
		728,492	683,823

Note: These relate to trade payables in which the Group has issued bills to the relevant suppliers for settlement of trade payables. The suppliers can obtain the invoice amounts from the bank on the maturity date of the bills. The Group continues to recognise these trade payables as the Group is obliged to make payments to the relevant banks on due dates of the bills, under the same conditions as agreed with the suppliers without further extension. In the condensed consolidated statement of cash flows, settlements of these bills by the Group are included within operating cash flows based on the nature of the arrangements.

附註： 此等與貿易應付款項有關，本集團已就結算貿易應付款項向相關供應商發出票據。供應商可於票據到期日從銀行獲取發票金額。本集團繼續確認該等貿易應付款項，原因為本集團有責任於票據到期日按與供應商協定的相同條件向相關銀行付款，且不得進一步延期。於簡明綜合現金流量表中，本集團結算該等票據乃根據安排的性質計入經營現金流量。

18. BILLS, TRADE AND OTHER PAYABLES *(Continued)*

18. 票據、貿易及其他應付款項*(續)*

The credit period of trade creditors is generally 30 days. The following is an aged analysis of trade payables presented based on the invoice dates:

貿易債權人的信貸期一般為30日。以下為按發票日期呈列的貿易應付款項的賬齡分析：

		June 30, 2026 2026年 6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年 12月31日 RMB'000 人民幣千元 (audited) （經審核）
0–90 days	0至90日	**135,440**	221,422
91–180 days	91至180日	**105,503**	35,095
181–365 days	181至365日	**70,756**	49,510
Over 1 year	1年以上	**149,029**	175,057
		460,728	481,084

The following is an aged analysis of bill payables based on the bill issuance dates at the end of each reporting period:

以下為按各報告期末發票日期的應付票據的賬齡分析：

		June 30, 2026 2026年 6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年 12月31日 RMB'000 人民幣千元 (audited) （經審核）
0–180 days	0至180日	**197,363**	78,335

19. BANK BORROWINGS 19. 銀行借款

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Unsecured and unguaranteed bank borrowings	無抵押及無擔保銀行借款	**298,100**	276,750
The carrying amounts of the above borrowings are repayable*:	上述借款的賬面值須予償還期限*：		
Within one year (shown under current liabilities)	於一年內（於流動負債中列示）	**250,600**	140,600
Within a year of more than one year but not exceeding two years (shown under non-current liabilities)	一年以上但不超過兩年的年度（於非流動負債中列示）	**47,500**	136,150
		298,100	276,750

* The amounts due are based on scheduled repayment dates set out in the loan agreements.

* 到期金額乃基於貸款協議所載的預定還款日期。

As at June 30, 2026, the Group's bank borrowings were dominated in RMB and carried fixed rates with effective interest rates from 2.11% to 2.40% (31 December 2025: 2.11% to 2.90%) per annum.

於2026年6月30日，本集團的銀行借款以人民幣計值，並按介乎2.11%至2.40%(2025年12月31日：2.11%至2.90%)的實際年利率以固定利率計息。

20. AMOUNT(S) DUE TO THE ULTIMATE HOLDING COMPANY/RELATED COMPANIES

20. 應付最終控股公司╱關聯公司款項

AMOUNT DUE TO THE ULTIMATE HOLDING COMPANY

應付最終控股公司款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) （經審核）
iFLYTEK	科大訊飛		
Trade related	貿易相關	**162,031**	127,998

The balance of trade nature is unsecured, non-interest bearing and repayable on demand.

貿易性質結餘為無抵押、免息且須按要求償還。

The following is an aged analysis of trade related balances presented based on the invoice dates:

以下為按發票日期呈列的貿易相關結餘的賬齡分析：

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) （經審核）
0–90 days	0至90日	**16,056**	17,995
91–180 days	91至180日	**17,977**	25,094
181–365 days	181至365日	**43,089**	33,669
1–2 years	1至2年	**55,585**	36,490
2–3 years	2至3年	**19,502**	6,060
Over 3 years	3年以上	**9,822**	8,690
		162,031	127,998

20. AMOUNT(S) DUE TO THE ULTIMATE HOLDING COMPANY/RELATED COMPANIES *(Continued)*

20. 應付最終控股公司／關聯公司款項*(續)*

AMOUNTS DUE TO RELATED COMPANIES

應付關聯公司款項

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) (經審核)
Trade related	*貿易相關*		
iFLYTEK (Beijing) Co., Ltd. (科大訊飛(北京)有限公司) (Note i)	科大訊飛(北京)有限公司(附註i)	**31,684**	27,697
iFLYTEK Central China (Wuhan) Co., Ltd. (訊飛華中(武漢)有限公司) (Note i)	訊飛華中(武漢)有限公司(附註i)	**21,021**	19,006
iFLYTEK Zhiyuan Technology Co., Ltd. (訊飛智元信息科技有限公司) (Note i)	訊飛智元信息科技有限公司(附註i)	**9,689**	9,577
Anhui Aibo Intelligent Technology Co., Ltd. (安徽愛博智能科技有限公司) (Note i)	安徽愛博智能科技有限公司(附註i)	**9,245**	9,245
iFLYTEK South China Co., Ltd. (科大訊飛華南有限公司) (Note i)	科大訊飛華南有限公司(附註i)	**8,440**	5,091
Sichuan iFLYTEK Super Brain Information Technology Co., Ltd. (四川訊飛超腦信息科技有限公司) (Note i)	四川訊飛超腦資訊科技有限公司(附註i)	**5,259**	4,214
Kexun Jialian Information Technology Co., Ltd. (科訊嘉聯信息技術有限公司) (Note ii)	科訊嘉聯信息技術有限公司(附註ii)	**3,996**	4,646
Xi'an Xunfei Super Brain Information Technology Co., Ltd. (西安訊飛超腦信息科技有限公司) (Note i)	西安訊飛超腦信息科技有限公司(附註i)	**3,606**	2,058
Wuhu Kexun Aerospace Information Technology Co., Ltd. (蕪湖科訊航天信息技術有限公司) (Note i)	蕪湖科訊航天信息技術有限公司(附註i)	**2,291**	2,140
Zhejiang iFLYTEK Intelligent Technology Co., Ltd. (浙江訊飛智能科技有限公司) (Note i)	浙江訊飛智能科技有限公司(附註i)	**1,932**	1,416
Anhui Jixun Information Technology Co., Ltd. (安徽極訊信息科技有限公司) (Note i)	安徽極訊信息科技有限公司(附註i)	**1,877**	5,157
iFLYTEK Zhigu Technology Co., Ltd. (訊飛智谷科技有限公司) (Note i)	訊飛智谷科技有限公司(附註i)	**1,507**	1,410
Liaoning iFLYTEK Information Technology Co., Ltd. (遼寧訊飛信息科技有限公司) (Note i)	遼寧訊飛信息科技有限公司(附註i)	**1,424**	1,836

20. AMOUNT(S) DUE TO THE ULTIMATE HOLDING COMPANY/RELATED COMPANIES *(Continued)*

20. 應付最終控股公司／關聯公司款項*(續)*

AMOUNTS DUE TO RELATED COMPANIES *(Continued)*

應付關聯公司款項*(續)*

		June 30, 2026 2026年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	December 31, 2025 2025年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Tianjin Zhihuigu Technology Service Co., Ltd. (天津智匯谷科技服務有限公司) (Note i)	天津智匯谷科技服務有限公司(附註i)	**1,280**	1,280
Hunan Xiangxun Future Technology Co., Ltd. (湖南湘訊未來科技有限公司) (Note i)	湖南湘訊未來科技有限公司(附註i)	**1,042**	824
Wuhan iFLYTEK Xingzhi Technology Co., Ltd. (武漢訊飛興智科技有限公司) (Note i)	武漢訊飛興智科技有限公司(附註i)	**732**	732
Nanjing iFLYTEK Smart City Technology Co., Ltd. (南京訊飛智慧城市科技有限公司) (Note i)	南京訊飛智慧城市科技有限公司(附註i)	**513**	386
Shandong Kexun Information Technology Co., Ltd. (山東科訊信息科技有限公司) (Note i)	山東科訊信息科技有限公司(附註i)	**462**	394
Anhui Tingjian Technology Co., Ltd. (安徽聽見科技有限公司) (Note i)	安徽聽見科技有限公司(附註i)	**375**	353
Tianjin iFLYTEK Information Technology Co., Ltd. (天津訊飛信息科技有限公司) (Note i)	天津訊飛信息科技有限公司(附註i)	**227**	353
Anhui iFLYTEK New Retail Co., Ltd. (安徽訊飛新零售有限公司) (Note i)	安徽訊飛新零售有限公司(附註i)	**170**	6,711
Hefei Intelligent Speech Innovation Development Co., Ltd. (合肥智能語音創新發展有限公司) (Note ii)	合肥智能語音創新發展有限公司(附註ii)	**125**	125
Shenzhen iFLYTEK Intelligent Technology Co., Ltd. (深圳訊飛智慧科技有限公司) (Note i)	深圳訊飛智慧科技有限公司(附註i)	**—**	785
Others (Note i)	其他(附註i)	**4,813**	3,358
		111,710	108,794

20. AMOUNT(S) DUE TO THE ULTIMATE HOLDING COMPANY/RELATED COMPANIES *(Continued)*

20. 應付最終控股公司／關聯公司款項*（續）*

AMOUNTS DUE TO RELATED COMPANIES *(Continued)*

應付關聯公司款項*（續）*

Notes:

i. The entities are the fellow subsidiaries of the Company.

ii. The entities are associates of iFLYTEK.

附註：

i. 該等實體為本公司的同系子公司。

ii. 該等實體為科大訊飛的聯營公司。

The balances of trade nature are unsecured, non-interest bearing and repayable on demand.

貿易性質結餘為無抵押、免息且須按要求償還。

The following is an aged analysis of trade related balances presented based on the invoice dates:

以下為按發票日期呈列的貿易相關結餘的賬齡分析：

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (unaudited) （未經審核）	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (audited) （經審核）
0–90 days	0至90日	**9,681**	34,755
91–180 days	91至180日	**8,097**	6,324
181–365 days	181至365日	**26,241**	20,070
1–2 years	1至2年	**22,917**	19,064
2–3 years	2至3年	**30,079**	20,073
Over 3 years	3年以上	**14,695**	8,508
		111,710	108,794

21. SHARE CAPITAL

21. 股本

		Number of ordinary shares 普通股數目 '000 千股	**Share capital 股本** RMB'000 人民幣千元
Ordinary shares of RMB1 each	每股面額為人民幣1元的普通股		
Authorized and issued	**法定及已發行**		
As at January 1, 2025 (audited), December 31, 2025 (audited) and June 30, 2026 (unaudited)	於2025年1月1日（經審核）、2025年12月31日（經審核）及2026年6月30日（未經審核）	120,879	120,879

22. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

FAIR VALUE MEASUREMENTS AND VALUATION PROCESSES

Fair value of financial assets and financial liabilities that are not measured at fair value on a recurring basis (but fair value disclosures are required)

The management of the Group considers that the carrying amounts of financial assets and financial liabilities recorded at amortized cost in the condensed consolidated financial statements approximate to their fair values.

22. 金融工具的公允價值計量

公允價值計量及估值程序

並非按持續基準按公允價值計量的金融資產及金融負債的公允價值

本集團管理層認為簡明綜合財務報表中按攤銷成本錄得的金融資產及金融負債的賬面值與其公允價值相若。

23. SHARE-BASED PAYMENT TRANSACTIONS

RESTRICTED SHARES SCHEME

To provide incentives to eligible employees and directors of the Group, an employee share incentive plan (the "**RSU Plan**") was adopted on September 1, 2021. Three employee stock ownership platforms, namely Nanjing Zhengyang Information Technology Partnership (Limited Partnership) ("**南京正暘信息科技合夥企業(有限合夥)**"), Nanjing Zhenghui Information Technology Partnership (Limited Partnership), ("**南京正暉信息科技合夥企業(有限合夥)**") and Nanjing Zhengchang Technology Partnership (Limited Partnership) ("**南京正昶科技合夥企業(有限合夥)**") (the "**Shareholding Platforms**") were set up to indirectly hold RMB3,016,000 registered capital of the Company.

Eligible employees and directors subscribed for partnership interest of the Shareholding Platforms at a consideration price of RMB2.5 for RMB1.0 registered capital and indirectly held the incentive shares of the Company.

23. 以股份為基礎付款的交易

受限制股份計劃

為激勵本集團的合資格員工及董事，本集團於2021年9月1日採納了員工股權激勵計劃(「**RSU計劃**」)，並設立了三個員工持股平台，即南京正暘信息科技合夥企業(有限合夥)、南京正暉信息科技合夥企業(有限合夥)及南京正昶科技合夥企業(有限合夥)(「**持股平台**」)，間接持有本公司註冊資本人民幣3,016,000元。

合資格員工及董事以每人民幣1.0元的註冊資本兑人民幣2.5元的代價認購持股平台的合夥權益，並間接持有本公司的激勵股份。

23. SHARE-BASED PAYMENT TRANSACTIONS *(Continued)*

23. 以股份為基礎付款的交易*(續)*

RESTRICTED SHARES SCHEME *(Continued)*

受限制股份計劃*(續)*

Details of the restricted shares issued under the RSU Plan are as follows:

根據RSU計劃所發行的受限制股份詳情如下：

Grant date 授出日期	Amount of registered capital 註冊資本金額 RMB in thousands 人民幣千元	Grantee 承授人	Vesting schedule defined in contract term 合同條款中界定的歸屬時間表	Sell back rights/ repurchase rights 回售權／購回權
September 1, 2021	3,016	Directors and employees	40% 32 months after grant date; 30% 44 months after grant date; 30% 56 months after grant date with the achievement of certain individual and the Group's performance conditions	Note
2021年9月1日	3,016	董事及僱員	授出日期後32個月歸屬40%；授出日期後44個月歸屬30%；授出日期後56個月歸屬30%且滿足若干個人及本集團績效條件	附註

Note: If the grantees terminate the labor relationship with the Group, the Shareholding Platforms have the right to repurchase the unvested shares from the grantees at original consideration plus interest at market rate of similar period and the vested shares from the grantees at the higher of original consideration plus interest at market rate of similar period and net book value of the Company indirectly held by the grantees.

On December 29, 2025, several eligible employees and directors voluntarily extended part of their RSU vesting end date to December 29, 2026.

附註： 倘承授人終止與本集團的勞動關係，則持股平台有權按原對價加同期市場利率計算的利息向承授人購回未歸屬股份及按原對價加同期市場利率計算的利息與承授人間接所持本公司賬面淨值的較高者向承授人購回已歸屬股份。

於2025年12月29日，若干合資格僱員及董事自願將其部分受限制股份單位的歸屬結束日期延長至2026年12月29日。

23. SHARE-BASED PAYMENT TRANSACTIONS *(Continued)*

23. 以股份為基礎付款的交易*(續)*

RESTRICTED SHARES SCHEME *(Continued)*

受限制股份計劃*(續)*

		Unvested restricted shares 未歸屬受限制股份 in thousands 千股	Weighted average grant date fair value per restricted shares 獲授予當日每股受限制股份的加權平均公允價值 RMB 人民幣元
As at January 1, 2025 (audited)	於2025年1月1日(經審核)	6,677	27.81
Forfeited	沒收	(20)	27.81
As at June 30, 2025 (unaudited)	於2025年6月30日(未經審核)	6,657	27.81
As at January 1, 2026 (audited) and June 30, 2026 (unaudited)	於2026年1月1日(經審核)及2026年6月30日(未經審核)	**3,338**	**27.81**

During the current interim period, the Group has recognized share-based payment expenses of RMB5,021,000 (unaudited) (30 June 2025: RMB16,048,000 (unaudited)).

於本中期期間，本集團已確認以股份為基礎的支付開支人民幣5,021,000元(未經審核)(2025年6月30日：人民幣16,048,000元(未經審核))。

In addition, the Group was also a party to the RSU plan of iFLYTEK whereas the restricted shares may be issued to the eligible grantees of the Group. The equity-settled share-based payment of the restricted shares was measured based on the fair value of iFLYTEK's ordinary shares on the date of grant. During the current interim period, the Group has recognized share-based payment expenses of RMB136,000 (unaudited) (30 June 2025: RMB51,000 (unaudited)).

此外，本集團亦為科大訊飛RSU計劃的訂約方，而受限制股份可能發行予本集團合資格承授人。受限制股份以權益結算以股份為基礎的支付按於授出日期科大訊飛普通股的公允價值計量。於本中期期間，本集團已確認以股份為基礎的支付開支人民幣136,000元(未經審核)(2025年6月30日：人民幣51,000元(未經審核))。

24. RELATED PARTY TRANSACTIONS

24. 關聯方交易

(I) DURING THE CURRENT INTERIM PERIOD, THE GROUP ENTERED INTO THE FOLLOWING TRANSACTIONS WITH RELATED PARTIES:

(I) 於本中期期間，本集團與關聯方訂立下列交易：

(a) Sale of products and services

(a) 銷售產品及服務

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		（未經審核）	（未經審核）
Anhui Heshuzhi Medical Technology Co., Ltd.	安徽省合數智醫科技有限公司	**163,022**	—
Guangxi Kexun Zhongmeng Artificial Intelligence Technology Co., Ltd.	廣西科訊中盟人工智能科技有限公司	**27,500**	—
iFLYTEK Zhiyuan Technology Co., Ltd.	訊飛智元信息科技有限公司	**25,408**	21,143
iFLYTEK	科大訊飛	**3,468**	3,416
Zhejiang Xunzhi Future Technology Co., Ltd.	浙江訊智未來科技有限公司	**1,249**	297
Others	其他	**181**	14,172
		220,828	39,028

24. RELATED PARTY TRANSACTIONS *(Continued)*

24. 關聯方交易*（續）*

(I) DURING THE CURRENT INTERIM PERIOD, THE GROUP ENTERED INTO THE FOLLOWING TRANSACTIONS WITH RELATED PARTIES: *(Continued)*

(I) 於本中期期間，本集團與關聯方訂立下列交易：*（續）*

(b) Receiving of services

(b) 收取服務

		Six months ended June 30, 截至6月30日止六個月	
		2026 2026年 RMB'000 人民幣千元 (unaudited) （未經審核）	2025 2025年 RMB'000 人民幣千元 (unaudited) （未經審核）
iFLYTEK	科大訊飛	**26,081**	26,055
iFLYTEK (Beijing) Co., Ltd.	科大訊飛（北京）有限公司	**3,690**	1,699
Anhui Jixun Information Technology Co., Ltd.	安徽極訊信息科技有限公司	**3,303**	—
Kexun Jialian Information Technology Co., Ltd.	科訊嘉聯信息技術有限公司	**2,314**	300
iFLYTEK Central China (Wuhan) Co., Ltd.	訊飛華中（武漢）有限公司	**1,836**	2,898
Xi'an Xunfei Super Brain Information Technology Co., Ltd.	西安訊飛超腦信息科技有限公司	**1,679**	1,316
Sichuan iFLYTEK Super Brain Information Technology Co., Ltd.	四川訊飛超腦信息科技有限公司	**985**	1,214
Anhui iFLYTEK New Retail Co., Ltd.	安徽訊飛新零售有限公司	**750**	6,083
iFLYTEK South China Co., Ltd.	科大訊飛華南有限公司	**663**	529
Zhejiang iFLYTEK Intelligent Technology Co., Ltd.	浙江訊飛智能科技有限公司	**486**	439
iFLYTEK South China Artificial Intelligence Research Institute (Guangzhou) Co., Ltd.	科大訊飛華南人工智能研究院（廣州）有限公司	**449**	—
Others	其他	**4,140**	2,934
		46,376	43,467

24. RELATED PARTY TRANSACTIONS *(Continued)*

24. 關聯方交易*（續）*

(I) DURING THE CURRENT INTERIM PERIOD, THE GROUP ENTERED INTO THE FOLLOWING TRANSACTIONS WITH RELATED PARTIES: *(Continued)*

(I) 於本中期期間，本集團與關聯方訂立下列交易：*（續）*

(b) Receiving of services *(Continued)*

iFLYTEK and its subsidiaries and associates provided various support services to the Group including information technology support service, human resources services. Transactions with related parties were determined based on prices and terms mutually agreed by the relevant parties involved.

(b) 收取服務*（續）*

科大訊飛及其子公司及聯營公司向本集團提供各種支援服務，包括信息技術支持服務及人力資源服務。與關聯方的交易按相關方共同協定的價格及條款釐定。

(c) Lease arrangements

(c) 租賃安排

		Six months ended/ As at June 30, 截至6月30日止六個月／於6月30日	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		（未經審核）	（未經審核）
iFLYTEK	科大訊飛		
Interest expense on lease liabilities	租賃負債利息開支	**26**	66
Lease liabilities	租賃負債	**579**	2,853
iFLYTEK (Beijing) Co., Ltd.	科大訊飛（北京）有限公司		
Short-term lease expenses	短期租賃開支	**–**	255

24. RELATED PARTY TRANSACTIONS *(Continued)*

24. 關聯方交易*(續)*

(II) COMPENSATION OF KEY MANAGEMENT PERSONNEL

(II) 主要管理人員薪酬

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(unaudited)** **(未經審核)**	2025 2025年 RMB'000 人民幣千元 (unaudited) (未經審核)
Salaries, discretionary bonus and other benefits	薪金、酌情花紅及其他福利	**2,153**	2,659
Retirement benefit scheme contributions	退休福利計劃供款	**79**	78
Equity-settled share-based payments	以權益結算以股份為基礎的支付	**232**	1,495
		2,464	4,232

25. CHANGE IN OWNERSHIP INTEREST IN A SUBSIDIARY

On April 15, 2026, the Group disposed of 22.87% of its interest in Beijing Huiji Zhiyi Technology Co., Ltd. (北京惠及智醫科技有限公司) ("**Beijing Huiji**"), reducing its continuing interest to 52.13% at a cash consideration of RMB5,473,000 to a non-controlling shareholder of the Group's other subsidiaries. An amount of RMB7,091,000 (being the proportionate share of the carrying amount of the net liabilities of Beijing Huiji) has been transferred to non-controlling interests. The difference of RMB12,564,000 between the increase in the non-controlling interests and the consideration received has been credited to capital reserve.

On June 18, 2026, the Company entered into a capital increase agreement with Sanya Gaozhuo Jiayin Information Technology Partnership (Limited Partnership) ("**Sanya Gaozhuo Jiayin**"), pursuant to which Sanya Gaozhuo Jiayin subscribed for new registered capital of Beijing Huiji at a cash consideration of RMB1,527,000, following which the Company's equity interest in Beijing Huiji was diluted from 52.13% to 49.00%. An amount of RMB182,000, being the proportionate share of the carrying amount of the net liabilities of Beijing Huiji attributable to non-controlling interests upon the dilution, was transferred to non-controlling interests. The difference of RMB1,709,000, representing the aggregate of the capital contribution received by Beijing Huiji and the amount transferred to non-controlling interests, was credited to capital reserve.

25. 於一家子公司的所有權權益變動

於2026年4月15日，本集團向本集團其他子公司之非控股股東出售其於北京惠及智醫科技有限公司(「**北京惠及**」)之22.87%權益，將其持續持股比例降至52.13%，現金代價為人民幣5,473,000元。金額人民幣7,091,000元(即北京惠及負債淨額的賬面值中的應佔份額)已轉撥至非控股權益。非控股權益增加額與已收代價之間的差額人民幣12,564,000元已計入資本公積。

於2026年6月18日，本公司與三亞高卓佳音信息科技合夥企業(有限合夥)(「**三亞高卓佳音**」)訂立增資協議，據此，三亞高卓佳音認購北京惠及新增的註冊資本，現金代價為人民幣1,527,000元，此後本公司於北京惠及的股權由52.13%攤薄至49.00%。金額人民幣182,000元(即攤薄後，北京惠及負債淨額的賬面值中歸屬於非控股權益的應佔份額)已轉撥至非控股權益。差額人民幣1,709,000元(即北京惠及收到的注資及轉撥至非控股權益的金額總和)已計入資本公積。

訊飛醫療科技股份有限公司
Xunfei Healthcare Technology Co., Ltd.